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The prevalence of moderate or severe aortic valve 
(AV) disease, namely aortic regurgitation (AR) and 
aortic stenosis (AS), has been estimated as 0.9% in 
the largest population-based study from the United 
States.1 The prevalence of AV disease rose strikingly 
with age, which is very low (<1%) before the age of 65, 
and increases to 2.3% for the ages between 65-74, and 
to 4.8% after the age of 75.1 Importantly, moderate or 
severe valvular diseases are not benign but have pro-
found consequences, with cardiac chamber remodeling 
on echocardiographic examinations (characteristic of 
volume or pressure overload) and are associated with 
excess mortality (relative risk of death was 1.36), after 
adjusted for coronary artery diseases and comorbid 
conditions despite the availability of surgical valve 
repair or replacement in the large population-based 
study.1 Therefore, the associated excess risk under-
scores the importance of accurate detection of valvular 
diseases. In this regard, advanced cardiac imaging 
plays a critical role in the early diagnosis and recogni-
tion, as well as the detection of its deleterious effect 
on myocardial function, which is the key to improving 
prognosis, as prompt referral for valve intervention will 
interrupt and alter the natural history of AV diseases. 
Therefore beyond the assessment of chamber dimen-
sions or left ventricular (LV) function, conventionally 
by ejection fraction (EF) assessment, the evaluation 
of myocardial tissue deformation and strain may help 
refine risk stratification and decision-making process 
in patients with AV diseases.
In the Euro Heart Survey, the most common val-
vular diseases referred to hospital were AV diseases 
(44%), and AS accounted for the majority (34%).2 
Similarly, valve interventions were performed mostly 
for AS (47%), and the predominant etiology was 
degenerative (82%).2 Therefore, the majority of AS 
were in the elderly population, affecting 56% in aged 
>70 and 14% were aged >80, in whom there are as-
sociated increased rates of comorbidities. In the Euro 
Heart Survey that analyzed the elderly patients with 
AS, 33% were not referred for surgery, with impaired 
LV ejection fraction and old age as the main reasons 
that determine the decision making.3 Until recently, 
AVR was the only definitive therapy but many elderly 
patients are considered high risk surgical candidates. 
Conversely, if symptomatic AS is left untreated, the 
prognosis is dismal with an average survival of 2 to 3 
years.4 Thus, there is a need for alternative treatment 
for AS, and transcatheter aortic valve implantation 
(TAVI) is a proven effective therapy in AS patients 
with extreme or high operative risk, with acceptable 
mortality and complication rates.5, 6 Besides technical 
advances and procedural experience, accurate patient 
selection is the key to achieve high success rates and 
low complications rates with TAVI. Multimodality 
imaging plays a crucial role in patient selection, guid-
ing the procedure and evaluation of the immediate 
and long-term results after TAVI.
Transthoracic echocardiography is the primary 
imaging modality for the diagnosis and assessment 
of its severity in AV disease, as well as to assess its 
prognosis by its hemodynamic consequences on the 
LV. There are many reasons why echocardiography 
is the preferred modality over the other modalities, 
due to its ability to provide real-time comprehensive 
evaluation of the anatomic and physiologic informa-
tion of all valves, including the aorta and ventricular 
functions, and its non-invasiveness and wide avail-
ability which allows for serial assessment. Current 
guidelines for intervention in patients with AV disease 
are based on the presence or absence of symptoms, 
as well as 2-dimensional (2D) echocardiographic 
parameters such as the LV size (LV dimensions) and 
LV function (LVEF).5, 6 However, conventional 2D 
echocardiography has several limitations and is less 
reproducible as it is affected by foreshortened apical 
views and the reliance on geometric assumptions for 
the calculation of LV volumes and EF.7
Regarding the assessment of valvular regur-
gitation, although it is recommended to quantify 
the severity of regurgitation,8, 9 this quantitative 
approach remains challenging in clinical practice 
due to multiple computations and assumptions 
inherent in its derivation using the proximal isove-
locity surface area (PISA) method.9 Yet, the widely 
used conventional semi-quantitative approach of 
assessment by color flow Doppler is not endorsed, 
as it is influenced by hemodynamic flow factors.8, 9 
Recent advances in echocardiography, in particular, 
3-dimensional (3D) echocardiography may have 
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overcome some of the above-mentioned limitations 
by permitting direct visualization and measurement 
of the regurgitant orifice area, without the need for 
additional computation or geometric assumptions.10
In addition, the advent of novel 2D speckle 
tracking echocardiography (STE) as a new, angle 
independent technique to evaluate myocardial defor-
mation and strain, have recently been reported to be 
clinically useful and reproducible.11 In this respect, 
the most commonly used measure of LV global 
systolic function is the global longitudinal strain 
(GLS), which has been shown to be an incremental 
predictor of adverse events, beyond LVEF.12, 13 
Moreover, impaired GLS strain may also predict 
worse outcomes after valve surgery in patients with 
valvular regurgitation.14, 15
Currently, the introduction of TAVI has revolution-
ized treatment of patients with symptomatic severe 
AS. In inopertable patients, TAVI has been shown to 
significantly improve survival over medical therapy.16 
Therefore, TAVI is now a class I recommendation 
in patients with severe AS and extreme operative 
risk.5, 6 Moreover, in patients with high operative 
risk, TAVI can be considered a viable alternative 
to surgical aortic valve replacement (SAVR) when 
TAVI is favored after a multidisciplinary Heart Team 
assessment,5, 6 as randomized trials have demonstrated 
that TAVI is non-inferior to SAVR,17 and is associated 
with significantly higher one-year survival rate than 
SAVR.18 Unlike SAVR where direct inspection is pos-
sible, TAVI mandates detailed pre-procedural plan-
ning and careful patient and prosthesis selection with 
the use of multimodality imaging of the AV, aortic 
root and peripheral arteries, for optimal procedural 
success. In addition, cardiac imaging plays a key role 
in the understanding of mechanisms of complications 
post-TAVI, and provides systematic evaluation and 
monitoring of the post-procedural results.
Three-DImeNsIoNAL echocArDIogrAphy 
IN AorTIc VALVe DIseAse
Currently, 3D echocardiography are readily avail-
able and recent advances have permitted real-time 
visualization of the entire cardiac structures from 
any imaging plane. This is a major innovation in the 
field of cardiovascular ultrasound, offering superior 
imaging to conventional 2D echocardiography. The 
clinical usefulness of 3D echocardiography has been 
demonstrated in: 1) the evaluation of LV volumes 
and EF19; 2) the ability to present unlimited views 
of heart valves and intracardiac structures using 
3D TEE, as it offers superior spatial resolution and 
3D anatomic definition, and thus it is the recom-
mended primary imaging modality for guiding 
transcatheter interventions and for device sizing20; 
3) the volumetric assessment of regurgitant lesions 
using 3D color Doppler, with direct quantification by 
planimetry of the 3D color regurgitation jet (Figure 
1), irrespective of a non-circular orifice area or ec-
centric jet, typically seen in patients with functional 
mitral regurgitation.21, 22
NoVeL ImAgINg moDALITIes To Assess LV 
DeformATIoN
Recently, myocardial strain imaging is proposed as 
a more sensitive technique to assess the contractile 
properties of the myocardium, by evaluating the 
active deformation of the myocardium in all 3 planes 
of cardiac motion, without being influenced by the 
tethering or translational cardiac motion. In contrast 
to previous technique of assessment using Tissue 
Doppler imaging that is angle-dependent on ultra-
sound insonation, the novel 2D STE overcomes this 
by tracking frame-by-frame of the national acoustic 
markers (the so-called speckles) on gray-scale 
images and permits measurement of deformation 
based on excursion between individual speckles 
throughout the cardiac cycle (Figure 2).23, 24 In most 
early disease process, the subendocardial fibers are 
preferentially affected, and thus the impairment of 
longitudinal function may occur with preservation of 
circumferential and radial function.25 The GLS, as a 
marker of subendocardial function, has been shown 
to be incremental and superior to resting LVEF12, 13 
Therefore, the conventional global measures of LV 
systolic function (such as LVEF, which is used to 
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determine intervention in the current guidelines5, 6) 
can be preserved until more advanced stage disease, 
as it lacks sensitivity in ascertaining the transition 
from compensated state to overt myocardial dys-
function and heart failure.14, 15 Hence, strain imaging 
using 2D STE may represent a promising tool, to 
detect subclinical myocardial dysfunction in patients 
with AV disease.
muLTImoDALITy ImAgINg IN TAVI for 
TreATmeNT of As
The critical steps in ensuring procedural success in 
TAVI are patient selection, sizing of prosthesis and 
procedural planning, and noninvasive multimodality 
imaging plays a key role in providing the important 
information involving the detailed 3D anatomy of 
AV, its spatial relationship with the coronary ostia 
and the ascending aorta, as well as the peripheral 
arteries. Advances in 3D echocardiography, comple-
ment with the superior spatial resolution of multi-
figure 1. Quantitative assessment of aortic regurgitation severity using the proximal isovelocity surface area (PISA) 
method using conventional 2-dimensional Doppler echocardiography (panel A). Real-time 3-dmensional (3D) 
echocardiography permits unlimited plane orientation, allowing for the true cross-sectional area of the regurgitant 
jet to be planimetered, without multiple computation steps (panel B).
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detector row computed tomography (MDCT) and 
magnetic resonance imaging (MRI) have enabled 
comprehensive pre-procedural evaluation, thus 
ensuring the best possible outcomes with TAVI.26, 27 
However, as with any new technology, pitfalls and 
limitations are present in the currently used trans-
catheter valves. Paravalvular regurgitation (PVR) 
is frequent after TAVI and its presence has been 
associated with worse clinical outcomes.28 Precise 
diagnosis and quantification of PVR is challenging, 
but advanced cardiac imaging provides insights 
into the understanding of the mechanism of PVR 
after TAVI, its assessment of severity, as well as its 
impact on outcomes over time. Finally, post-TAVI 
evaluation can also be systematically studied using 
cardiac imaging from several perspectives and in 
different patient groups.
objecTIVes AND ouTLINe of The ThesIs
The objectives of this thesis were to investigate the 
role of advanced cardiac imaging modalities in the 
management of patients with AV diseases, and its 
clinical applications in transcatheter AV therapy.
In part I, the incremental value of novel imaging 
in patients with AR will be discussed. In particular, 
the additional diagnostic value of 3D echocar-
diography, over the conventional method of AR 
quantification using 2D Doppler echocardiography 
will be explored. Moreover, the value of 2D STE, 
over the conventional echocardiographic parameters 
to characterize LV performance in patients with 
chronic AR will be introduced.
Part II will focus on the clinical applications 
of multimodality cardiac imaging in TAVI for the 
treatment of severe AS. First, the evolving role of 
MDCT in the pre-procedural assessment and plan-
ning of patients undergoing transcathether valve 
therapy will be introduced. Next, the application 
figure 2. Two-dimensional speckle tracking echocardiography enables comprehensive assessment of active defor-
mation of the myocardium in all 3 planes of cardiac motion, that is angle-independent on ultrasound insonation. 
Longitudinal strain (panel A) is calculated from apical views of the left ventricle (LV). Circumferential (panel B) 
and radial strain (panel C) are calculated from mid-ventricular short-axis views of the LV.
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of multimodality imaging in patient selection and 
procedural planning is proposed in the pre-TAVI 
evaluation algorithm.
After TAVI, the use of cardiac imaging to im-
age, understand and quantify AR post-TAVI, and 
to guide further maneuvers intra-procedurally will 
be discussed. In addition, whether the AV calcium 
and its distribution, have an influence on AR after 
TAVI will be explored. Finally, the clinical and 
echocardiographic outcomes after TAVI will be 
further studied in patients with: 1) significant AR 
post-TAVI; 2) prosthesis-patient mismatch; 3) 
baseline impaired LV systolic function; 4) different 
procedural access, comparing transfemoral (TF) 
versus transapical (TA) approach.
refereNces
(1) Nkomo VT, Gardin JM, Skelton TN et al. Burden of 
valvular heart diseases: a population-based study. 
Lancet 2006;368:1005-1011.
(2) Iung B, Baron G, Butchart EG et al. A prospective 
survey of patients with valvular heart disease in 
Europe: The Euro Heart Survey on Valvular Heart 
Disease. Eur Heart J 2003;24:1231-1243.
(3) Iung B, Cachier A, Baron G et al. Decision-making in 
elderly patients with severe aortic stenosis: why are 
so many denied surgery? Eur Heart J 2005;26:2714-
2720.
(4) Bonow RO, Carabello BA, Chatterjee K et al. 2008 
Focused update incorporated into the ACC/AHA 
2006 Guidelines for the management of patients 
with valvular heart disease: a report of the American 
College of Cardiology/American Heart Association 
Task Force on Practice Guidelines. J Am Coll Cardiol 
2008;52:e1-e142.
(5) Vahanian A, Alfieri O, Andreotti F et al. Guidelines 
on the management of valvular heart disease (version 
2012): The Joint Task Force on the management of 
valvular heart disease of the European Society of 
Cardiology (ESC) and the European Association 
for Cardio-Thoracic Surgery (EACTS). Eur Heart 
J 2012;33:2451-2496.
(6) Nishimura RA, Otto CM, Bonow RO et al. 2014 
AHA/ACC guideline for the management of patients 
with valvular heart disease: a report of the American 
College of Cardiology/American Heart Association 
Task Force on Practice Guidelines. J Am Coll Cardiol 
2014;63:e57-e185.
(7) Lang RM, Badano LP, Mor-Avi V et al. Recom-
mendations for cardiac chamber quantification by 
echocardiography in Adults: an update from the 
American Society of Echocardiography and the 
European Association of Cardiovascular Imaging. 
Eur Heart J Cardiovasc Imaging 2015;16:233-271.
(8) Zoghbi WA, Enriquez-Sarano M, Foster E et al. 
Recommendations for evaluation of the severity of 
native valvular regurgitation with two-dimensional 
and doppler echocardiography. J Am Soc Echocar-
diogr 2003;16:777-802.
(9) Lancellotti P, Tribouilloy C, Hagendorff A et al. Euro-
pean Association of Echocardiography recommenda-
tions for the assessment of valvular regurgitation. part 
1: aortic and pulmonary regurgitation (native valve 
disease). Eur J Echocardiogr 2010;11:223-244.
(10) Yosefy C, Hung J, Chua S et al. Direct measurement 
of vena contracta area by real-time 3-dimensional 
echocardiography for assessing severity of mitral 
regurgitation. Am J Cardiol 2009;104:978-983.
(11) Yingchoncharoen T, Agarwal S, Popovic ZB et al. 
Normal ranges of left ventricular strain: a meta-
analysis. J Am Soc Echocardiogr 2013;26:185-191.
(12) Mignot A, Donal E, Zaroui A et al. Global longitudinal 
strain as a major predictor of cardiac events in patients 
with depressed left ventricular function: a multicenter 
study. J Am Soc Echocardiogr 2010;23:1019-1024.
(13) Stanton T, Leano R, Marwick TH. Prediction 
of all-cause mortality from global longitudinal 
speckle strain: comparison with ejection fraction 
and wall motion scoring. Circ Cardiovasc Imaging 
2009;2:356-364.
(14) Olsen NT, Sogaard P, Larsson HBW et al. Speckle-
tracking echocardiography for predicting outcome 
in chronic aortic regurgitation during conservative 
management and after surgery. JACC Cardiovasc 
Imaging 2011;4:223-230.
(15) Witkowski TG, Thomas JD, Debonnaire PJMR et al. 
Global longitudinal strain predicts left ventricular 
dysfunction after mitral valve repair. Eur Heart J 
Cardiovasc Imaging 2013;14:69-76.
(16) Leon M, Smith C, Mack M et al. Transcatheter 
aortic-valve implantation for aortic stenosis in pa-
tients who cannot undergo surgery. N Engl J Med 
2010;363:1597-1607.
(17) Smith CR, Leon MB, Mack MJ et al. Transcatheter 
versus surgical aortic-valve replacement in high-risk 
patients. N Engl Med 2011;364:2187-2198.
(18) Adams DH, Popma JJ, Reardon MJ et al. Transcath-
eter aortic-valve replacement with a self-expanding 
prosthesis. New Engl J Med 2014;370:1790-1798.
16 Chapter 1
(19) Dorosz JL, Lezotte DC, Weitzenkamp DA et al. 
Performance of 3-dimensional echocardiography 
in measuring left ventricular volumes and ejection 
fraction: a systematic review and meta-analysis. J 
Am Coll Cardiol 2012;59:1799-1808.
(20) Zamorano JL, Badano LP, Bruce C et al. EAE/ASE 
recommendations for the use of echocardiography 
in new transcatheter interventions for valvular heart 
disease. Eur Heart J 2011;32:2189-2214.
(21) Kahlert P, Plicht B, Schenk IM et al. Direct assess-
ment of size and shape of noncircular vena contracta 
area in functional versus organic mitral regurgitation 
using real-time three-dimensional echocardiography. 
J Am Soc Echocardiogr 2008;21:912-921.
(22) Marsan NA, Westenberg JJM, Ypenburg C et al. 
Quantification of functional mitral regurgitation by 
real-time 3D echocardiography: comparison with 3D 
velocity-encoded cardiac magnetic resonance. JACC 
Cardiovasc Imaging 2009;2:1245-1252.
(23) Korinek J, Wang J, Sengupta PP et al. Two-dimen-
sional strain - a Doppler-independent ultrasound 
method for quantitation of regional deformation: 
validation in vitro and in vivo. J Am Soc Echocar-
diogr 2005;18:1247-1253.
(24) Leitman M, Lysyansky P, Sidenko S et al. Two-
dimensional strain-a novel software for real-time 
quantitative echocardiographic assessment of 
myocardial function. J Am Soc Echocardiogr 
2004;17:1021-1029.
(25) Stanton T, Marwick TH. Assessment of subendo-
cardial structure and function. JACC Cardiovasc 
Imaging 2010;3:867-875.
(26) Bax JJ, Delgado V, Bapat V et al. Open issues in 
transcatheter aortic valve implantation. Part 1: patient 
selection and treatment strategy for transcatheter 
aortic valve implantation. Eur Heart J 2014;35:2627-
2638.
(27) Bax JJ, Delgado V, Bapat V et al. Open issues in trans-
catheter aortic valve implantation. Part 2: procedural 
issues and outcomes after transcatheter aortic valve 
implantation. Eur Heart J 2014;35:2639-2654.
(28) Athappan G, Patvardhan E, Tuzcu EM et al. Incidence, 
predictors, and outcomes of aortic regurgitation after 
rranscatheter aortic valve replacement: meta-analysis 





Novel imaging to assess aortic valve regurgitation – 
incremental role in diagnosis

2Accuracy of three-dimensional versus  two-dimensional echocardiography for quantification of aortic regurgitation and  validation by three-dimensional three-directional velocity-encoded magnetic resonance imagingewe sh, Delgado V, van der Geest R, Westenberg JJ, Haeck ML, Witkowski TG, Auger D, Marsan NA, Holman ER, de Roos A, Schalij MJ, Bax JJ, Sieders A, Siebelink HMAm J Cardiol. 2013 Aug 15;112(4):560-6.

232D versus 3D echocardiography to quantify AR
Accuracy of Three-Dimensional Versus Two-Dimensional
Echocardiography for Quantification of Aortic Regurgitation
and Validation by Three-Dimensional Three-Directional
Velocity-Encoded Magnetic Resonance Imaging
See Hooi Ewe, MBBSa,b, Victoria Delgado, MD, PhDa,*, Rob van der Geest, MSc, PhDc,
Jos J.M. Westenberg, PhDc, Marlieke L.A. Haeck, MDa, Tomasz G. Witkowski, MDa,
Dominique Auger, MDa, Nina Ajmone Marsan, MDa, Eduard R. Holman, MD, PhDa,
Albert de Roos, MD, PhDc, Martin J. Schalij, MD, PhDa, Jeroen J. Bax, MD, PhDa, Allard Sieders, MDd,
and Hans-Marc J. Siebelink, MD, PhDa
Quantitative assessment of aortic regurgitation (AR) remains challenging. The present
study evaluated the accuracy of 2-dimensional (2D) and 3-dimensional (3D) transthoracic
echocardiography (TTE) for AR quantification, using 3D 3-directional velocity-encoded
magnetic resonance imaging (VE-MRI) as the reference method. Thirty-two AR patients
were included. With color Doppler TTE, 2D effective regurgitant orifice area (EROA) was
calculated using the proximal isovelocity surface area method. From the 3D TTE multi-
planar reformation data, 3D-EROA was calculated by planimetry of the vena contracta.
Regurgitant volumes (RVol) were obtained by multiplying the 2D-EROA and 3D-EROA by
the velocity-time integral of AR jet and compared with that obtained using VE-MRI. For
the entire population, 3D TTE RVol demonstrated a strong correlation and good agreement
with VE-MRI RVol (r [ 0.94 and L13.6 to 15.6 ml/beat, respectively), whereas 2D TTE
RVol showed a modest correlation and large limits of agreement with VE-MRI (r [ 0.70
and L22.2 to 32.8 ml/beat, respectively). Eccentric jets were noted in 16 patients (50%). In
these patients, 3D TTE demonstrated an excellent correlation (r [ 0.95) with VE-MRI,
a small bias (0.1 ml/beat) and narrow limits of agreement (L18.7 to 18.8 ml/beat). Finally,
the kappa agreement between 3D TTE and VE-MRI for grading of AR severity was good
(k [ 0.96), whereas the kappa agreement between 2D TTE and VE-MRI was suboptimal
(k [ 0.53). In conclusion, AR RVol quantification using 3D TTE is accurate, and its
advantage over 2D TTE is particularly evident in patients with eccentric jets.  2013
Elsevier Inc. All rights reserved. (Am J Cardiol 2013;112:560e566)
Quantification of aortic regurgitation (AR) remains chal-
lenging in clinical practice. Currently, the proximal isovelocity
surface area (PISA) method, using 2-dimensional (2D)
Doppler echocardiography, is the recommended approach to
estimate the regurgitation volume (RVol) and effective regur-
gitation orifice area (EROA).1,2 However, several assumptions
inherent in its derivationmay hamper the accuracy of 2D PISA
method to quantify AR, such as noncircular orifices3 and
eccentric jets.4 Real-time 3-dimensional (3D) echocardiog-
raphy permits direct visualization of the vena contracta and
measurement of the EROA, without the need for additional
computation or geometric assumptions.5e8 In addition, 3D
echocardiography is not restrictedbyany imaging plane, unlike
2Dechocardiography,which is limited to quantifyflowaligned
along the ultrasound beam.4,8 Therefore, quantification of AR
would be more accurate using 3D than 2D echocardiography,
and this would probably become more evident in patients with
eccentric AR. Recently, 3D 3-directional velocity-encoded
magnetic resonance imaging (VE-MRI) has been proposed as
a more accurate method to assess transvalvular flow.7,9,10 The
current evaluation assessed the accuracy of 2D and 3D trans-
thoracic echocardiography (TTE) for quantification of AR,
using 3D 3-directional VE-MRI as the reference method.
Methods
Thirty-two patients with AR who were clinically referred
for TTE and MRI to quantify AR, aortic root, and aortic
dimensions were retrospectively evaluated. Patients with
acute AR or concomitant valvular disease of more than mild
severity, atrial fibrillation, or contraindications for MRI
(i.e., implanted devices, claustrophobia) were not included.
Clinical data including demographics and symptoms were
collected in the departmental electronic patient file (EPD
vision version 8.3.3.6; Leiden, The Netherlands) and retro-
spectively analyzed. All patients underwent standard 2D and
aDepartment of Cardiology, Leiden University Medical Center, Leiden,
The Netherlands; bDepartment of Cardiology, National Heart Centre,
Singapore; cDepartment of Radiology, Leiden University Medical Center,
Leiden; and dDepartment of Cardiology, Rijnland Ziekenhuis, Leiderdorp,
The Netherlands. Manuscript received February 11, 2013; revised manu-
script received and accepted April 11, 2013.
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3D color Doppler TTE to quantify AR RVol and EROA.
In addition, cardiac MRI was performed in all patients to
assess left ventricular (LV) size and function, aortic valve
morphology, AR severity, and aortic root and ascending
aorta dimensions.2 Severity of AR was assessed using 3D
3-directional VE-MRI data to quantify the AR Rvol.
Patients were imaged at rest in the left lateral decubitus
position using a commercially available ultrasound system
(iE33, Philips Medical Systems, Andover, Massachusetts)
equipped with a S5-1 transducer. A complete 2D, color,
pulsed, and continuous wave Doppler examination was
performed according to the standard guidelines.1,2,11 For AR
quantification, color Doppler images of the aortic valve were
acquired with optimized gain and Nyquist scale (50 to
60 cm/s).1,2 From the zoomed color Doppler view of the AR
jet, the vena contracta was identified as the narrowest
portion of the regurgitant jet that occurred at or just down-
stream from the regurgitant orifice.1,2 For a more quantita-
tive assessment of AR, the PISA method was used. In brief,
by shifting the baseline of the aliasing velocity toward the
direction of the regurgitant jet (between 20 and 40 cm/s),
a well-defined hemisphere of the convergence zone could
be identified. From this, the maximal 2D-EROA could
be estimated. Subsequently, the RVol was calculated as
2D-EROA multiplied by the velocity-time integral of the
AR jet, from the continuous wave Doppler obtained either at
the apical 5- or 3-chamber views.1,2 AR severity was graded
based on RVol: grade 1 (mild), <30 ml; grade 2 (mild-to-
moderate), 30 to 44 ml; grade 3 (moderate-to-severe), 45 to
59 ml; and grade 4 (severe), 60 ml.1,2
Figure 1. Three-dimensional transthoracic echocardiography for assessment of aortic EROA. First, the 3D color Doppler data set was manually cropped to
provide a cross-sectional plane through the vena contracta of the regurgitant jet, perpendicular to the direction of the aortic regurgitant jet (A). Next, from the en
face view of the vena contracta, selecting the plane with the narrowest cross-sectional area of the regurgitant jet, the 3D-EROA was measured by manual
planimetry of the color Doppler signal (B). The figure provides an example of a patient with central and circular jet.
Figure 2. Postprocessing of aortic valve flow from 3D 3-directional VE-MRI data sets. The 3D acquisition volume was positioned at the level of the aortic
valve, covering its full excursion during the entire cardiac cycle (A). From the 2 orthogonal views of the aortic valve (B), retrospective valve tracking and
reformatting plane (with 5 parallel planes spaced at 5 mm) were reconstructed at the level of the aortic annulus, perpendicular to the aortic flow. The through-
plane velocity-encoded images were thus obtained by reformatting in the center of the valvular plane in each cardiac phase (C). During systole, the aortic
forward flow was acquired (inner border of the aortic annulus was traced in red for flow analysis). During diastole, the regurgitant flow could be identified (red
line). Region within the left ventricular wall was traced (in green) for correction of the myocardial motion, at the caudal-most reformatted plane where
myocardial tissue was best visualized. (D) Finally, integration of the velocities over the aortic annulus, subtracted by the through-plane velocity of the
myocardium, yielded the flow graph. The regurgitant volume was calculated by the Riemann sum of backward flow during diastole in the flow graph.
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The 3D TTE was performed using the same ultrasound
system (the iE33 system) with a fully sampled matrix-array
X3 transducer. Apical and parasternal full-volume color
Doppler data sets of the AR jets were obtained using elec-
trocardiographic gating over 7 consecutive heart beats to
obtain 7 small real-time subvolumes in a larger pyramidal
volume. To minimize stitch artifact, the acquisition was
performed during 5 to 7 seconds of breath-holding. The
color gain and scale were set as previously mentioned. All
images were digitally stored and analyzed offline (Q-Lab
3DQ, Philips Medical Systems). To measure 3D-EROA,
multiplanar reconstruction of the 3D data sets and manual
cropping were performed. First, a cross-sectional plane
through the vena contracta of the regurgitant jet, perpen-
dicular to the direction of the AR jet, was obtained. Next,
from the en face view of the vena contracta, the 3D-EROA
of the narrowest cross-sectional area of the regurgitant jet
was measured by manual planimetry from the diastolic
frame with the most relevant lesion size (Figure 1). The 3D-
RVol was derived by multiplying the 3D-EROA by the
velocity-time integral of the AR jet.
MRI was performed using a 1.5-T scanner (Philips
Medical Systems, Best, The Netherlands) equipped with
a 5-element cardiac synergy coil. First, from a series of short-
axis images, encompassing the LV from apex to base and
throughout the entire cardiac cycle, quantification of LV
volumes and ejection fraction were obtained by using the
MASS research software (Division of Image Processing,
Department of Radiology, LUMC, Leiden, The Netherlands)
with contour segmentation of the epicardial and endocardial
borders.12 For AR quantification, 3D 3-directional VE-MRI
was used. A detailed description of the 3D VE-MRI acqui-
sition protocol has been described.9,10 In brief, a free-
breathing 3D phase-contrast acquisition was used with
velocity encoding in 3 orthogonal directions. Imaging
parameters were as follows: repetition time 7.5 milliseconds,
echo time 4.3milliseconds; field of view 370mm, 3D volume
imaging with 48-mm slab thickness reconstructed into
12 slices of 4 mm, flip angle of 10�, acquisition voxel size
2.9� 3.8� 4.0 mm voxel reconstructed into 1.4� 1.4� 4.0
mm voxel, 1 acquired signal, and with 30 phases recon-
structed during 1 average cardiac cycle from the retrospective
gated acquisition (temporal resolution between 25 and
40 milliseconds, depending on the heart rate). Echo-planar
imaging was performed with a factor of 5 resulting in scan
duration of approximately 5 minutes. The velocity encoding
was initially set at 150 cm/s in all 3 directions. However,
additional 2D VE-MRI of the aortic valve was used to
determine if a higher maximal velocity was required and the
optimized velocity was then applied for 3D VE-MRI in all
3 directions.
The 3D VE-MRI acquisitions were postprocessed with
the in-house developed MASS research software package.10
Two orthogonal views of the aortic valve were used for
retrospective valve tracking and a reformatting plane (with
5 parallel planes equally spaced at 5 mm apart) was marked
at the level of the valve annulus in every cardiac phase,
perpendicular to the aortic regurgitant flow (Figure 2). Next,
the 3D velocity data were reformatted in the center of the
valvular plane to generate 1-directional through-plane
velocity-encoded images. If aliasing occurred in any of the
velocity directions as a result of high-velocity regurgitant
jets, the phase unwrapping option of the software was used
to correct the velocity data and to avoid underestimation of
regurgitation. Background correction was performed to
correct for through-plane motion of the myocardium in
basal-to-apical direction and local phase offset.10 The
background region of interest was placed at the most caudal
plane (i.e., 10 mm distance from the central plane in the LV
anterior wall). Finally, the transvalvular volume flow was
obtained by integrating the resulting velocities taken over
the annular area. The MRI RVol was obtained by calcu-
lating the Riemann sum of backward flow during diastole in
the flow graph (Figure 2).13 The reformatting process
required 5 minutes, and subsequent image analysis took
another 5 to 10 minutes.
Continuous data are presented as mean � SD, and
categorical variables as absolute numbers (percentages).
Chi-square or Fisher’s exact tests were used for comparison
of categorical variables as appropriate. Linear regression
analysis (Pearson correlation) for continuous variables was
performed to evaluate the relation between RVol measure-
ments derived from 2D TTE, 3D TTE, and MRI. Bland-
Altman plots were used for agreement analysis between 2D
TTE, 3D TTE, and MRI derived RVol measurements. In
Table 1
Patient characteristics
Variable Patients (n ¼ 32)
Age (yrs) 53 � 18
Male 22 (69%)
Body surface area (m2) 1.97 � 0.23
Heart rate (beats/min) 67 � 13
Systolic blood pressure (mm Hg) 142 � 20
Diastolic blood pressure (mm Hg) 73 � 9







Diabetes mellitus 4 (13%)
Coronary artery disease 4 (13%)
Aortic regurgitation etiology
Calcific degeneration 14 (44%)
Bicuspid 14 (44%)
Previous infective endocarditis 1 (3%)
Rheumatic 2 (6%)
Idiopathic dilatation of the aorta 1 (3%)
LV end-diastolic volume (ml) 210 � 77
LV end-systolic volume (ml) 93 � 46
LV ejection fraction (%) 58 � 9
Aortic annulus (mm) 26 � 4
Aortic sinus (mm) 37 � 6
Sinotubular junction (mm) 31 � 6
Ascending aorta (mm) 34 � 7
Data are expressed as mean � SD or as number (%).
* Hypertension was defined as blood pressure �140/90 mm Hg or on
antihypertensive medication for hypertension. Hypercholesterolemia was
defined as a serum low-density lipoprotein cholesterol >160 mg/dl or on
lipid-lowering medication for hypercholesterolemia.
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addition, the kappa statistics were used to assess the
agreement among different imaging methods with regard to
AR severity grading. In 20 randomly selected patients,
interobserver reproducibility for 3D TTEederived
measurements were performed by 2 independent, blinded
observers and evaluated by intraclass correlation coefficient
(ICC). To evaluate intraobserver reproducibility, the same
observer repeated the measurements at 2 time points. Good
agreement was defined as ICC >0.8. All statistical analyses
were performed using SPSS for Windows version 16.0
(SPSS Inc., Chicago, Illinois) and MedCalc 10.0 (Maria-
kerke, Belgium).
Results
Table 1 summarizes the clinical characteristics and
parameters of the patients, with bicuspid aortic valve anatomy
in 14 patients (44%). AR was equally divided into central
(50%) and eccentric (50%) jets. In patients with eccentric jets,
a higher proportion of bicuspid comparedwith tricuspid valve
anatomy was observed (75% vs 25%, p ¼ 0.001). Figures 1
and 3 show examples of a central and an eccentric AR jet,
respectively.
For the entire population, the mean aortic RVol obtained
by 2D, 3D TTE, and VE-MRI were 29.6 � 14.3, 25.3 �
14.8, and 24.3 � 19.6 ml/beat, respectively. There was
a significant but modest correlation between the RVol as
assessed by 2D TTE and VE-MRI (r ¼ 0.70, p <0.001), and
the RVol quantification by 3D TTE showed a strong
correlation with VE-MRI (r ¼ 0.94, p <0.001; Table 2).
When Bland-Altman plots were performed for entire pop-
ulation, 3D TTE derived RVol showed a small bias (1.0 ml/
beat) and narrow limits of agreement (�13.6 to 15.6 ml/
beat) versus VE-MRI. In contrast, the bias and limits of
agreement between 2D TTE and VE-MRI derived RVol
were large (5.3 ml/beat and �22.2 to 32.8 ml/beat, respec-
tively; Figure 4).
In patients with central jets, 2D TTE demonstrated
a relatively good correlation with VE-MRI in the assessment
of RVol (r ¼ 0.80, p <0.001), but this correlation with
VE-MRI could be improved by using 3D TTE (r ¼ 0.93,
p <0.001). On the other hand, in patients with eccentric jets,
the correlation between RVol as assessed by 2D TTE and
VE-MRI was weak (r ¼ 0.66, p ¼ 0.005), whereas the
correlation between 3D TTE and VE-MRI derived RVol
was strong (r ¼ 0.95, p <0.001; Table 2). On Bland-Altman
analysis, 3D TTE derived RVol had the best agreement with
VE-MRI regardless of the direction of AR jet (central or
eccentric), with the least bias and narrowest limits of
agreement (Figure 4). Particularly for eccentric AR, 3D TTE
demonstrated a good agreement with VE-MRI, with a small
bias (0.1 ml/beat) and narrow limits of agreement (�18.7 to
18.8 ml/beat).
Based on the RVol measurements derived from 2D, 3D
TTE, and VE-MRI, the severity of AR was graded
accordingly.1,2 There was a moderate agreement, in terms
of AR severity grading, between 2D TTE and VE-MRI
(kappa index ¼ 0.53). In 62.5% of patients, including
central (n ¼ 13) and eccentric (n ¼ 7) jets, 2D TTE, and
VE-MRI provided concordant grading (Figure 5). Of the
12 patients who were differently graded by 2D TTE, the
majority of patients had eccentric (n ¼ 9) instead of central
jets (n ¼ 3; 75% vs 25%, p ¼ 0.07). In patients with central
AR who were misclassified by 2D TTE, the AR severity
was marginally overestimated (from mild to moderate).
Figure 3. An example of a patient with eccentric aortic regurgitation. Multiplanar reformation of the 3D transthoracic Doppler echocardiography data sets (A)
revealed an irregularly shaped effective regurgitant orifice area, as shown in the en face view (B).
Table 2
Relationship between aortic regurgitant volume measured by
echocardiography and magnetic resonance imaging
Regurgitant Volume Total Population
(n ¼ 32)
Central AR
Jet (n ¼ 16)
Eccentric AR
Jet (n ¼ 16)







p value <0.001 <0.001 0.005







p value <0.001 <0.001 <0.001
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Among the eccentric AR with incorrect grading, 2D TTE
underestimated AR severity in 3 patients compared with
VE-MRI, misclassifying grade 3 instead of 4 (n ¼ 2) and
grade 1 instead of 2 (n ¼ 1). In the remaining 6 patients,
2D TTE overestimated AR severity compared with VE-MRI
(grade 2 instead of 1 in 5 patients, and grade 3 instead of 2
in 1 patient). Importantly, the agreement between 3D TTE
and VE-MRI was markedly improved (kappa index ¼ 0.96).
All patients were correctly graded with 3D TTE (Figure 5),
except 1 patient with eccentric AR (misclassifying as grade
2 instead of 1). Finally, the interobserver and intraobserver
reproducibility for 3D echocardiography derived EROA
were good as expressed by intraclass correlation (ICC ¼
0.95 and 95% confidence interval: 0.88 to 0.98 and ICC ¼
0.97, 95% confidence interval: 0.92 to 0.99, respectively).
Discussion
The present evaluation showed that quantification of AR
with 2D TTE is challenging, particularly in eccentric
regurgitant jets. In contrast, quantification of AR with direct
measurement of the vena contracta area using 3D TTE is
feasible and the measurement of AR RVol shows good
correlation and agreement with 3D 3-directional VE-MRI,
the reference standard. In addition, the measurement of 3D
Figure 4. Scatter plots of Bland-Altman analysis for 2D and 3D TTE measurements of aortic regurgitant volume versus the 3D VE-MRI reference values for
overall population (A), central (B), and eccentric (C) jets.
Figure 5. Comparison between 2D and 3D TTE versus the 3D VE-MRI as
the reference method.
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TTE derived AR RVol showed high inter- and intraobserver
reproducibility.
Accurate assessment of valvular regurgitation severity is
paramount for prognosis and clinical management of patients
with AR.14,15 This is primarily performed using echocardiog-
raphy, with the integration of multiple parameters, including
the hemodynamic consequences of AR on the LV.1,2 The
assessment of AR severity is usually performed using both
quantitative and semiquantitative echocardiographic criteria.1,2
However, Messika-Zeitoun et al have shown that the
commonly used semiquantitative methods in AR assessment,
such as pressure half-time, diastolic flow reversal, and LV
cardiac output, lack sensitivity.16 In contrast, the quantitative
assessment ofAR, usingRVol and EROA, not only supersedes
the semiquantitative markers of AR severity but also has
prognostic clinical implications in patients with AR.17 Thus,
quantitative assessment of AR should always be used, as
recommended.1,2
The present evaluation shows the superior accuracy of 3D
TTE to quantify AR compared with 2D TTE, particularly in
eccentric regurgitant jets. 3D TTE-derived AR RVol had the
best agreement with that obtained by 3D 3-directional
VE-MRI. It is not surprising that 3D TTE provides a more
accurate quantification for AR than 2D PISAmethod because
direct planimetry of the AR vena contracta can be performed
without any geometric or flow assumptions or multiple
computation steps.1,5e8 By using multiplanar reconstruction
of the 3D full-volume data set, 3D TTE has the advantage of
unlimited plane orientation, allowing the exact shape and size
of the true cross-sectional view of the regurgitant orifice to be
measured accurately. In addition, the use of 3D 3-directional
VE-MRI sequences as the method of reference, with retro-
spective valve tracking,7,9,10 further strengthens the results of
the present evaluation because the 3D VE-MRI sequence
permits direct measurement of the through-plane transaortic
blood flow, taking into consideration the valve and heart
motion throughout the cardiac cycle. Moreover, MRI is
the reference standard to evaluate LV size and function
(a measure of the hemodynamic consequence of AR) and
dimensions of the thoracic aorta,18 all of which are important
parameters to consider in clinical decision making for
managing patients with AR.14,15
Most important, the present evaluation demonstrated
a high accuracy of using 3D TTE to quantify AR especially in
patients with eccentric jets, whereas 2D TTE was less precise
in AR quantification in these patients. Indeed, this translated
into less accurate grading of eccentric ARwith 2D TTE based
on the PISA-derived method, causing significant misclassi-
fication in 56.3% of patients (9 of 16). With 3D TTE,
misclassification only occurred in 3.1% (1 of 16 patients).
These results are in line with the series reported by Pouleur
et al., including 21 patients with central jets and 29 patients
with eccentric jets.4 The PISA derived RVol obtained by 2D
echocardiography had only fair correlation (r ¼ 0.69) with
that measured byMRI in patients with eccentric jets, whereas
the correlation between 2D echocardiography and MRI in
central AR jets was good (r ¼ 0.92). In addition, that study
also demonstrated that in eccentric jets, the differences
between 2D TTEederived PISA and MRI-derived RVol
could be nullified by imaging from the left parasternal
window, yielding a better view of the AR jet and flow
convergence compared with the conventional apical window,
thus underscoring the limitation of 2D TTE in aligning the
eccentric jets with ultrasound beam.4 Of interest, the present
evaluation demonstrated that 3D TTE permitted accurate
quantification of AR, even in the presence of an eccentric jet.
Moreover, nonplanar flow convergence angle, commonly
seen in AR patients with concomitant aneurismal dilatation of
the ascending aorta, could represent another source of error in
the calculation of AR quantification using the PISA derived
method.19 However, this would not be a consideration if the
3D TTE approach was used.
The retrospective design of the present evaluation
precluded investigation of the clinical and prognostic impli-
cations of these findings, which should be further evaluated in
prospective studies.
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Aims The aim of this study was to characterize left ventricular (LV)mechanics in symptomatic and asymptomatic patients with
moderate-to-severe or severe aortic regurgitation (AR) and preserved ejection fraction (left ventricular ejection frac-
tion) using two-dimensional speckle tracking echocardiography (2D-STE). The association between baseline LV strain
and development of indications for surgery in asymptomatic patients was also evaluated.
Methods
and results
Atotal of 129patientswithmoderate-to-severeor severeARandLVEF.50%(age55+17years, 64%male, 53%asymp-
tomatic at baseline)were included. Standard echocardiography and2D-STEwereperformedat baseline.Comparedwith
asymptomatic patients, symptomatic patients had significantly impaired LV longitudinal (214.9+3.0 vs.216.8+2.5%,
P, 0.001), circumferential (217.5+2.9 vs. 219.3+ 2.8%, P ¼ 0.001), and radial (35.7+12.2 vs. 43.1+14.7%,
P ¼ 0.004) strains. Among 49 asymptomatic patientswhowere followedup, 26 developed indications for surgery (symp-
toms onset or LVEF ≤50%). These patients had comparable LV volumes, LVEF, and colour Doppler assessments of AR
jet at baseline, but more impaired LV longitudinal (P ¼ 0.009) and circumferential (P ¼ 0.017) strains compared with
patients who remained asymptomatic. Impaired baseline LV longitudinal (per 1% decrease, HR ¼ 1.21, P ¼ 0.04) or cir-
cumferential (per 1% decrease, HR ¼ 1.22, P ¼ 0.04) strain was independently associated with the need for surgery.
Conclusion Multidirectional LV strain was more impaired in symptomatic than in asymptomatic patients with moderate-to-severe
or severe AR, despite preserved LVEF. In asymptomatic AR patients, longitudinal and circumferential strains identified
patients who would require surgery during follow-up.
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Introduction
Currently, the class I indications for aortic valve (AV) surgery in
severe aortic regurgitation (AR) are when patients are symptomatic
and/or when there is impairment of left ventricular ejection fraction
(LVEF ≤50%).1,2 However, as the LV enlarges with time, and in the
presence of inadequate preload reserve and/or excessive increase
in afterload, impairment of LV function may occur even before the
onset of symptoms.3 Previous studies have also reported that
some indices of LV function (such as myocardial strain and mitral
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annular plane systolic excursion) may be abnormal in asymptomatic
patients with chronic severe AR, despite preserved LVEF.4,5 When
symptoms of heart failure develop in these patients, irreversible
damage to myocardial structure (fibrosis)6 and function may have
already occurred,7 which may preclude the recovery of LV function
following AV surgery.8–10 Thus, accurate detection of subclinical
LV dysfunction before the onset of symptoms and a drop in LVEF
may be clinically helpful to identify asymptomatic severe AR patients
who are at risk, necessitating early referral for surgery.
Strain imaging is a more sensitive technique (when compared
with LVEF) to evaluate the contractile properties of themyocardium
in patients with chronic AR.5,11,12 Recently, myocardial deformation
can be assessed using two-dimensional speckle tracking echo-
cardiography (2D-STE), which allows angle-independent assessment
of LV deformation by tracking the frame-to-frame natural acoustic
markers (the so-called speckles) within the myocardium wall.13–15
Myocardial strain values may indirectly reflect structural changes in
themyocardium including fibrosis.14,15Wehypothesized that impair-
ment in LV strain can be demonstrated in patients with moderate-
to-severe and severe chronic AR, despite being asymptomatic and
having preserved LVEF, and that 2D-STE would be a helpful tool to
identify those asymptomatic high-risk individuals who progress to
requireAV surgery. Therefore, the aims of this studywere as follows:
(1) To evaluate the presence of subtle LV systolic dysfunction, using
2D-STE, in symptomatic and asymptomatic patientswithmoder-
ate-to-severe or severe chronic AR and preserved LVEF, and
(2) Toevaluate thepotential roleofbaselineLVstrain, using2D-STE,
in identifying asymptomatic AR patients who later develop indi-
cations for AV surgery.
Methods
Patient population and data collection
Thepatient population comprised 129patientswithmoderate-to-severe
or severe AR who were identified in the echocardiographic database of
the Cardiology Department at the Leiden University Medical Center
(Leiden, the Netherlands). Patients with acute AR, concomitant valvular
diseaseofmore thanmild in severity, known ischaemic heart disease, pre-
vious cardiac or valve surgery, reduced LVEF (≤50%), and inadequate
echocardiographic data for 2D-STE analysis were excluded.
All clinical data were retrospectively retrieved from the departmental
electronic patient dossier information system (EPD-visionw; Leiden, the
Netherlands) and analysed. All patients were followed up by the treating
physicians according to routine clinical practice. A detailed clinical history
was retrospectively retrieved, focusing on patients’ symptoms that were
deemed to be related to AR by the attending physicians. Subsequently,
patients were divided into two groups based on the presence or
absence of symptoms at the time of first echocardiographic examination.
LV myocardial functions (radial, circumferential, and longitudinal strains)
were evaluated using 2D-STE and compared between symptomatic and
asymptomatic patients. In addition, in the group of patients who were
asymptomatic at the initial echocardiographic examination, the clinical in-
formationwas retrospectively analysed to identify thosewho later devel-
oped symptoms or deterioration in LV function (LVEF ≤50%), meeting
the indications for AV surgery (according to the current guidelines).1,2,16
The institutional review board approved this retrospective analysis
of clinically acquired data and waived the need for patients’ written
informed consent.
Echocardiography
Transthoracic echocardiographic images were acquired at rest with the
patient in the left lateral decubitus position using a commercially available
ultrasound system (Vivid-7 and E9, General Electric Vingmed, Horten,
Norway) and were digitally stored for offline analysis (EchoPAC version
110.0.0, GE-Vingmed). Standard 2D, colour, pulsed, and continuous-
wave Doppler echocardiographic acquisitions were performed.16–18 LV
dimensions were obtained from the standard M-mode images at a para-
sternal long-axis view,18 and LV mass index was calculated according to
Devereux et al. and corrected for body surface area (BSA).18,19 In addition,
the relativewall thickness was calculated as a ratio of (2× PWTd)/LVIDd,
where PWTd is the posterior wall thickness and LVIDd is the LV internal
diameter at end-diastole. Next, LV end-diastolic and end-systolic volu-
mes were measured from the apical views (two- and four-chamber)
using biplane Simpson’s method and corrected for BSA.18 LVEF was sub-
sequently calculated and expressed as a percentage.
Detailed examination of the AV, aortic root, and proximal ascending
aorta were performed according to the standard guidelines.16,18 To
assess AR severity, comprehensive, colour, continuous, and pulsed-wave
Doppler recordingswereperformedaccording to the recommendations
that included the measurement of vena contracta width, regurgitant jet
width, pressure half-time, and diastolic flow reversal in the descending
aorta.16,17 The final grading of AR severity required integration of data
from imaging of the aortic root, AV, and LV.16,17
Two-dimensional speckle tracking
echocardiography
Myocardial deformation can be assessed using 2D-STE, performed
ongreyscale imagesof theLVobtained in the apical two-, three-, and four-
chamber views and parasternal mid-ventricular short-axis view.13–15 An
LV longitudinal strain was evaluated in the three apical views, whereas LV
circumferential and radial strains were evaluated in the mid-ventricular
short-axis view. From the 2D images, the endocardial border wasmanu-
ally traced at end-systole, and the region-of-interest width was adjusted
to include the entire myocardial wall thickness. After verification of
myocardial tracking, the software package (EchoPAC version 110.0.0,
GE-Vingmed) automatically tracked themyocardium.Manual adjustment
wasperformed if necessary. In each echocardiographic view, themyocar-
dium was automatically divided into six segments. Thus, global peak sys-
tolic longitudinal strain was calculated by averaging the peak systolic
values of all the 18 segments, derived from the three apical views (six seg-
ments in each apical view).Global peak systolic circumferential and radial
strains were calculated by averaging the peak systolic values of all the six
segments from the mid-ventricular short-axis view. Accordingly, the
global systolic LV performance was evaluated in all the three myocardial
directions using advanced 2D-STE.
Follow-up and end points
Patients who were asymptomatic were divided into two groups: those
who met and those who did not meet indications for AV surgery at
follow-up.1,2,16 Fromtheclinical andechocardiographic variables recorded
at the time of first echocardiographic examination, independent determi-
nants of AV surgery were identified.
Statistical analysis
Continuous variables were presented as mean and standard deviation.
Categorical variables were presented as frequencies and percentages.
Differences in baseline variables between the two groups were analysed
using unpaired Student’s t-tests (for continuous variables) andx2 or Fisher’s
exact test (for categorical variables). In the group of patients who were ini-
tially asymptomatic at the first echocardiographic examination and were
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followed up conservatively, uni- and multivariate Cox regression analyses
(with an enter method) were performed to identify baseline clinical and
echocardiographic determinants of AV surgery. The independent associ-
ation between LV systolic strains and need of AV surgery, was assessed in
a multivariate Cox regression analysis including known predictors of need
for AV surgery (such as age, gender, LV end-systolic volume index, and AR
vena contracta width)1 into the model. Receiver operating characteristic
(ROC) curve analysiswas performed todetermine the cut-off valueof base-
line LV strain to predict AV surgery at follow-up. All statistical analyses were
performed using SPSS for Windows, version 16 (SPSS, Inc., Chicago, IL,
USA). A two-tailed P-value of,0.05 was considered statistically significant.
Results
Patient population
Atotal of 129patients (age 55+ 17years, 64%male)withmoderate-
to-severe or severe chronic AR were evaluated. Of these, 61 (47%)
patients reported to have symptoms at the time of the first echocar-
diographic examination. Table 1 summarizes the clinical characteris-
tics of patients with and without symptoms recorded at baseline.
Therewere no significant differences in age, gender, and cardiovascu-
lar risk factors between the two groups. In terms of the mechanism
underlying AR, asymptomatic patients were more likely to have
bicuspid AVs but less likely to have inflammatory/infective causes
(Table 1).
Echocardiography in patients
with and without symptoms
Table 2 summarizes the comparison of echocardiographic para-
meters in patients with and without symptoms at baseline. Patients
with symptoms had a significantly larger LV end-diastolic volume
index and a trend towards a larger LV end-systolic volume index
when compared with those without symptoms. Accordingly, the
LVEF was lower in patients with symptoms, although all patients
had by definition a preserved LVEF (.50%). In terms of colour
Doppler assessment of the AR, patients with symptoms had a signifi-
cantly larger vena contracta width, a higher jet to LV outflow tract
width ratio, and a shorter pressure half-time when compared with
those without symptoms (Table 2).
Regarding the assessment of LV performance using 2D-STE,
patients with symptoms demonstrated a significantly larger impair-
ment in myocardial function in all three directions when compared
with those without symptoms (Table 2). Patients with symptoms
had a significant worse longitudinal strain compared with those
without symptoms (214.9+3.0 vs. 216.8+ 2.5%, P, 0.001).
Similarly, circumferential (217.5+2.9 vs. 219.3+ 2.8%, P ¼
0.001) and radial (35.7+ 12.2 vs. 43.1+ 14.7%, P ¼ 0.004) strains
were more impaired in patients with symptoms than in those
without symptoms.
Asymptomatic patients
Of the 68 patients who were initially asymptomatic, 49 patients
had clinical data at follow-up permitting retrospective analysis.
Over a mean follow-up period of 4.2+ 3.2 years (interquartile
range 1.2–6.6 years), 26 (53%) patients progressed to meet indica-
tions for AV surgery (onset of symptoms in 21 patients and LVEF
≤50% in 5 patients). The remaining 23 patients were symptom-free
with preservation of LVEF. Table 3 summarizes the baseline clinical
and echocardiographic data of the 49 asymptomatic AR patients.
Of note, no significant differences in clinical characteristics were
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline clinical characteristics of the study population
Symptomatic (n5 61) Asymptomatic (n 5 68) P-value*
Age (years) 55+16 54+17 0.74
Male, n (%) 42 (69) 40 (59) 0.27
BSA (m2) 1.93+0.21 1.89+0.22 0.26
Heart rate (bpm) 74+13 70+12 0.11
Systolic blood pressure (mmHg) 131+22 134+17 0.50
Diastolic blood pressure (mmHg) 70+14 70+11 0.89
MDRD glomerular filtration rate (mL/min/1.73 m2) 81+24 85+20 0.35
Cardiovascular risk factors
Hypertension, n (%) 41 (67) 40 (59) 0.37
Hypercholesterolaemia, n (%) 21 (34) 19 (28) 0.45
Diabetes, n (%) 7 (11) 4 (6) 0.35
Current smoking, n (%) 23 (38) 18 (26) 0.47
AR aetiology
Degenerative, n (%) 23 (38) 32 (47) 0.38
Bicuspid, n (%) 13 (21) 27 (40) 0.035
Rheumatic, n (%) 3 (5) 2 (3) 0.67
Inflammatory/infective, n (%) 12 (20) 2 (3) 0.003
Annuloaortic ectasia, n (%) 10 (16) 6 (9) 0.29
AR, aortic regurgitation; MDRD, Modification of Diet in Renal Disease.20
*P-values for comparison between symptomatic and asymptomatic patients.
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35Myocardial strains in chronic AR
observed, except that thosewho required surgerywereolder. In par-
ticular, baselineLVvolume indexes, LVEF, andcolourDopplerassess-
ment of the AR were not significantly different between the two
groups (Table 3). However, 2D-STE demonstrated that baseline LV
myocardial strain was significantly more impaired in the longitudinal
(215.7+2.0 vs. 217.6+2.7%, P ¼ 0.009) and circumferential
(218.3+2.4 vs. 220.2+2.9%, P ¼ 0.017) directions in patients
who later required surgery than those who remained symptom-free
without surgery (Table 3).
Next, Cox regression analyses were performed to identify base-
line clinical and echocardiographic determinants of AV surgery.
On univariate analysis, age and LV longitudinal and circumferential
strains were significantly related to AV surgery (Table 4). Table 4
presents thatbesides a largerARvenacontractawidth, both impaired
LV longitudinal and circumferential strains were independently asso-
ciated with AV surgery at follow-up, after correcting for age, gender,
and LV volumes. Importantly, either LV longitudinal or circumferen-
tial strain provided a modest and significant incremental value over
clinical and echocardiographic variables in predicting AV surgery
(Figure 1). By ROC curve analysis, LV longitudinal strain ≥ 217.4%
provided the highest sensitivity (77%) and specificity (57%) to
predict the future need of AV surgery [area under the curve
(AUC) ¼ 0.70, P ¼ 0.008]. Table 5 summarizes the predictive ability
of LV longitudinal strain to identify patients who will require AV
surgery, using several proposed cut-off values. Importantly, LV longitu-
dinal strain ≥ 219.3% provided the highest sensitivity (100%) to
predict AV surgery, with a negative predictive value of 100%. There-
fore, patients with a better longitudinal strain of 219.3% would be
free from symptoms and surgery.
Discussion
The present analysis demonstrated that, despite preserved LVEF,
multidirectional LV strain was more impaired in patients with
moderate-to-severe or severe AR with symptoms than those
without symptoms. Furthermore, in asymptomatic patients with
moderate-to-severe and severe AR, LV strain (in particular, longitu-
dinal strain), as assessed using 2D-STE, appeared to be a valuable
tool to identify patients who are at risk of requiring AV surgery.
Multidirectional myocardial strain
in chronic AR
ChronicARoftenprogresses slowlyover theyears, and theLVadapts
by replication of sarcomeres in series in the presence of chronic
volume overload. This allows for elongation of myocytes, thereby
increasing LV volume to generate a larger stroke volume to maintain
forward output.21–23 The gradual LV enlargement is followed by
LV wall thickening, resulting in the development of eccentric hyper-
trophy. This is an adaptive process in the early course of the disease,
normalizingwall stress andpermittingnormalfillingpressuresdespite
a substantial increase in LV volume overload.22 In addition, LVEF is
normally preserved during the compensated phase of chronic AR,
and many patients may remain asymptomatic for years. With time,
however, the combination of progressive LV enlargement and the
increase in LV pressure will reach a point when it is no longer
offset by an adequate increase in LV wall thickness and will result in
an increase in systolic LV wall stress.21 This afterload mismatch,
together with a limited preload reserve in dilated ventricles, marks
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Table 2 Baseline echocardiographic parameters of the study population
Symptomatic (n 5 61) Asymptomatic (n5 68) P-value*
Conventional echocardiography
LV end-diastolic diameter (mm) 57+8 55+8 0.11
LV end-systolic diameter (mm) 36+9 34+7 0.25
Relative wall thickness 0.39+0.09 0.40+0.06 0.30
LV end-diastolic volume index (mL/m2) 95+33 83+27 0.034
LV end-systolic volume index (mL/m2) 40+16 34+17 0.064
LVEF (%) 59+6 61+5 0.012
LV mass index (g/m2) 134+36 130+37 0.50
LV outflow tract (mm) 24.1+3.2 24.1+3.4 0.97
Aortic sinus (mm) 38.1+6.1 37.5+6.3 0.55
Sinotubular junction (mm) 32.9+6.4 31.6+6.7 0.27
Ascending aorta (mm) 37.2+9.5 34.6+7.1 0.083
Vena contracta width (mm) 6.2+1.1 5.5+1.0 ,0.001
Jet to LV outflow tract width ratio (%) 58+11 50+10 ,0.001
Pressure half-time (ms) 278+95 367+90 ,0.001
Two-dimensional speckle tracking echocardiography
LV longitudinal strain (%) 214.9+3.0 216.8+2.5 ,0.001
LV circumferential strain (%) 217.5+2.9 219.3+2.8 0.001
LV radial strain (%) 35.7+12.2 43.1+14.7 0.004
*P-values for comparison between symptomatic and asymptomatic patients.
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the onset of impairment in LV performance in patients with chronic
AR.23,24 When the LV adaptive mechanisms fail or are inadequate,
symptoms generally occur and LVEF becomes reduced. This,
however, is an insidious process. Although LVEF is a widely accepted
and utilized method for the assessment of LV systolic function, it is a
reflection of the global ejection performance of the LV, which is
derived from volume-based parameters. Given that it is calculated
using geometric assumptions and it is affected by loading conditions,
LVEF alone may not reflect the true LV performance.18
New parameters such as strain imaging are more sensitive techni-
ques than LVEF to assess LV function and to detect subtle changes in
myocardial performance, particularly early in the disease process. In
fact, several studies reported that impairment of myocardial deform-
ation (thickening or shortening) was observed in asymptomatic patients
with chronicmoderate and severeARwith preserved LVEF.11,12 In con-
trast to studies assessing myocardial deformation with tissue Doppler
imaging-derived strain, novel 2D-STE was employed in the present
study. 2D-STE overcomes the angle insonation dependency of tissue
Doppler imaging and permits the assessment of myocardial strain in all
directions (longitudinal, circumferential, and radial).13,14 Importantly,
the present study showed that LVmyocardial strain wasmore impaired
in all the three directions in symptomatic patients with moderate-
to-severe and severe AR when compared with asymptomatic patients,
although all patients had a preserved LVEF by virtue of the inclusion
criteria.
Symptomatic vs. asymptomatic patients
and baseline predictors of AV surgery
In the present study, it is not surprising that the group of patientswith
symptoms exhibited features of more severe AR when compared
with the group of asymptomatic patients. Symptomatic patients
showed larger vena contracta width and LV dimensions, and lower
LVEF. Despite significant differences in LVEF, both groups of patients
had preserved LVEF (.50%). However, when LV function was eval-
uated using 2D-STE, symptomatic patients had significantly more
reduced LV performance when compared with asymptomatic
patients. In a recent longitudinal study of 64 patients who had
moderate-to-severe AR with a wide range of LVEF,25 Olsen et al.25
showed that global LV longitudinal systolic strain was lower in
patients with symptoms of heart failure (n ¼ 26) when compared
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Table 3 Baseline characteristics of asymptomatic patients with clinical and echocardiographic data at follow-up
Need AV surgery (n5 26) No need AV surgery (n 5 23) P-value*
Age (years) 55+16 42+15 0.006
Male, n (%) 16 (62) 15 (65) 1.00
BSA (m2) 1.91+0.17 1.89+0.25 0.75
Heart rate (bpm) 69+15 70+11 0.82
Systolic blood pressure (mmHg) 129+14 133+18 0.47
Diastolic blood pressure (mmHg) 68+12 70+9 0.60
MDRD glomerular filtration rate (mL/min/1.73 m2) 84+19 86+23 0.83
Cardiovascular risk factors
Hypertension, n (%) 15 (58) 11 (48) 0.57
Hypercholesterolaemia, n (%) 8 (31) 4 (17) 0.33
Diabetes, n (%) 3 (12) 1 (4) 0.61
Current smoking, n (%) 8 (31) 4 (17) 0.33
Conventional echocardiography
LV end-diastolic diameter (mm) 55+7 55+6 0.90
LV end-systolic diameter (mm) 35+7 33+6 0.28
LV end-diastolic volume index (mL/m2) 81+30 83+18 0.84
LV end-systolic volume index (mL/m2) 32+15 35+22 0.54
LV ejection fraction (%) 61+5 62+5 0.50
LV mass index (g/m2) 131+33 130+32 0.93
LV outflow tract (mm) 23.6+2.7 24.8+3.5 0.20
Ascending aorta (mm) 35.4+7.7 33.4+5.6 0.30
Vena contracta width (mm) 5.5+1.2 5.3+1.0 0.37
Jet to LV outflow tract width ratio (%) 52+10 48+10 0.24
Pressure half-time (ms) 367+118 374+69 0.83
Two-dimensional speckle tracking echocardiography
LV longitudinal strain (%) 215.7+2.0 217.6+2.7 0.009
LV circumferential strain (%) 218.3+2.4 220.2+2.9 0.017
LV radial strain (%) 38.6+13.8 43.5+13.2 0.22
Abbreviations as listed in Table 1.
*P-values for comparison between patients who developed indications for surgery and those who remained asymptomatic during follow-up.
S.H. Ewe et al.996





37Myocardial strains in chronic AR
with patients without symptoms (n ¼ 38). Our findings extend this
observation to a larger cohort of chronic moderate and severe AR
patients with preserved LVEF.
More importantly, the present study showed that among asymp-
tomaticpatientswithmoderate-to-severeorsevereARandpreserved
LVEF, the group of patientswhowould later requireAV surgery during
follow-up had more impaired LV longitudinal and circumferential
strains when compared with patients who remained asymptomatic.
Very often in clinical practice, the distinction between the onset of
mild symptoms and the total absence of symptoms is challenging,
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Table 4 Uni- andmultivariate determinants of AV surgery in asymptomatic patientswith clinical and echocardiographic
data at follow-up (n5 49)
Variable Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Model included longitudinal strain
Age (years) 1.03 (1.00–1.05) 0.023 1.02 (1.00–1.05) 0.059
Male gender 1.16 (0.51–2.64) 0.725
LV end-systolic volume index (mL/m2) 0.97 (0.98–1.02) 0.706
Vena contracta width (mm) 1.31 (0.89–1.94) 0.173 1.61 (1.02–2.52) 0.041
Longitudinal strain (per 1% worsening) 1.21 (1.02–1.45) 0.030 1.20 (1.01–1.44) 0.044
Model included circumferential strain
Age (years) 1.03 (1.00–1.05) 0.023 1.02 (1.00–1.05) 0.094
Male gender 1.16 (0.51–2.64) 0.725
LV end-systolic volume index (mL/m2) 0.97 (0.98–1.02) 0.706
Vena contracta width (mm) 1.31 (0.89–1.94) 0.173 1.50 (0.95–2.37) 0.079
Circumferential strain (per 1% worsening) 1.18 (1.02–1.36) 0.025 1.22 (1.01–1.46) 0.039
CI, confidence interval; LV, left ventricular; HR, hazard ratio.
Figure 1 Incremental value of LV peak systolic longitudinal (or circumferential) strain over clinical and echocardiographic variables in predicting
AV surgery in asymptomatic patientswith clinical and echocardiographic data at follow-up (n ¼ 49).Model 1 included clinical variables (age andmale
gender). Model 2 included clinical and echocardiographic variables (LV end-systolic volume index and vena contracta width of the AR jet). Model 3
included clinical and echocardiographic variables and advanced speckle tracking strain imaging-derived LV peak systolic longitudinal strain. Corre-
sponding values for peak systolic circumferential strain are given in parentheses.
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and if the decision to proceed with corrective surgery is based exclu-
sivelyonLVEForsymptomsonsetalone, it ispossible that significantLV
dysfunction has already developed, thereby precluding full benefit of
AV surgery. In a series of 52 patients with chronic severe AR undergo-
ing surgery, Onishi et al.26 demonstrated that preoperative LV radial
strain rate had the largest AUC among other parameters (including
LVEF or LV dimensions) in predicting postoperative LV dysfunction
at 12 months.26 A recent study by Kusunose et al.27 also showed
that resting global LV strain, using velocity vector imaging, was inde-
pendently associated with the need for early valve surgery in asymp-
tomatic patients with moderately severe-to-severe AR. In line with
this, the present study demonstrated that the presence of subtle
myocardial changes occurring early in the disease process could be
detected by 2D-STE, when other conventional parameters remain in-
distinguishable during the follow-up of asymptomatic patients with
chronicAR. In fact, amoremarked impairment in both the longitudinal
and circumferential strains was already noted at the time of first echo-
cardiography inpatientswho later requiredAVsurgerycomparedwith
patientswhodid not need surgeryon follow-up. This is also consistent
with the findings ofOlsen et al.,25 who demonstrated that impaired LV
longitudinal strainwasassociatedwithdiseaseprogressionor impaired
outcomes after surgery in 62 patients with moderate-to-severe AR,
although nomultivariate analysis was performed in that study. Import-
antly, the present study showed that either LV longitudinal or circum-
ferential strainprovideda significant incremental valueoverclinical and
established echocardiographic predictors of poor outcome, including
LV volume and parameters of AR severity (vena contracta width),1 in
predicting those who would require AV surgery. Moreover, when
applying the LV longitudinal strain cut-off value of 219.3% (which
has a negative predictive value of 100%), it is capable of ruling out
the risk of developing indications for AV surgery and thus, watchful
waiting should be recommended. Accordingly, LV longitudinal strain
may be viewed as a sensitivemarker for detectionof subtlemyocardial
changes andmayserve asapotential screening tool inclinical risk strati-
fication of asymptomatic patients with chronic moderate-to-severe
AR and preserved LVEF. It has the ability to identify those at risk,
when the longitudinal strain was more impaired, in whom more
aggressive follow-up and early intervention should be considered.
We acknowledge that, due to the relatively small population, the
present study should be considered as a hypothesis-generating study
to examine the ability of LV strain in the predictionofAV surgery. Add-
itional prospective studies including a larger patient population are
warranted to further validate the usefulness of LV longitudinal strain
for accurately predicting the need for AV surgery in asymptomatic
AR patients with preserved LVEF.
Conclusions
Multidirectional LV strain was more impaired in patients with
moderate-to-severe or severe AR who had symptoms than those
without symptoms, although LVEF was still preserved. Furthermore,
subtle impairment in myocardial function, detectable with 2D-STE,
can be used to identify asymptomatic patients who progress to
require AV surgery during follow-up.
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Abstract During the last decade, the development
of transcatheter based therapies has provided feasible
therapeutic options for patients with symptomatic
severe valvular heart disease who are deemed inop-
erable. The promising results of many nonrandom-
ized series and recent landmark trials have increased
the number of percutaneous transcatheter valve proce-
dures in high operative risk patients. Pre-procedural
imaging of the anatomy of the aortic or mitral valve
and their spatial relationships is crucial to select the
most appropriate device or prosthesis and to plan the
percutaneous procedure. Multidetector row computed
tomography provides 3-dimensional volumetric data
sets allowing unlimited plane reconstructions and
plays an important role in pre-procedural screening
and procedural planning. This review will describe
the evolving role of multidetector row computed
tomography in patient selection and strategy planning
of transcatheter aortic and mitral valve procedures.
Keywords Transcatheter heart valve implantation 
Computed tomography  Imaging
Introduction
During the last decade, the development of trans-
catheter based therapies has provided feasible ther-
apeutic options for patients with symptomatic severe
valvular heart disease who are deemed inoperable.
The promising results of many nonrandomized series
and recent landmark trials, such as the PARTNER
trial with the Edwards SAPIEN transcatheter aortic
valve prosthesis (Edwards Lifesciences, Irvine, CA,
USA) or the EVEREST II trial with the MitraClip
device (Abbott Vascular, Structural Heart, Menlo
Park, CA, USA), have increased the number of
percutaneous transcatheter valve procedures in high
operative risk patients [1, 2].
In contrast to open heart surgery where direct
inspection of the valve is possible, the decision for
device/prosthesis selection and planning of the per-
cutaneous procedure is mainly based on pre-proce-
dural imaging of the anatomy of the aortic or mitral
valve and their spatial relationships. These data are
usually acquired using 2-dimensional (2D) imaging
modalities such as conventional echocardiography
and/or invasive angiography. However, 2D echocar-
diography imaging relies on geometrical assumptions
that may reduce the accuracy of the measurements
while fluoroscopy has limited soft-tissue resolution.
In contrast, advanced cardiovascular imaging modal-
ities such as multidetector row computed tomography
(MDCT), provide detailed information on the afore-
mentioned anatomy. MDCT, which has the advantage
S. H. Ewe  R. J. Klautz  M. J. Schalij  V. Delgado (&)
Department of Cardiology and Cardio-Thoracic Surgery,
Leiden University Medical Center, Albinusdreef 2,
2333 ZA Leiden, The Netherlands
e-mail: v.delgado@lumc.nl
123
Int J Cardiovasc Imaging (2011) 27:1179–1193
DOI 10.1007/s10554-011-9830-5
45Role of CT in transcatheter valvular interventions
of 3-dimensional (3D) volumetric data sets allowing
unlimited plane reconstructions, plays an important
role in pre-procedural screening and procedural
planning with the aim of minimizing procedural-
related complications. This review will describe the
evolving role of MDCT in patient selection and
strategy planning of transcatheter aortic and mitral
valve procedures.
Transcatheter aortic valve implantation
Transcatheter aortic valve implantation (TAVI) has
emerged as an effective alternative in high risk
patients with symptomatic severe aortic stenosis
(AS). Recently, this percutaneous intervention has
demonstrated superior survival at 1 year over stan-
dard therapy (69.3% vs. 49.3%, with an absolute 20%
increase with TAVI procedure) in a selected group of
patients with AS who were deemed not suitable for
aortic valve surgery [1]. In addition, a recent review
involving more than 2,000 patients receiving TAVI
reported an implantation success of 94% and a 30-day
survival rate of 89% [3]. Accurate assessment of the
anatomy of the peripheral arteries and aorta, together
with the anatomy of the aortic valve, aortic annular
and root dimensions, are the key determinants of
procedural feasibility and safety.
Pre-procedural patient evaluation
The multidisciplinary pre-procedural evaluation of
patients who are candidates for TAVI includes the
assessment of the aortic valvular complex, including
the aortic valve and aortic root (for determination of
anatomical suitability and prosthesis sizing), and the
anatomy of the peripheral arteries and aorta (for
determination of the access site) (Table 1).
First, assessment of the aortic valve should begin
with confirmation of the aortic valve morphology.
Usually, this can easily be identified from the short-
axis view on transthoracic echocardiography, which
remains the initial modality of choice to assess the
aortic valve pathology and its hemodynamic conse-
quences [4]. However, in patients with poor acoustic
windows and/or in the presence of heavy calcifica-
tion, differentiating tricuspid from bicuspid valvular
anatomy may be challenging [5]. This information is
important before the procedure as it is currently not
recommended to perform TAVI on bicuspid valves
due to the potential risk of an unfavorable deploy-
ment [6, 7]. In a recent study of 50 patients with AS
(17 bicuspid and 33 tricuspid) [8], transthoracic
echocardiography was unable to identify the anatomy
of the valve in 10 patients (20%) due to extensive
calcification. In contrast, MDCT was able to provide
direct visualisation of the aortic valve and thus could
correctly identify the valve anatomy in 49 of 50 cases
(98%) [8]. Furthermore, the accuracy of the patient
selection process can be further improved with
additional systolic reconstruction using ECG-gating,
which permits differentiation between a bicuspid
valve with raphe and a tricuspid valve [9].
Next, the assessment of the extent and location of
the aortic valve calcification is important before the
TAVI procedure. With high spatial resolution and the
possibility of direct visualization of the aortic valve,
MDCT allows detailed analysis of the quantification
and localization of aortic valve calcification (Fig. 1).
Several studies [10–12] have indicated the signifi-
cance of aortic valve calcification and its specific
location, as assessed by MDCT, in relation to the
presence of post-procedural aortic regurgitation. For
example, in a study of 100 patients who underwent
TAVI with self-expandable devices, John et al. [11]
demonstrated a strong linear correlation (r = 0.86,
P\ 0.001) between the degree of aortic regurgitation
immediately post-TAVI and the severity of calcifi-
cation in the device ‘‘landing zone’’, defined as the
area extending from the left ventricular outflow tract
to the aortic valvular cusps. Similar findings were
reported in a series of 53 patients undergoing TAVI
[10] whereby moderate post-procedural aortic regur-
gitation following the implantation of balloon-
expandable valves was found in patients who exhib-
ited more calcification of the native aortic valves,
especially at the valve commissures (Fig. 1). It has
been suggested that bulky calcification may pose
resistance during the deployment of the prosthesis,
resulting in paravalvular leakage arising from the gap
between the prosthesis and the native valve [13]. In
addition, very bulky calcification at the edge of native
valvular leaflets has been related to increased risk of
coronary occlusion when it is displaced over the
coronary ostium [14]. Furthermore, TAVI has to be
performed with caution when there is heavy calcifi-
cation in the sinotubular junction as it may cause
restriction during balloon expansion at the aortic end,
1180 Int J Cardiovasc Imaging (2011) 27:1179–1193
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causing ventricular displacement of the device at the
time of deployment [15]. Hence, appreciation of the
extent and location of calcification, more precisely
measured using MDCT, may help to anticipate and
thus avoid potential procedural complications.
Besides its implications on the procedural outcome
of TAVI, the assessment of aortic valve calcification
can be a useful adjunct in the evaluation of AS
severity during pre-procedural screening [16, 17]. In
a recent study, the degree of aortic valve calcification
Table 1 Evaluation before transcatheter aortic valve implantation: anatomic requirements of the currently available prosthesis
Anatomy CoreValve revalving system Edwards SAPIEN XT
26 mm 29 mm 23 mm 26 mm
Peripheral arteries and aorta






Annular diameter (mm) 20–23 24–27 18–22 21–25
Aortic root
Sinus of Valsalva diameter (mm) C27 C28 NA
Sinotubular junction diameter (mm) B40 B43 NA
Ascending aorta diameter (mm) B43 NA
Height of the coronary ostia from the
aortic annular plane (mm)
C10 C8
Left ventricular septal thickness (mm) \17 NA
Coronary artery anatomy Not in severe proximal coronary lesions
not amenable to revascularization
Not in severe proximal coronary lesions
not amenable to revascularization
Intracardiac thrombus Absent Absent
Fig. 1 Aortic valve calcification assessed using multidetector
row computed tomography (MDCT): implications for trans-
catheter aortic valve implantation. a shows a calcified tricuspid
aortic valve with bulky calcification mainly in the left cusp,
left–right commissure and extending to the base of the anterior
mitral valve leaflet (indicated by arrows in b). Following
TAVI, paravalvular leak was observed with colour Doppler
transesophageal echocardiography in the long-axis view
(c) that coincided with the location of bulky calcification at
the left–right commissure on MDCT (in a). In this example, the
bulky calcified cusp and commissure might pose resistance
during transcatheter prosthesis deployment, resulting in
subsequent paravalvular leak (arising from the gap between
the prosthesis and native valve). LA left atrium, RV right
ventricle
Int J Cardiovasc Imaging (2011) 27:1179–1193 1181
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measured using MDCT was highly correlated with
the hemodynamic severity of AS measured using
echocardiography [16].
Accurate evaluation of the aortic valve annular
dimension is key for appropriate selection of pros-
thesis size. This process is unique in percutaneous
procedures as direct inspection of the valve is not
possible. Currently, the Edwards SAPIEN XT device
is available in two sizes: 23 mm valve for aortic
annulus between 18 and 22 mm and 26 mm valve for
aortic annulus between 21 and 25 mm. Similarly, the
Medtronic CoreValve system has two sizes: 26 mm
valve for aortic annulus between 20 and 23 mm and
29 mm valve for aortic annulus between 24 and
27 mm (Table 1) [18]. This step is critical as
inaccurate sizing will result in undesirable peri-
procedural consequences such as prosthesis migra-
tion, significant aortic regurgitation (if undersized) or
rupture of the aortic root (if oversized). In most
centers, the measurement of the aortic annular
diameter is performed using 2D echocardiography.
In clinical practice, it is widely recognised that the
aortic annulus is defined at the lowest attachment
point of the aortic valve leaflets within the left
ventricle (LV), forming a virtual ring [19]. As
previously shown, this functional ring is not circular
but oval in shape (Fig. 2), and is more accurately
visualized with 3D imaging techniques [20, 21]. In a
recent study of patients undergoing open aortic valve
surgery, Smı́d et al. [22] compared pre-operative
measurements of the aortic annulus using MDCT,
magnetic resonance imaging (MRI) and 2D trans-
esophageal echocardiography. Using intra-operative
direct measurement as the reference, the accuracy of
pre-operative measurement using either MDCT or
MRI were superior compared to echocardiographic
measurement, highlighting the high precision achiev-
able with MDCT [22]. This is partly due to the high
spatial resolution of MDCT which permits improved
visualization of the aortic valve. Another explanation
is that the anatomical planes of measurement
obtained with different modalities are not identical
[23, 24]. For example, the parasternal long-axis view
for transthoracic or transesophageal echocardiogra-
phy represents an oblique cut through the aortic
annulus and provides a single annular dimension that
usually does not correspond to a true anatomical
diameter measurement (either the maximum or
minimum diameter visualised on MDCT) (Fig. 2).
Given that the aortic annulus is oval in shape, only
3D imaging techniques can provide the most accurate
assessment of the aortic annulus dimension. As such,
MDCT permits reconstructions in unlimited planes,
allowing multiple measurements of the aortic annulus:
minimum (Dmin), maximum (Dmax), mean (Dmean =
[Dmin ? Dmax]/2) diameters and cross-sectional areas
(Fig. 2) [21, 25]. Depending on how the aortic
annulus is measured, the selection of the prosthesis
size may differ. For example, in a recent study of 75
patients with severe AS undergoing MDCT as part
of procedural planning for TAVI, Schultz and
co-workers [25] showed that ineligibility for the
currently available Medtronic CoreValve system
differed substantially if Dmin or Dmax were used.
Thus, 26 or 39% of patients would not qualify for
TAVI with Medtronic CoreValve system due to too
small or too large annular dimensions, respectively. In
50 patients who subsequently received the Medtronic
Fig. 2 Aortic valve annular dimensions. Multidetector row
computed tomography (MDCT) permits excellent visualization
of the oval-shaped aortic annulus with correct alignment of the
orthogonal multiplane reformation planes (a and b). The
correct aortic annular plane is defined at the lowest attachment
point of all the three valve leaflets (c) and multiple
measurements of the aortic annulus can be made: minimum
(Dmin), maximum (Dmax), mean (Dmean = [Dmin ? Dmax]/2)
diameters and cross-sectional areas (CSA)
1182 Int J Cardiovasc Imaging (2011) 27:1179–1193
123
48 Chapter 4
CoreValve prosthesis, the sizing based on Dmean had
the best agreement with the operator choice (n = 37,
74%), whereas the agreement with the operator choice
was only 44 or 32% if Dmin or Dmax were used,
respectively [25]. For the Edwards SAPIEN prosthe-
sis, Messika-Zeitoun et al. [26] reported that using
Dmean, as measured by MDCT, would have changed
the prosthesis size in 38% of patients. Prospective
studies examining the value of different imaging
modalities in sizing of prosthesis and its immediate
impact on procedural outcomes are lacking but are
important to establish the gold standard methodology
to size the aortic valve annulus and select the
prosthesis size.
In addition, the assessment of the dimensions of the
sinus of Valsalva, sinotubular junction and ascending
aorta is an essential step in the pre-procedural
evaluation. Using the ‘‘center-line approach’’ and
reformations of the aortic root and ascending aorta,
MDCT permits accurate measurement of these
dimensions. This information is critical especially
in patients undergoing the self-expandable device
implantation as a dilated aortic root/ascending aorta
is currently a contraindication (Table 1) [6].
Next, the 3D analysis of MDCT permits compre-
hensive and detailed evaluation of the spatial rela-
tionship of the aortic valve with the surrounding
structures. In particular, the information on the height
of the coronary ostia relative to the aortic annular
plane is important to ensure patency of the coronary
arteries following ballooning and deployment of the
transcatheter prosthesis (Fig. 3). Currently, a mini-
mum distance of 10 mm is recommended for both
devices [18]. In addition, MDCT is an ideal modality
to measure the length of the valvular leaflets as it can
potentially increase the risk of coronary occlusion,
notably in patients with bulky calcification of the
aortic leaflets (Fig. 3b) [14]. However, this require-
ment may vary from individual to individual as the
final position of the prosthesis depends on the
interaction between the prosthesis and the aortic
annulus [15].
Fig. 3 Assessment of the height of the coronary ostia relative
to the aortic annular plane. Multidetector row computed
tomography (MDCT) permits accurate orientation of the aortic
annular plane (a) and precise measurement of the distance
between the left and right coronary ostia and the annular plane
(b and c). In addition, the length of the valvular leaflet,
measured from the aortic annulus to the cusp tip, can be
obtained on MDCT (red arrow in b)
Int J Cardiovasc Imaging (2011) 27:1179–1193 1183
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Finally, evaluation of the peripheral access artery
and aortic anatomy is fundamental to plan the
procedural strategy: retrograde (through a transarte-
rial approach, transfemoral or transsubclavian) or
antegrade (through a transapical approach). Although
recent advances have allowed for a lower crimped
profile delivery device, the transfemoral approach for
self- or balloon-expandable systems can only be con-
sidered when the minimal diameter of the iliofemoral
vessel is C6 mm (to accommodate a 18F sheath size)
[27]. As adequate access is one of the most important
determinants of procedural success [28], the decision
for selecting the transfemoral approach relies on the
precise measurement of vessel dimension, tortuosity
and calcification of the peripheral arteries and aorta
[6]. In the recent multicenter SOURCE registry of
1,038 patients who received a balloon-expandable
prosthesis, the rate of vascular complications with the
transfemoral approach was higher (22.9% vs. 4.7%)
when compared with the transapical approach, high-
lighting the need for careful patient selection, to
select the most suitable procedural approach to avoid
procedural-related vascular complications [29].
Although conventional angiography is the refer-
ence method to assess the luminal diameter, tortuos-
ity and calcification of the peripheral arteries and
aorta [6], true cross-sectional diameters and areas are
better visualized on MDCT. Typically, the curved
multiplanar reformation planes (MPR), using the
‘‘center-line approach’’, permits reconstruction of the
curved planes, following the course of the vessel
regardless of its tortuous course. Ideally, the precise
measurement of the vascular structures should be
obtained from the axial view, perpendicular to the
long axis of the vessel (Fig. 4c, d). In the presence of
calcification, the blooming effect has to be brought to
a low level when these measurements are being
performed.
With the 3D volume rendering images, current
MDCT techniques permit rotation and display to best
define the total number and severity of angulations
along the vessel of interest. Post-processing imaging
software is available to detect all angulations along
the vessel automatically and allows precise measure-
ment of the severity of angulations (Fig. 4e), which
helps to systematically quantify the extent of tortu-
osity in patients who are being considered for a
transfemoral procedure. In addition, MDCT can
accurately delineate the location and the extent of
calcification along the vessel. This is particularly
important in case of a tortuous vessel as significant
calcification does not allow straightening of the
vessel during advancement of the sheath and should
prompt the consideration of an alternative access
(either the transapical or transsubclavian approach).
Furthermore, severe calcification at the bifurcation of
the iliac vessels may become a concern for the
transfemoral approach as it may restrict sheath
advancement and increase the risk of vessel perfora-
tion or dissection. In a recent study by Kurra et al.
[30] that examined 100 patients who were considered
for TAVI, as many as 35% of patients had unsuitable
iliofemoral anatomy defined as one of the following:
minimal diameter of the iliofemoral vessel \8 mm
(a requirement for the older generation delivery
system), [60% circumferential calcification at the
external-internal iliac bifurcation or severe angulation
\90. Among those with MDCT criteria of unsuit-
able anatomy (n = 35), 5 patients proceeded with
transfemoral-TAVI. Of these 5 patients, 2 (40%) had
vascular complications requiring surgical interven-
tion [30].
Besides the anatomical requirement of the ilio-
femoral arteries, the pre-procedural assessment of the
aorta and its lumen is necessary as it may guide the
approach of TAVI. Presence of bulky atherosclerosis
of the aorta, a porcelain aorta, a transverse course of
the ascending aorta or a previous aorto-femoral
bypass is a contraindication for the transfemoral
approach [6]. Fluoroscopy, commonly used to eval-
uate the luminal diameter of the peripheral arteries,
does not allow accurate assessment of arterial wall
disease or atherosclerotic plaques. In contrast, MDCT
provides a comprehensive evaluation including arte-
rial luminal diameter and wall assessment. The pres-
ence of extensive aortic atherosclerosis as detected
with MDCT may preclude the transfemoral approach
due to the increased risk of cerebrovascular events
during manipulation of the catheters along the
diseased aorta.
Although suitable vessel anatomy is the key
consideration in the transfemoral approach, other
aspects need to be considered, which may favour one
approach over another. For instance, pericardial
calcification, a deformed chest wall anatomy or
severe pulmonary disease may make the transapical
approach unsuitable and MDCT is helpful to provide
such information.
1184 Int J Cardiovasc Imaging (2011) 27:1179–1193
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Planning of interventional access planes
Pre-operative CT has been demonstrated to accu-
rately predict the location of the aortic valve and
ascending aorta relative to the chest wall in patients
undergoing a minimally invasive approach for aortic
valve replacement [31]. Several groups have reported
that 3D data obtained from MDCT can help to predict
the fluoroscopic projections that are optimal for
TAVI procedures [32–34]. An ideal angiographic
plane (the so called ‘‘implanter’s view’’) should be
the projection that aligns all three aortic cusps in a
straight line, perpendicular to the aortic valve plane
(Fig. 5) [15]. A recent study by Gurvitch et al. [32]
compared 2 groups of patients who underwent
TAVI with (20 patients) and without (20 patients)
pre-procedural MDCT. When MDCT information
was available to guide the fluoroscopic projection
angle, an excellent or satisfactory final implant
projection was achieved in 90% of cases (n = 18),
as compared to only 65% of cases (n = 13) when
pre-procedural MDCT was not available [32].
With regard to the transapical approach, the
relation of the LV apex and the aortic annulus plane
(the so called ‘‘ventriculo-aortic angle’’) can be
important (Fig. 6). Recently, the first-in-man series
of a new self-expanding prosthesis implantation via
the transapical approach was reported in 30 patients
[35]. The initial experience highlighted the impor-
tance of this ventriculo-aortic angle, which may pose
as a challenge during the introduction of a straight
and rigid delivery system (via the LV apex) which
Fig. 4 Evaluation of peripheral arteries with multidetector
row computed tomography (MDCT). a shows an example of
infrarenal aorta, iliac and femoral arteries in a 3-dimensional
volume rendering view. Using the center-line approach, the
curved multiplanar reformation (MPR) permits reconstruction
of the curved planes, following the course of the vessels.
Subsequently, the true cross-sectional internal diameter and
area of the iliac artery can be measured from the double
oblique transverse view in (c and d). With the current MDCT
post-processing imaging software (3mensio ValvesTM, version
4.2., 3mensio Medical Imaging BV, Bilthoven, The Nether-
lands), the minimum diameter threshold required for the
currently available transfemoral devices is 6 mm (18 Fr) and
this minimum requirement is simultaneously displayed side-
by-side in the curved MPR views (b). Therefore, the presence
of a minimal luminal diameter of the iliofemoral arteries
\6 mm does not favor the transfemoral approach. In contrast,
the example in d shows a vessel with a minimal luminal
diameter[6 mm, as indicated by the dotted green circle which
is larger than the size of a simulated 18 Fr sheath (in solid red
circle). In addition, the 3-dimensional reconstruction volume
rendering technique of MDCT allows rotations and displays the
tortuous course of the iliofemoral arteries. e gives the precise
measurement of one of the angulations seen in the left external
iliac artery (51), rendering it unsuitable for the transfemoral
approach
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may not be able to conform to this angle, subjecting
patients to a risk of aortic dissection when the device
is advanced into the ascending aorta [35]. Novel 3D
based post-processing imaging software is currently
available to permit direct visualization of this ventri-
culo-aortic relationship to aid in the planning for the
Fig. 5 Planning of angiographic planes. Using reformation
reconstruction of multidetector row computed tomography
(MDCT), the appropriate aortic valve plane for transcatheter
aortic valve implantation can be anticipated (a). The ideal
angiographic projection should be one that aligns all the three
aortic cusps in a straight line, perpendicular to the aortic valve
plane (b). LCC left coronary cusp, NCC non-coronary cusp,
RCC right coronary cusp
Fig. 6 Assessment of the left ventricular geometry may be of
relevance in the planning of the transapical approach. The
relation of the left ventricular apex and the aortic annulus valve
plane (the so called ‘‘ventriculo-aortic angle’’) can be reliably
measured on multidetector row computed tomography
(MDCT). Insert a shows the direction of a simulated delivery
system through the left ventricular apex, towards the aortic
valve. In addition, the thickness of the left ventricular septum
wall can be measured on MDCT (arrow in insert b). Post-
processing imaging software (3mensio ValvesTM, version 4.2.,
3mensio Medical Imaging BV, Bilthoven, The Netherlands)
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transapical approach. This allows the anticipation of
the angulation required during insertion of the apical
sheath and the delivery system, towards the direction
of the aortic valve and the ascending aorta (Fig. 6). In
addition, the measurement of the LV septal wall
thickness with MDCT is important (Fig. 6b) as the
presence of severe sigmoid basal septum may pre-
vent stable positioning of the deployed prosthesis
(Table 1).
Other factors to be considered before TAVI
In addition to the aforementioned considerations,
additional factors need to be evaluated before TAVI,
which completes the pre-procedural screening. The
evaluation of coronary artery anatomy is mandatory
as the presence of significant coronary artery disease
needs to be revascularized. Current position state-
ment does not recommend TAVI in patients with
severe proximal coronary stenoses not amenable to
percutaneous coronary interventions [6]. Although
MDCT has shown its diagnostic accuracy in the
evaluation of coronary artery disease [36], the
prevalence of coronary atherosclerosis in the elderly
population may limit its accuracy in detecting
significant coronary artery stenoses. Therefore, inva-
sive coronary angiography remains the reference
modality to evaluate the coronary anatomy in this
highly selected group of patients [6].
Finally, LV dimensions, function and the presence
of concomitant mitral regurgitation (MR) need to be
evaluated before TAVI. This information is usually
available from the standard echocardiography, which
is still the initial imaging modality in patients
scheduled for TAVI. However, in patients with poor
acoustic window, MDCT allows assessment of LV
dimensions and function using ECG-gating. More
importantly, it permits detection of intracardiac
thrombus, which is an established contraindication
for TAVI (Table 1) [6].
Transcatheter mitral valve repair procedures
Mitral valve repair is the treatment of choice for
patients with symptomatic MR [4]. Advances in
surgical techniques have led to improved clinical
results in young and elderly patients [37]. However,
associated comorbidities and low LV ejection
fraction increase the operative morbidity and mortal-
ity risks in the elderly population and may lead to
non-referral or denial for surgery in as many as 50%
of the patients with symptomatic severe MR [38].
Transcatheter-based and minimally invasive sur-
gical therapies have been developed over the last
years. Several therapeutic options are now available
for patients with symptomatic severe MR and high
operative risk. These percutaneous techniques can be
classified as leaflet-based (edge-to-edge repair,
Mitraclip device [Abbott Vascular, Structural Heart,
Menlo Park, CA, USA]), coronary sinus or mitral
annulus-based (Carillon, Monarc or Viacor devices
and Quantum cor and Mitralign devices, respectively)
and LV-based (Coapsys device [Myocor, Maple
Grove, MN]). The EVEREST II trial has shown the
feasibility, safety and efficacy of the Mitraclip device
in reducing MR and improving clinical symptoms
[39]. In addition, initial experiences with devices
designed to reduce the mitral annulus perimeter and
improve the mitral leaflet coaptation (the AMADEUS
and the EVOLUTION trials) demonstrated that trans-
catheter mitral restrictive annuloplasty approaches
may be a feasible alternative to surgery in selected
patients [40–42]. Furthermore, the results of the
RESTORE-MV trial showed that patients with func-
tional MR benefited from ventricular reshaping with
the Coapsys device, with significant improvement in
clinical symptoms and survival [43].
The feasibility and efficacy of these transcatheter-
based or minimally invasive surgical therapies rely on
the presence of suitable valve and LV anatomy and
geometry. Evaluation of the underlying mechanism of
MR is crucial to select the most appropriate trans-
catheter based therapy (Table 2). In brief, MR can be
divided into organic or primary MR when the mitral
valve itself is diseased (i.e. Barlow’s disease, healed
infective endocarditis) and secondary or functional
MR when the mitral valve is anatomically normal but
a remodeled and dysfunctional LV prevents adequate
coaptation of the mitral leaflets. Two-dimensional and
recently, 3D transesophageal echocardiography are
the mainstay imaging techniques used in surgical
decision-making (mitral valve repair or replacement).
However, the high spatial resolution of MDCT
permits accurate assessment of the anatomy, geometry
and spatial relationships of the mitral valve complex
and thus provides important information for selecting
candidates for these therapies.
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MDCT before mitral leaflet repair
The Mitraclip device is delivered to the mitral valve
via percutaneous femoral venous transseptal puncture
and creates a double-orifice valve, resulting in
improved mitral leaflet coaptation and MR reduction.
After crossing the interatrial septum, the delivery
system is steered toward the mitral valve plane and
the clip is aligned perpendicular to the mitral leaflets
and centered in the area with the largest effective
regurgitant orifice area. Afterwards, the delivery
system is advanced into the LV and the arms of the
clip are opened for subsequent grasping and coapta-
tion of the leaflets at the targeted scallops.
Transesophageal echocardiography plays a central
role in pre-procedural screening and procedural
guidance during the intervention. Current 3D trans-
esophageal echocardiography permits visualization of
the mitral valve from multiple perspectives, orienta-
tion of the MPR to localize the largest regurgitant
orifice and accurate characterization of the underly-
ing mechanism of MR. Similarly, MDCT enables
accurate 3D visualization of the mitral leaflets and
detailed evaluation of the anatomic criteria essential
in percutaneous Mitraclip implantation:
– Central regurgitant jet, located at the central
scallops of the anterior (A2) and posterior (P2)
mitral leaflets.
– Coaptation length C2 mm and coaptation depth
B11 mm (for functional MR).
– flail gap \10 mm and flail width \15 mm (for
organic MR).
Multidetector row computed tomography data
reconstructed in smaller (such as 5%) increments
throughout the RR interval provide high spatial
resolution images with improved temporal resolution
and enable identification of the systolic frame where
mitral leaflet coaptation failure occurs.
In addition, MDCT provides information on the
underlying mechanism of MR. For example, the
diagnostic performance of MDCT to identify mitral
valve prolapse was recently evaluated in a series of
53 patients [44]. The orientation of the MPR across
the mitral valve plane provides the LV 4-, 2- and
3-chamber apical views and enables localization of
the mitral valve prolapse, billowing and flail leaflet
(Fig. 7). The sensitivity, specificity, positive predic-
tive value and negative predictive value of MDCT for
diagnosis of mitral valve prolapse were 96, 93, 93
and 96%, respectively [44]. Furthermore, the assess-
ment of the mitral valve geometry and the measure-
ment of the tenting heights (coaptation depth) and
leaflet angles can be accurately performed in patients
with functional MR [45]. The orientation of the
orthogonal MPR across the modified short-axis view
of the mitral valve provides the 4-chamber view at
the anterolateral (A1–P1), central (A2–P2) and pos-
teromedial (A3–P3) levels (Fig. 8). In a series of 67
heart failure patients, including 29 patients with
significant functional MR, the mitral valve geometry
was evaluated with MDCT [45]. In patients with
significant MR, the maximum tenting height and
tethering of the posterior mitral leaflet were located at
the central and posteromedial levels. The knowledge
of these data beforehand permits accurate planning of
the procedural strategy and may result in a significant
shortening of fluoroscopy and procedure timings.
MDCT before coronary sinus annuloplasty
Coronary sinus-based mitral annuloplasty devices
have been designed to treat functional MR percuta-
neously. Two anchors or stents connected by a bridge
Table 2 Transcatheter-based mitral valve repair techniques
Mitral valve repair technique Device Trial Indication
Leaflet repair MitraClip EVEREST I
EVEREST II
Organic mitral valve regurgitation
Functional mitral valve regurgitation






Functional mitral valve regurgitation
Direct LV remodelling Coapsys RESTOR-MV Functional mitral valve regurgitation
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element are placed within the distal part of the
coronary sinus or the great cardiac vein and in the
coronary sinus ostium. The bridging connector con-
straints the coronary sinus and reduces the antero-
posterior diameter of the mitral annulus, improving
the coaptation of the mitral leaflets and reducing the
MR. Data from the AMADEUS trial have demon-
strated the feasibility, safety and efficacy of this
therapy [42]. Out of 48 heart failure patients enrolled
with significant functional MR, 30 patients received
the Carillon device (Cardiac Dimensions, Inc., Kirk-
land, WA). At 6 months follow-up, significant reduc-
tions in regurgitant volume, effective orifice
regurgitant area and vena contracta were observed,
together with significant improvements in clinical
status [40]. However, one of the main concerns of this
therapy is the possibility of impingement of the
epicardial coronary arteries. In 17% of implants, a
significant arterial impingement involving the cir-
cumflex coronary artery was observed. In addition, an
Fig. 7 Evaluation of underlying mechanism of mitral regur-
gitation with multidetector row computed tomography
(MDCT). Mitral valve prolapse can be identified accurately
with MDCT. a shows an example of a patient with prolapse of
the posterior leaflet (arrow). Color Doppler echocardiography
permits quantification of the regurgitant volume and the
direction of the regurgitant jet (b). Modified with permission
from Feutchner et al. [44]
Fig. 8 Mitral valve geometry assessment with multidetector
row computed tomography (MDCT) in functional mitral
regurgitation. From the short-axis view of the mitral valve at
the level of the mitral leaflets and commissures, the orthogonal
planes across the anterolateral (A1–P1), central (A2–P2) and
posteromedial (A3–P3) provide the apical views of the mitral
valve apparatus and permits the measurement of the leaflet
angles and tenting heights (arrows)
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insufficient change in MR grade was observed in 4
patients. The variable position and course of the
coronary sinus relative to the mitral annulus is one of
the determinants of the efficacy of this therapy.
Multidetector row computed tomography provides
useful information on the dimensions of the coronary
sinus and its position relative to the mitral annulus
and the circumflex coronary artery [46–48]. Com-
bining the axial views and 3D volume renderings,
MDCT permits evaluation of the feasibility and
safety of coronary sinus-based mitral annuloplasty
procedures (Fig. 9). Tops et al. [47] evaluated the
dimensions, course and spatial relationships of the
coronary sinus in 105 patients undergoing MDCT. In
90% of patients, the coronary sinus was superior to
the mitral valve annulus with a distance that ranged
between 1.4 and 16.8 mm. Importantly, this distance
was significantly larger in patients with heart failure
as compared to controls (6.2 ± 3.4 mm vs. 4.4 ±
3.4 mm, P\ 0.05). Therefore, in a significant num-
ber of patients the coronary sinus coursed along the
posterior wall of the left atrium rather than along
the mitral annular plane reducing the efficacy of
this device to improve MR. In addition, in 68% of
Fig. 9 Multidetector row computed tomography (MDCT)
prior to coronary sinus-based mitral valve annuloplasty.
Combination of 3-dimensional volume rendering and axial
views of the mitral valve annulus permit assessment of the key
anatomic relationships of the coronary sinus: its position
relative to the mitral annular plane and the circumflex coronary
artery. a shows an example of a patient with the coronary sinus
properly aligned with the mitral annulus (as seen with the
3-dimensional volume rendering). However, at the level of the
distal part of the coronary sinus, where the distal anchor is
positioned, the circumflex coronary artery courses between the
mitral annulus and the coronary sinus. The risk of coronary
impingement in this example may contraindicate the proce-
dure. In contrast, b shows an example where the coronary sinus
courses superiorly to the posterior mitral annulus. The coronary
sinus-based mitral annuloplasty may be less effective in this
case, since the tension is applied to the posterior wall of the left
atrium rather than the mitral annulus. In addition, there is a
potential risk of circumflex coronary artery compromise as the
distal part of the coronary sinus courses over the artery
(arrow). CS coronary sinus, CX left circumflex artery
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patients, the circumflex coronary artery coursed
between the coronary sinus and the mitral annulus,
indicating an increased risk of arterial impingement
during percutaneous coronary sinus-based annulo-
plasty. This information can be also obtained with
MRI, a valuable alternative to MDCT in patients with
severe renal dysfunction in whom the use of iodinated
contrast may be contraindicated [49].
MDCT before direct LV remodeling
The RESTOR-MV trial evaluated the efficacy of the
Coapsys device (Myocor, Inc., Maple Grove, MN) in
reducing MR and improving clinical outcomes of
heart failure patients with functional MR undergoing
surgical revascularization [43]. This device is placed
without the need of cardiopulmonary bypass and aims
to reduce the mitral valve annular dimensions and
correct the displacement of the papillary muscles.
The anterior and posterior pads are positioned on the
epicardial surface of the heart and the expanded
polytetrafluoroethylene-coated subvalvular cord that
connects both pads is tightened under echocardio-
graphic guidance until significant reduction or elim-
ination of MR is achieved [50]. Several anatomic and
geometric criteria determine the eligibility for this
procedure. Presence of structural abnormality of the
mitral valve apparatus (i.e. leaflet prolapse, chordal
rupture, mitral annular calcification or calcified
leaflets) and LV end-diastolic diameter [70 mm
contraindicate this procedure. In addition, the poten-
tial interference with the papillary muscles or the
inability to avoid main epicardial coronary arteries
during device positioning may influence the feasibil-
ity of this treatment.
As previously mentioned, MDCT provides accu-
rate characterization of the LV dimensions, anatomy
and location of the papillary muscles and location
and extent of mitral valve apparatus calcification [45,
51]. Furthermore, the position of the anterior and
posterior pads can be anticipated during pre-proce-
dural screening, by visualizing the position of the
main epicardial coronary arteries in the 3D volume
renderings. Compared to the group of patients
undergoing surgical coronary artery bypass grafting
alone or in combination with mitral valve repair, the
RESTOR-MV showed a significant improvement in
MR, LV systolic function and survival of patients
with ischemic heart failure and functional MR [43].
Conclusions
Accurate selection of patients who are candidates for a
transcatheter-based valve repair/implantation technique
results in high success rates and reduces the number of
procedural complications. MDCT should play a central
role in both aortic and mitral transcatheter-based
interventions as it provides a comprehensive assessment
of the anatomy prior to the procedure and helps to select
the most appropriate procedural approach, making the
procedure as safe as possible. In addition, the use of state
of the art scanners and dose modulation MDCT
protocols can potentially optimise the iodined-based
contrast load and reduce the radiation exposure.
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Selecting patients for transcatheter 
aortic valve implantation
 REVIEW
Transcatheter aortic valve implantation (TAVI) is a feasible therapeutic alternative for patients with severe 
symptomatic aortic stenosis who are considered high risk for surgical aortic valve replacement. The clinical 
results of TAVI are promising, with over 90% procedural success rates and superior 1-year survival, as 
compared with medical treatment. Appropriate selection of patients is crucial to optimize procedural 
success and to minimize the complication rate. A careful multidisciplinary evaluation of clinical symptoms 
and assessment of aortic valve annular size and dimensions of the peripheral arteries is mandatory to plan 
the TAVI strategy. Multimodality imaging plays a central role in the preprocedural evaluation of patients 
who are candidates for TAVI. Patient selection procedure and planning strategy for TAVI will be extensively 
discussed in the present article.
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Aortic valve replacement (AVR) is the standard 
treatment for patients with symptomatic severe 
aortic stenosis (AS) [1,2]. Despite the fact that AVR 
can improve survival and provide symptomatic 
relief for these patients, as many as one third of 
elderly patients with indications for surgery were 
not operated on [3]. This is at least partly due to 
the perceived high operative risk associated with 
a combination of factors including advanced age, 
multiple comorbidities and/or left ventricular dys-
function. As the survival of unoperated patients 
with symptomatic severe AS is dismal [4], this has 
led to the search and development for a less inva-
sive but effective therapeutic alternative for this 
group of patients, who are deemed unsuitable or 
have contraindications for surgery. 
Since the first successful experience in humans 
in 2002 [5], transcatheter aortic valve implanta-
tion (TAVI) has been rapidly expanding with 
more than 17,000 procedures performed world-
wide to date [6]. Besides the promising proce-
dural success rates of 91–94% observed in recent 
studies [7–9], a marked improvement in transval-
vular hemodynamics [8,10] and functional status 
have been reported following TAVI [10,11]. More 
importantly, the results of the first randomized 
controlled trial (the PARTNER trial) comparing 
TAVI and standard medical therapy (including 
balloon valvuloplasty) have demonstrated that 
TAVI was associated with a superior survival rate 
at 1 year (69 vs 49%) [12]. 
Advances in transcatheter technology and 
its delivery systems over the last few years have 
helped to improve the clinical results of TAVI 
resulting in a significant reduction in the 30-day 
mortality rate (from the initial 14.3 to 6% in 
the most recent series) [8,9,12–15]. However, there 
are still several areas of concern, including vas-
cular complications, stroke, atrioventricular 
conduction block, coronary artery obstruction, 
prosthesis malpositioning/malfunctioning and 
paravalvular leakage. Careful patient selection 
is therefore crucial to minimize procedural com-
plications and optimize the success of TAVI. In 
this selection process, noninvasive imaging plays 
a key role in providing information on proce-
dural feasibility and helps to select the most 
appropriate TAVI approach. This article will 
describe the steps involved in patient selection 
(both clinical and anatomic aspects) and TAVI 
strategy planning.
Clinical risk assessment & evaluation 
of symptoms
Transcatheter aortic valve implantation is cur-
rently restricted to patients with high operative 
risk for AVR and a life expectancy of 1 year, 
as recommended by a joint position statement 
from the European Association of Cardio-
Thoracic Surgery and the European Society of 
Cardiology, in collaboration with the European 
Association of Percutaneous Cardiovascular 
Interventions [16]. As risk assessment and deci-
sion making is a complex process in these elderly 
patients, a multidisciplinary team approach is 
essential in making accurate and unbiased clini-
cal assessments on an individual basis [17]. Often, 
the multidisciplinary team (or so-called ‘Heart 
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Team’) involves the clinical cardiologist, imag-
ing specialist, surgeon, interventionalist, anes-
thesiologist and geriatrician. To evaluate the 
risk of surgery, multiple risk scores are available 
such as the logistic European System for Cardiac 
Operative Risk Evaluation (EuroSCORE) [18], 
the Society of Thoracic Surgeons Predicted Risk 
of Mortality (STS-PROM) score [101] or the 
Ambler score [19]. However, as these risk scores 
are not designed for isolated AVR, there is a 
discrepancy between the expected and observed 
mortality for patients undergoing AVR based on 
these scoring systems [20–22]. While the widely 
used logistic EuroSCORE has been shown to 
overestimate mortality [20,21], the STS-PROM 
score appears to underestimate but closely 
approximates the actual observed perioperative 
mortality for this high-risk group undergoing 
AVR [20]. As a general guide, several risk scores 
should be used together to provide a better esti-
mate of the risk involved. The current position 
statement considers a high-risk patient for sur-
gery when the expected mortality is >20% as 
calculated with the Logistic EuroSCORE and 
>10% as calculated with the STS-PROM score 
[16]. However, owing to the aforementioned 
limitations, clinical judgment takes precedence 
over these currently applied scoring systems. 
In addition, some important factors, which are 
not reflected in the risk scores, such as chest 
radiation, porcelain aorta, liver cirrhosis and 
prior aorto-coronary bypass surgery with pat-
ent grafts, may preclude an open heart surgery, 
and in such cases, TAVI may be the next best 
therapeutic option [16]. 
In addition, detailed assessment of comorbid-
ities and physical activity status are an integral 
part of the pre-procedural screening as these 
factors have an impact on the life expectancy 
of the elderly patients [23]. Currently, TAVI 
should not be performed in patients with a life 
expectancy <1 year [16]. Moreover, the base-
line physical frailty score, as assessed with the 
Karnofsky index [24], is an independent predic-
tor of in-hospital outcomes following TAVI [7]. 
Therefore, detailed clinical assessment is criti-
cal to ensure that TAVI should be reserved for 
patients who would derive the maximal benefit 
from such a procedure.
Next, the evaluation of patients’ symptoms is 
another important aspect of the pre-procedural 
patient screening. Often, there is a myriad of rea-
sons that may account for the symptoms expe-
rienced in the elderly population. At the present 
stage, TAVI is only recommended for patients 
with symptoms that are attributed to AS [16]. 
Thus, a complete clinical assessment may need 
to involve inputs from other expertise such as 
those from respiratory physicians and geriatri-
cians in order to be certain that these patients 
truly have symptoms related to AS before they 
proceed to TAVI.
Assessment & confirmation of  
AS severity
Transthoracic echocardiography (TTE) is the 
initial modality of choice to assess AS as it 
readily provides information on valve anatomy, 
transvalvular hemodynamics and left ventricular 
response to chronic pressure overload state [25]. 
Quantification of AS severity relies primar-
ily on the hemodynamic parameters, obtained 
from echocardiographic Doppler measurements 
(FIGURE 1A). Severe AS is defined as an aortic jet 
velocity >4 m/s and/or a mean pressure gradi-
ent >40–50 mmHg and/or an aortic valve area 
<1 cm2 (or 0.6 cm2/m2 indexed to body surface 
area) [1,2,25]. In the presence of severe left ven-
tricular systolic dysfunction (ejection fraction 
40%), patients with true severe AS can present 
with a relatively low transvalvular pressure gra-
dient (<40 mmHg). The diagnosis of this sub-
group of patients with ‘low flow, low gradient 
AS’ may be challenging and differentiation from 
other patients with a primary cardiomyopathic 
disease and a nonstenotic aortic valve (pseudos-
evere AS) may be difficult [26]. In such cases, 
dobutamine stress echocardiography should be 
performed to distinguish between true severe AS 
from pseudosevere AS [25]. During dobutamine 
infusion, an increase in transvalvular flow will 
occur and patients with pseudosevere AS will 
show an increase in valve area, with little change 
in transvavular gradient. By contrast, patients 
with true severe AS will respond by an increase 
in transvalvular gradient while the aortic valve 
area remains unchanged [27]. Intervention should 
be performed in patients with true severe AS 
who have developed symptoms [1,2].
Evaluation of TAVI feasibility & 
selection of procedural approach
After confirmation of severe AS and detailed 
clinical assessment, a comprehensive and accurate 
evaluation of the feasibility of TAVI is important 
to ensure the success of the procedure and mini-
mize procedural related complications. Currently, 
two types of prosthesis are available: the balloon 
expandable Sapien XT™ prosthesis (Edwards 
Lifesciences, Irvine, CA, USA) and the self 
expandable Medtronic CoreValve Revalving™ 
(MCR)
 
prosthesis (Medtronic Inc., Luxembourg). 
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The Sapien XT prosthesis is a trileaflet pericar-
dial bovine valve, mounted within a cobalt-chro-
mium frame that permits thinner struts and lower 
crimped profile. The available sizes are 23 and 
26 mm for an aortic valve annulus of 18–22 mm 
and 21–25 mm, respectively. The 23 mm pros-
thesis is mounted onto an 18F transfemoral 
NovaFlex delivery system (Edwards Lifesciences), 
whereas the 26-mm valve is crimped onto a 19F 
NovaFlex delivery system. In addition to a retro-
grade transfemoral approach, this transcatheter 
aortic valve can also be implanted antegrade via 
a transapical approach using the 22F Ascendra 2 
delivery system (Edwards Lifesciences). Recently, 
a 29 mm device has been launched for aortic valve 
annular dimensions between 25–28 mm. This 
device can be implanted through a transapical 
approach. The MCR prosthesis has a different 
design and is characterized by a 50 mm nitinol 
frame with three different functional levels: the 
upper third level that exerts a low radial flow 
and is placed in the ascending aorta; the middle 
third level that includes the trifoliate porcine valve 
and has a constraint design to avoid jailing of 
the coronary ostia; and the lower third level that 
exerts a high radial force and anchors the pros-
thesis within the left ventricular outflow tract. In 
addition, the lowest 12-mm skirt portion helps 
to prevent significant paravalvular regurgitation 
after deployment. This prosthesis is currently 
available in two sizes (26 and 29 mm for aortic 
valve annulus of 20–23 and 23–27 mm, respec-
tively) and can be implanted via a transfemoral 
or trans subclavian approach [28]. These differ-
ent designs and procedural approaches demand 
accurate evaluation of the aortic valve annulus 
and peripheral artery anatomy in order to plan 
the most appropriate therapeutic strategy. Besides 
these two key aspects, evaluation of the anatomy 
of the aortic valve, dimensions of the aortic root 
and its spatial relationship with coronary ostia 
and exclusion of contraindications complete the 
pre-procedural evaluation of patients who are 
candidates for TAVI (TABLE 1). The use of multi-
modality imaging is therefore essential to assess 
these requirements, and to ensure a successful 
procedure and prevent complications.
  Aortic valve anatomy
Transcatheter aortic valve implantation is indi-
cated in patients with a severely stenotic tricus-
pid aortic valve. The current position statement 
considers bicuspid aortic valve anatomy as a con-
traindication for TAVI due to the risk of incom-
plete and unfavorable deployment [29]. However, 
several reports have demonstrated that TAVI is 
a feasible and safe treatment for bicuspid aortic 
valve [30,31]. Echocardiography remains the main-
stay imaging technique to evaluate the anatomy 
of the aortic valve. However, poor acoustic win-
dows may challenge the diagnosis of this valvular 
phenotype. Transesophageal echocardiography 
(TEE) may be an alternative as it provides supe-
rior image quality, permitting better visualization 
of valve anatomy (FIGURE 1). In addition, multi-
detector row computed tomography (MDCT) 
or MRI may help to differentiate truly bicuspid 
anatomy from functional bicuspid valves [32].
  Aortic valve calcification
Degenerative aortic valve stenosis is character-
ized by thickening, retraction and calcification 






Mean gradient = 4VMAX2
VLVOT
LVOT
Figure 1. Assessment of the severity of aortic stenosis and aortic valve 
anatomy. Calculation of mean pressure gradient requires the VMAX of AS jet 
obtained from continuous-wave Doppler, using the Bernoulli equation (A). Using 
the continuity equation, AVA is calculated. The LVOT diameter is measured and the 
CSALVOT is calculated. In addition, the VLVOT is obtained from pulsed-wave Doppler in 
the apical long-axis view and the VMAX jet is measured from the continuous wave 
Doppler recordings through the aortic valve. Either the velocity time integrals or 
velocities can be applied in the equation for the calculation of AVA. 
Transesophageal echocardiography permits direct visualization of the aortic valve: 
tricuspid (B) or bicuspid (C). 
AS jet: Aortic jet; AVA: Aortic valve area; CSA: Cross-sectional area;  
LVOT: Left ventricular outflow tract; VLVOT: LVOT velocity;  VMAX: Maximum velocity. 
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helps to anchor the transcatheter aortic valve 
prosthesis. However, extensive and bulky calcifi-
cations of the aortic valve may challenge deploy-
ment of the prosthesis and has been related to 
the presence of significant postprocedural aor-
tic valve regurgitation [29,33,34]. Fluoroscopy and 
echocardiography permit gross evaluation of the 
extent and location of calcification. However, the 
spatial resolution of MDCT provides improved 
image quality to evaluate this aspect (FIGURE 2). 
Several studies have demonstrated the role of 
MDCT to evaluate native aortic valve calcifica-
tion and have related the extent of valve calcifica-
tion to the presence of paravalvular aortic regur-
gitation post-TAVI [33,34]. In a recent study by 
John and coworkers including 100 patients who 
underwent TAVI, acute post-procedural valvu-
lar regurgitation was significantly correlated 
with the extent of aortic valve calcification in 
the landing zone [34]. Furthermore, in a series 
of 53 patients who underwent TAVI, the extent 
of valve calcification detected with MDCT 
was significantly higher in patients with non-
circular deployment of prosthesis (3862 vs 1837 
Hounsfield unit; p = 0.04) and significant val-
vular regurgitation (4174 vs 2444 Hounsfield 
unit; p < 0.001) [33]. Moreover, valve calcification 
located at the native valve commissures (but not 
at the valve hinge points or free edge of leaflets) 
seemed to play a role in determining significant 
valvular regurgitation following TAVI.
  Aortic valve annular dimensions
Accurate assessment of the aortic valve annular 
dimensions is key to select the most appropriate 
transcatheter prosthesis size. Migration of the 
Table 1. Anatomic requirements for Sapien XTTM and Medtronic CoreValve Revalving systemTM implantation.
Anatomy Sapien XT Medtronic CoreValve Revalving 
system
Anatomical structure
Annulus (width) 18–22 mm  23 mm device 
21–25 mm  26 mm device
25–28 mm  29 mm device
20–23 mm  26 mm device
24–27 mm  29 mm device
Annulus-to-aorta (angle) – 45º
Height of sinus of Valsalva 15 mm 15 mm
Coronary ostia (height) from aortic annulus 8 mm 10 mm
Ascending aorta (width) – 40 mm  26 mm device
43 mm  29 mm device
Data taken from [51].
Figure 2. Aortic valve calcification: implication for transcatheter aortic valve implantation. 
Multidetector row computed tomography (MDCT) allows assessment of the extent of calcification 
and its location on the native aortic valve. The photographs shows a tricuspid aortic valve with bulky 
calcification at the valve commissure (between left and right leaflets) and the body of the left 
coronary cusp in (A). After transcatheter aortic valve implantation, paravalvular leak (arrow) was 
observed with color Doppler transesophageal echocardiography in the long-axis view (B) and in the 
short axis view (C) that coincided with the location of bulky calcification at the valvular commissure 
on MDCT (arrow in (A)). 
LA: Left atrium; RA: Right atrium; RV: Right ventricle.
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prosthesis, when the prosthesis size is too small, 
or rupture of the aortic valve annulus, when the 
prosthesis size is too large, are two potential 
procedural complications that can be avoided 
by accurate measurement of the aortic valve 
annulus and appropriate sizing of the prosthe-
sis. 2D echocardiography is the most commonly 
used technique to measure the aortic valve annu-
lus [35,36]. However, 3D imaging techniques have 
demonstrated that the aortic valve annulus is not 
circular, but oval shaped (FIGURE 3A). Currently, 
the gold standard imaging technique for the 
measurement of aortic valve annulus has not 
been established. However, several studies have 
demonstrated the superior accuracy of 3D imag-
ing techniques to assess this functional structure 
[37]. In a recent series of 53 patients undergoing 
TAVI, the accuracy of 2D and 3D TEE to mea-
sure the aortic valve annulus was evaluated, using 
MDCT as the gold standard [38]. Circular areas 
calculated with 2D and 3D TEE significantly 
underestimated the planimetered cross-sectional 
areas obtained with MDCT (16.4 and 12.9% 
underestimation, respectively). By contrast, pla-
nimetered areas of the aortic valve annulus, mea-
sured with 3D TEE, had better agreement with 
MDCT plani metered cross-sectional areas and 
the percentage of underestimation was signifi-
cantly lower (9.6%). Although the clinical impli-
cations of these different evaluations have not 
been fully elucidated, 3D imaging techniques 
such as 3D TEE or MDCT may be helpful in 
patients with borderline aortic annular measure-
ment. In a recent study including AS patients 
who underwent MDCT prior to TAVI with 
MCR prosthesis, Schultz et al. demonstrated 
that prosthesis sizing based on the mean annular 
diameter ([minimal diameter + maximal diame-
ter]/2) obtained from MDCT had the best agree-
ment with the operator choice (74%) [39]. By 
contrast, the agreement with the operator choice 
was only 44 or 32% if only the minimal diam-
eter or maximal diameter was used, respectively. 
Similarly, the study by Messika-Zeitoun et al. 
reported that using the mean annular diameters 
measured by MDCT would have changed the 
prosthesis size in 38% of patients who received 
Edwards Sapien™ prosthesis [35]. These findings 
suggest the clinical relevance from incorporating 
detailed anatomy assessment of the aortic annu-
lus with 3D imaging modalities such as that of 
3D TEE or MDCT or MRI.
 Assessment of aortic root anatomy
In addition to the measurement of the aortic valve 
annular diameter, the dimensions of the sinus 
of Valsalva, sino-tubular junction and ascending 
aorta should be assessed (FIGURE 3B). Particularly, 
the dimensions of the aortic root and the 
ascending aorta are of importance when a MCR 
prosthesis is implanted. The distal part of this 
prosthesis accommodates these two anatomical 
structures, exerting a low radial force and orient-
ing the prosthesis in the direction of blood flow. 
Dilated ascending aorta (>43 mm) are considered 
contraindications for self-expandable prostheses 
(TABLE 1) [16].
Furthermore, measurement of the height of 
the coronary ostia, relative to the aortic valve 
annular plane, is important in order to anticipate 
Figure 3. Multidetector row computed tomography assessment of the anatomy of aortic 
annulus and its surrounding structure. (A) Shows the cross-sectional area of the aortic annulus 
demonstrating the oval-shaped structure. The sagittal diameter of the aortic annulus is shorter than 
the coronal diameter. (B) Shows the oblique transverse view of multiplanar reformation (MPR) 
measuring the diameter of AA, STJ, SOV and the coronal aortic annulus diameter. The distance of 
SOV and coronary cusps from the aortic annulus can be derived. (C) Shows the sagittal view of MPR 
measuring the sagittal diameter of the aortic annulus resembling measurement from 
echocardiography and distance to the right coronary artery from aortic annulus. 
AA: Ascending aorta; SOV: Sinus of Valsalva; STJ: Sinotubular junction.
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potential fatal complications such as occlusion 
of one of the coronary ostia by a bulky calcified 
cusp [40,41]. The design of the current prosthe-
ses, with open struts in the upper two-thirds 
of the frame, assures normal flow through the 
coronary ostia. In particular, the MCR device 
has a constrained middle part, to avoid jailing 
of the coronary ostia. By contrast, the Sapien 
XT device seldom reaches the coronary ostia 
(11% in a recent series) [33]. A coronary ostia 
height relative to the aortic valve annular plane 
of at least 10 mm is currently the recommended 
minimum height to proceed with the procedure 
(FIGURE 3C). These characteristics are best evalu-
ated with MDCT, providing a 3D visualization 
and accurate measurement.
  Assessment of the aorta & 
peripheral arteries
Once the prosthesis size has been selected, the 
procedural approach (retrograde or antegrade) 
has to be planned. The retrograde approach via 
the transfemoral access is usually the approach 
of first choice. In this aspect, the dimensions of 
the ilio-femoral arteries will directly determine 
the feasibility of this procedural approach as 
the currently available devices require a mini-
mum diameter of at least 6 mm. Traditionally, 
conventional angiography was considered the 
gold standard method to assess the dimensions 
of the ilio-femoral arteries. However, the poor 
soft-tissue resolution of this imaging technique 
does not allow accurate assessment of arterial 
wall disease and calcification. MDCT has dem-
onstrated its superior accuracy to assess the inter-
nal diameter of the arterial lumen, the presence 
of significant atherosclerosis and calcification 
and the tortuosity of the arteries. These are the 
crucial determinants of success and feasibility 
of the transfemoral approach (FIGURE 4) [42,43]. In 
a recent series including 37 patients undergoing 
TAVI, it was demonstrated that MDCT had a 
high accuracy to evaluate the anatomy of the 
peripheral arteries, with the advantage of using 
a lower volume of iodinated contrast compared 
with invasive angiography [42]. In addition, a 
Figure 4. Evaluation of peripheral arteries with multidetector computed tomography. 
(A) Shows an example in volume-rendered image, highlighting the tortuous course of the vessel. 
Using the center-line approach, the distribution of calcification along the vessel (stretched view in 
(B)) and the internal luminal diameter of the vessel (double oblique transverse view in (D)) can be 
accurately assessed. In addition, the exact angulation within the artery can be measured on the 
volume-rendered image with multidetector computed tomography (C). Post-processing imaging 
software: 3mensio ValvesTM, version 4.2., 3mensio Medical Imaging BV, Bilthoven, The Netherlands.
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new sequence of magnetic resonance angiog-
raphy, the true-fast imaging with steady-state 
precession (a hybrid T2/T1-weighted acquisi-
tion), provides excellent visualization of vessels 
without the need for a paramagnetic contrast 
agent such as gadolinium (FIGURE 5) [44]. 
Evaluation of the aortic arch and descend-
ing aorta is also of importance when a trans-
femoral approach is considered. According to 
current recommendations, severe angulation 
of the aorta, severe atherosclerosis of the arch, 
and coarctation and aneurysm of the abdominal 
aorta with protruding mural thrombosis con-
traindicate the transfemoral approach. Severe 
atherosclerosis of the descending aorta and 
aortic arch can be detected with TEE (FIGURE 5). 
In addition, intravascular ultrasound permits 
characterization of atherosclerotic plaque [45]. 
MDCT provides 3D visualization of the aorta 
and is the method of choice to evaluate the pres-
ence of extensive calcification (porcelain aorta). 
Moreover, MRI provides accurate assessment of 
the aortic wall without need for paramagnetic 
contrast. Presence of severe aortic atherosclero-
sis indicates the need for careful manipulation 
of the catheters during the procedure, in order 
to avoid thrombo-embolic complications. In 
such cases, transfemoral approach may not be 
suitable and an alternative approach (transapi-
cal or transsubclavian) should be considered. 
FIGURE 6 summarizes the procedural approach 
selection algorithm. The transapical approach 
has the advantage of overcoming the problem of 
aorto–ilio-femoral vascular disease. However, it 
requires general anesthesia and a small anterior 
minithoracotomy with direct puncture of the 
left ventricular apex. This approach is contra-
indicated in patients with calcified pericardium, 
severe respiratory insufficiency, major chest 
deformity and previous left ventricular surgery 
using a patch [16]. In patient candidates for TAVI 
with MCR prosthesis who show unsuitable ilio-
femoral anatomy, transsubclavian approach has 
been demonstrated to be feasible and safe [28,46]. 
Exclusion of contraindications
Additional factors concerning the left ventricular 
function, coronary artery disease and presence of 
concomitant valvular disease (i.e., severe organic 
mitral valve regurgitation) must be evaluated 
prior to TAVI. 
A detailed evaluation of left ventricular 
dimensions and ejection fraction should be 
performed in patients undergoing TAVI. 
Impaired left ventricular ejection fraction may 
increase the risk of hemodynamic instability 
during TAVI procedures. In addition, severe 
left ventricular hypertrophy with pronounced 
sigmoid septum at the level of the left ven-
tricular outflow tract may prove challenging 
when attempting this procedure using MCR 
prosthesis. Moreover, the presence of left ven-
tricular thrombus is an established contrain-
dication for TAVI and can be better evaluated 
by contrast echocardiography [16]. 
Evaluation of coronary artery anatomy is man-
datory before TAVI, as the presence of significant 
proximal lesions, not amenable to percutaneous 
coronary intervention, is considered a contrain-
dication to TAVI [16]. Invasive coronary angi-
ography is the gold standard for evaluation of 
coronary artery anatomy. By contrast, the high 
Figure 5. Evaluation of aorta with magnetic resonance angiography and 
transesophageal echocardiography. (A) Shows the contrast-enhanced 
magnetic resonance angiography image of the infrarenal aorta with suspected 
intramural thrombus (arrow and arrowhead). Using the true-fast imaging with 
steady-state precession (a hybrid T2/T1-weighted acquisition), the thrombus can be 
clearly differentiated from the lumen in the axial (B) and sagittal (C) images 
(adapted from [44], with permission from Elsevier ) and presents as a 
contraindication to the transfemoral approach. Severe atherosclerosis of the 
descending aorta and the aortic arch can be detected on transesophageal 
echocardiography. (D & E) show an example of a protruding plaque in the 
descending aorta (arrows).
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prevalence of severe coronary artery calcifica-
tion in this group of patients may challenge the 
assessment of coronary artery anatomy using 
MDCT. In patients with concomitant coronary 
artery stenoses, the decision of whether to per-
form coronary revascularization prior to TAVI 
has to be based on the clinical condition and the 
anatomy of individual patients. In a recent study 
of 136 patients with pre-procedural coronary 
angiogram who underwent TAVI, Masson and 
coworkers [47] reported that the early mortality 
and overall 1-year mortality rates did not differ 
between patients with no coronary artery stenoses 
(n = 32), patients with completely revascularized 
coronary lesions (n = 41) and patients with nonre-
vascularized or incompletely revascularized coro-
nary lesions of varying ischemic burden (n = 63) 
as assessed with the Duke Myocardial Jeopardy 
Score [48]. Of these 136 patients, 15 patients were 
treated with percutaneous coronary interventions 
prior to TAVI (with a median time interval of 
26 days between procedures; range: 3–100 days). 
Currently, it is generally advisable to perform 
revascularization in cases with severe lesions of 
the left main or the proximal coronary arteries 
before TAVI as per the current EACTS, ESC and 
EAPCI position statement [16].
Finally, the presence of significant organic 
mitral valve regurgitation increases the proce-
dural risk. Particularly, using a MCR prosthe-
sis, the ventricular end of the prosthesis frame 
may interfere with the motion of the anterior 
mitral leaflet resulting in or worsening mitral 
regurgitation [49].
Conclusion
TAVI is a feasible alternative to surgical AVR in 
patients with severe symptomatic AS and high 
operative risk. Multidisciplinary evaluation, 
including accurate clinical evaluation and precise 
assessment of aortic valve anatomy and function, 
aortic valve annular dimensions and peripheral 
artery anatomy, are crucial to optimize the results 
while reducing the procedural complications 
rate. Importantly, multimodality imaging plays 
an important role in the patient selection pro-
cess. A summarized patient selection algorithm 
is detailed in FIGURE 7, highlighting the important 
factors that need to be considered before TAVI. 
Future perspective
The number of TAVI procedures is increasing 
rapidly. Selecting the appropriate patients by 
detailed clinical assessment and multimodality 
Favorable ilio-femoral arterial and aorta anatomy?








Luminal diameter >6 mm
Contraindications
v
Figure 6. Transcatheter aortic valve implantation: procedural approach selection.
Data taken from [16,28,42,43].
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Figure 7. Summarized patient selection algorithm for transcatheter aortic valve 
implantation. �P: Increase in transvalvular gradient; AS: Aortic stenosis; AVA: Aortic valve area; 
CAD: Coronary artery disease; CAG: Coronary angiography; EuroSCORE: Logistic European System 
for Cardiac Operative Risk Evaluation; LV: Left ventricular; LVEF: Left ventricular ejection fraction; 
MDCT: Multidetector row computed tomography; PCI: Percutaneous coronary intervention;  
STS-PROM: Society of Thoracic Surgeons Predicted Risk of Mortality; SV: Stroke volume;  
TEE: Transesophageal echocardiography; TTE: Transthoracic echocardiography. 
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imaging techniques (the Heart team approach) 
can improve the results and reduce the rate 
of complications to a minimum. However, a 
number of questions still need to be answered. 
In particular, the reference method and imag-
ing modality to size the aortic valve annulus 
(TTE/TEE/MDCT/MRI) needs to be defined. 
In addition, vascular complications and a high 
rate of atrioventricular conduction block (and 
the need for a pacemaker, especially with MCR 
prosthesis) are the main safety issues that 
remain to be improved. Ongoing research aims 
to improve the current technology and provide 
lower profile delivery systems that may help to 
reduce the number of vascular complications. 
In the coming years, data on prosthesis dura-
bility are eagerly awaited. Degeneration and 
dysfunction of current transcatheter prosthesis 
is currently uncommon [10,50]. A transcatheter 
prosthesis, with durability comparable to that 
of conventional surgical bioprosthesis, would 
probably allow this technique to be expanded 
to younger patients in the future. While awaiting 
further developments in this technology, patient 
selection, according to the current recommenda-
tion, should be adhered to stringently to increase 
the success rate of the procedures and minimize 
the procedural-related complications.
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Executive summary
Survival after transcatheter aortic valve implantation in patients with symptomatic aortic 
stenosis who are not suitable for surgical aortic valve replacement
  The PARTNER trial demonstrated that transcatheter aortic valve implantation (TAVI) was associated 
with better survival at 1-year, compared with standard therapy.
  Requires longer follow-up study to provide data on long-term prosthesis durability and outcomes of 
patients who underwent TAVI.
Clinical risk assessment before TAVI
  A multidisciplinary team approach is essential when making accurate and unbiased clinical assessment.
  TAVI is currently restricted to patients with very high operative risk for surgery and a life expectancy 
of 1year.
  High operative risk patients are those with a logistic European System for Cardiac Operative Risk 
Evaluation (EuroScore) >20% and Society of Thoracic Surgeons Predicted Risk of Mortality (STS-
PROM score) >10%.
Confirmation of aortic stenosis severity
  Severe aortic stenosis (AS) is primarily assessed by echocardiography and is defined as an aortic jet 
velocity >4m/s and/or a mean pressure gradient >40–50 mmHg and/or an aortic valve area <1 cm2 
(or 0.6 cm2/m2 indexed to body surface area).
  Dobutamine stress echocardiography should be performed in patients with low flow, low gradient 
AS to distinguish between true severe AS from pseudosevere AS.
There are two currently available transcatheter prostheses
  The prostheses are balloon expandable Sapien XTTM (size 23 and 26 mm for aortic valve annulus 
18–21 and 22–25 mm, respectively) and self-expandable Medtronic CoreValve Revalving system™ 
(size 26 and 29 mm for aortic valve annulus 20–23 and 23–27 mm, respectively).
  Retrograde transarterial (transfemoral or transsubclavian) or antegrade transapical are the 
procedural approaches.
Evaluation of TAVI feasibility & procedural planning
  Multimodality imaging is essential to optimize procedural success and to avoid complications.
  Aortic valve annular dimensions will determine the prosthesis size, whereas peripheral artery 
anatomy will determine the procedural approach.
  Exclusion of contraindications: bicuspid aortic valve, severe proximal coronary artery stenosis not 
amenable to percutaneous intervention and presence of left ventricular thrombus are established 
contraindications for TAVI.
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Abstract
During the last decade, transcatheter aortic valve implantation (TAVI) techniques have evolved rapidly pro-
viding several systems that conform to a broad spectrum of aortic valve annulus sizes, developing new deliv-
ery systems that provide an alternative to patients with difficult vascular access and permitting more controlled 
and accurate prosthesis deployment that result in improved procedural outcomes. However, residual aortic 
regurgitation (AR) (paravalvular or transvalvular) remains a recurrent observation and patients with moder-
ate or severe AR have a reduced mid-term prognosis Therefore, postprocedural AR should be carefully and 
accurately evaluated in order to decide whether additional procedures such as re-ballooning or valve-in-valve 
are needed to reduce AR severity, and changes in AR at follow-up should be monitored. In the current review, 
the role of cardiac imaging to understand the mechanism underlying AR after TAVI and to quantify the sever-















Transcatheter aortic valve implantation (TAVI) is now an accepted 
standard of care for patients with symptomatic severe aortic steno-
sis (AS) who are not candidates for surgery or have high surgical 
risk. Over the past decade, the combined effect of learning curve, 
improvement in transcatheter device technology, a better under-
standing of aortic root anatomy, together with careful patient selec-
tion have gradually resulted in an improved clinical outcome for 
patients undergoing TAVI1. However, aortic regurgitation (AR) 
remains a common phenomenon following TAVI. Experience in 
large multicentre studies and registries, including over 6,000 
patients, revealed that the incidence of AR after TAVI ranged from 
48 to 93% of patients, with comparable prevalence between self- 
and balloon-expandable prostheses (Table 1)2-10. Trace or mild 
paravalvular AR is a common finding in the majority of patients, 
whereas only 14-21% of patients may have at least moderate AR 
following TAVI (Table 1)2-10. The observed variation in AR after 
TAVI may be related to the use of different modalities to assess AR 
(angiography, transoesophageal [TEE] or transthoracic [TTE] 
echocardiography), the different timing of AR assessment after 
TAVI (immediately post deployment, before hospital discharge and 
at 30-day follow-up) and the lack of a standardised protocol to 
grade AR severity (qualitative versus semi-quantitative methods). 
Accurate assessment of AR after TAVI is clinically relevant since 
moderate and severe post-procedural AR have been associated with 
poor treatment response11, early in-hospital death2 and mid-term 
mortality3,5,8,11. In addition, a recent report has suggested that resid-
ual AR grade >1 may also be associated with reduced survival12. 
Conversely, serial evaluations have shown that the severity of AR 
tends to reduce over time3,13,14. Current recommendations to charac-
terise and quantify the severity of AR post TAVI include the mor-
phology and location of the regurgitant jet, as well as the percentage 
of the circumference of the prosthesis occupied by the regurgitant 
jet. The value of cardiac imaging to evaluate the mechanisms 
underlying AR after TAVI and to quantify its severity will be dis-
cussed in this review.
Mechanisms	of	AR	after	TAVI
AR following TAVI can be categorised according to the location of 
the AR jet in relation to the prosthesis: either paravalvular AR 
(PAR) (between the prosthesis and the native annulus), transvalvu-
lar AR (TAR) (within the prosthesis) or both, and is best appreci-
ated using colour-flow Doppler echocardiography (Figure 1).
PAR can be due to incomplete annular sealing of the transcathe-
ter valve. With conventional aortic valve surgery the native aortic 
valve is removed and the prosthesis is sewn onto the decalcified 
annulus, but in TAVI the native calcified aortic leaflets are dis-
placed to accommodate the newly implanted prosthesis. The 



















Time of recruitment, yr Jan 2005 - Jun 2009
Nov 2007 - 
Jan 2009
May 2007 - 
Mar 2009
May 2007 - 
Aug 2009
Apr 2008 - 
Mar 2011
Jun 2007 - 
Dec 2009
Jan 2007 - 
Dec 2009
Jan 2009 - 
Dec 2009
Jan 2010 - 
Oct 2011
Patients, n 339 1,038 179 348 358 663 870 697 3,195
Edwards, % 100 100 100 100 100 – 47 15.6 67
CoreValve, % – – – – – 100 52 84.4 33
Transfemoral, % 49 45 100 70 – 90 69 92 75
Non-transfemoral, % 51 55 – 30 100 10 31 8 25
AR assessment TTE TTE TTE TTE Angio/TEE TTE Angio Angio TTE
Postprocedural any AR
None, % 16 – 6 11 52 – 39 28
Trace/mild, % 78 – 78 76 47 – 47 55
Mod/severe, % 6 1.9 15 13 1 21 14 17
Postprocedural PAR
None, % – – 14 23 – – – – 38
Trace/mild, % – – 68 65 – – – – 46
Mod/severe, % – – 12 12 – 21 14 – 16
Postprocedural TAR
None, % – 31 35 – – – – 91
Trace/mild, % – 67 64 – – – – 8
Mod/severe, % – 1 1 – – – – 1
Angio: angiography; PAR: paravalvular aortic regurgitation; TAR: transvalvular aortic regurgitation; TEE: transoesophageal echocardiography; TTE: transthoracic echocardiography; yr: year 
*Included only AR >grade 2 (severe AR).
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presence of asymmetrical/bulky aortic valve calcification has been 
related to the presence of PAR (Figure 2)10,15-18. Exact localisation of 
calcium in the aortic root and valve may predict PAR after TAVI19,20. 
Particularly, calcification of the commissures has been associated 
with PAR but calcification of the body or the edge of the aortic 
cusps did not increase the risk of PAR20,21. Other phenomena related 
to PAR include prosthesis undersizing18,22,23, bicuspid valve (asym-
metrical expansion)24, incorrect depth of implantation (too high or 
low implantation without apposition to annular tissue) and an 
increased angle of the left ventricular outflow tract (LVOT) to the 
ascending aorta25. Multidetector row computed tomography is 
a valuable preprocedural imaging technique providing accurate siz-
ing of the aortic annulus, precise characterisation of aortic valve 
anatomy and aortic root dimensions, and localisation of calcifica-
tions in the landing zone (Figure 2)20,22,23.
In contrast, TAR is less often observed and may arise from val-
vular obstruction (from stiff guidewire or pigtail catheter or an 
overhanging native leaflet resulting in improper leaflet closure)26,27, 
valvular damage (during crimping process or overexpansion fol-
lowing post-dilatation)26,28 or prosthesis oversizing (suboptimal 
stent expansion or impaired leaflet mobility). Prompt recognition of 
TAR and its mechanism is crucial, so that appropriate interventions 
such as manipulation of catheter or implantation of a second pros-
thesis (valve-in-valve procedure) can be performed in a timely 
manner to ensure good clinical outcome.
Imaging	and	quantification	AR	after	TAVI
Currently, AR after TAVI is largely assessed using angiography, 
echocardiography or both. Using supra-aortic angiography, the 
degree of postprocedural AR is determined qualitatively by visual 
Figure 1. Panel A shows the long-axis view of the aortic root on conventional 2-D transoesophageal echocardiography of a patient who underwent 
transcatheter aortic valve implantation with a balloon-expandable valve. The arrow indicates the presence of mild paravalvular regurgitation at the 
level of the anterior part of the aortic annulus. The short-axis views show the exact location of the two jets of paravalvular regurgitation (arrows). 
Panel B shows a patient with transvalvular regurgitation, best noted on the short-axis view on transoesophageal echocardiography.








estimation of the concentration of contrast medium (regurgitation 
volume) in the left ventricle (LV) and classified into four grades: 
absent (grade 0), trace or mild (grade 1), mild-to-moderate 
(grade 2), moderate-to-severe (grade 3) and severe (grade 4)29. 
Although this is a commonly used method of assessment during 
TAVI, it lacks accurate quantification and has limited sensitivity in 
differentiating PAR from TAR (Figure 3). Moreover, this modality 
is not preferred for serial AR evaluation after TAVI.
The other widely used method for AR assessment is echocardi-
ography, and TEE is frequently performed to help guide transcath-
eter valve deployment and to detect complications during TAVI30. 
In addition, it permits assessment of the position and function of the 
prosthesis, including determination of the presence/severity and 
mechanism of AR immediately after valve deployment. In the set-
ting of TAVI, it is critical to distinguish PAR from TAR and to 
determine its severity rapidly so as to allow for manoeuvres such as 
re-ballooning, attempting maximal expansion of the prosthesis in 
the presence of significant PAR or deployment of a second valve in 
the presence of severe TAR. Using the standard long- and short-axis 
views of colour Doppler TEE, PAR and TAR can both be accurately 
detected. With the current three-dimensional matrix array TEE 
probes, simultaneous display of two orthogonal real-time images 
(biplane long- and short-axis views) with superimposed colour flow 
Doppler imaging allows further delineation and exact localisation 
of the PAR (Figure 4). However, accurate quantification of PAR 
remains challenging as it frequently consists of multiple small jets, 
origins of which may be obscured by the prosthesis stent/frame. 
Current recommendations for AR assessment after TAVI are derived 
from native valvular regurgitation, using multi-parametric 
approaches (Table 2)31,32. In the setting of TAVI, modifications are 
required as the grading for PAR differs from that of TAR, with 
emphasis on the “jet anatomy” classification. For example, the 
width of the proximal AR jet relative to the LVOT diameter is the 
suggested criterion for semi-quantitative assessment of TAR sever-
ity (Figure 5). In contrast, as PAR is frequently eccentric and irreg-
ular in shape, the proportion of the circumference of the prosthesis 
covered by the AR jet provides semi-quantitative assessment of 
PAR severity. However, this approach does not take into considera-
Figure 2. Panel A shows a calcified tricuspid aortic valve of a patient with bulky calcification mainly in the non-coronary (arrow) and right 
cusps, and extending to the base of the interventricular septum (arrow) on multidetector computed tomography (MDCT). Following TAVI with 
a balloon-expandable (SAPIEN XT) valve, a paravalvular leak was observed with colour-coded Doppler transoesophageal echocardiography 
(TEE) that coincided with the location of the bulky calcification at the commissure between the right and non-coronary cusps on MDCT. 
Panel B shows the deployed frame and the arrow indicates the gap at the level of the commissure between the non-coronary and right cusps. 
Panel C shows the colour-coded Doppler TEE in a transgastric view with the paravalvular leak in the location of the calcification at right to 
non-coronary commissure.
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tion the presence of multiple jets (unknown validity of summation 
of all the jets) and the possible contamination from the radial extent 
of PAR jets, which may result in overestimation of the AR sever-
ity32. Finally, with the currently available 3-D colour full volume 
echocardiographic data sets, direct planimetry of the AR vena con-
tracta may provide an accurate quantitative assessment of AR 
severity (Figure 5). Recently, Goncalves and co-workers showed 
that quantitative assessment of PAR after TAVI was feasible by 
planimetry of the vena contracta obtained with 3-D TTE33. The 3-D 
approach provided a better correlation between the AR volume and 
the vena contracta as compared to 2-D TTE.
Localisation of the PAR based on the standard parasternal short-axis 
TTE view of the aortic prosthesis is possible. In addition to a direct 
measurement of the vena contracta33, 3-D TTE may provide a more 
accurate calculation of the total stroke volume (both the regurgitant and 
forward stroke volumes) by subtracting LV end-systolic from LV end-
diastolic volumes34. In the absence of significant mitral regurgitation, 
this method may be highly accurate since it is independent of geomet-
ric assumptions and is not hampered by foreshortened views. Therefore, 
3-D echocardiography may become the method of choice for assessing 
complicated AR such as that following TAVI, although it requires fur-
ther validation before widespread implementation in clinical routine.
Figure 3. Assessment of aortic regurgitation (AR) after TAVI. Panel A shows supra-aortic angiography to estimate the AR grade. In contrast to 
echocardiography, angiography has limited resolution to differentiate between paravalvular and transvalvular AR. Panel B shows the TEE 
120º transgastric view of the same patient. The arrow indicates the presence of a wide regurgitant jet in the valve due to a frozen cusp.
Table 2. Recommended criteria for aortic regurgitation (paravalvular and transvalvular) after transcatheter aortic valve implantation.
Parameter Mild Moderate Severe
Valve structure and motion Usually normal Usually abnormal Usually abnormal
Left ventricular size Normal Normal/mildly dilated Dilated
Doppler parameters (qualitative or semi-quantitative)
Jet width in central jets (%LVOT): coloura ≤25% 26-64% ≥65%
Jet density: continuous-wave Incomplete or faint Dense Dense
Jet deceleration rate (PHT, ms): continuous-waveb Slow (>500 ms) Variable (200-500 ms) Steep (<200 ms)
LVOT versus pulmonary flow: pulsed-wave Slightly increased Intermediate Greatly increased
Diastolic flow reversal in descending aorta: pulsed-wave Absent or brief early diastolic Intermediate Prominent/holodiastolic
Circumferential extent of paravalvular leak (%): colourc 10-20 10-20 >20
Doppler parameters (quantitative)
Regurgitant volume (mL) <30 30-59 >60
Regurgitant fraction (%) <30 30-50 >50
LVOT: left ventricular outflow tract; PHT: pressure half time; aparameter applicable to central jets (less accurate in eccentric jets); bparameter influenced 
by left ventricular compliance; c for paravalvular aortic regurgitation








The feasibility of magnetic resonance imaging (MRI) for quanti-
fication of AR post TAVI has been evaluated: particularly velocity-
encoded phase imaging permits measurement of blood flow 
velocity and volume across the valve and calculation of the regurgi-
Table 3. Progression of aortic regurgitation after transcatheter aortic valve implantation.
Patients, n CoreLab Prosthesis
AR,% (none / trace-mild / moderate-severe)
Postprocedure 1-year 2-year 3-year
REVIVAL40 84 Yes Edwards 100% 20 / 37 / 23 9 / 22 / 18 4 / 6 / 12 2 / 4 / 8
PARTNER B41 179 Yes Edwards 100% 6 / 78 / 15 11 / 71 / 15 34 / 61 / 5 –
PARTNER A14 348 Yes Edwards 100% 11 / 76 / 13 13 / 80 / 7 32 / 6 / 7 –
Buellesfeld et al13 126 No CoreValve 100% 59 / 32 / 9 63 / 34 / 3 63 / 37 / 0 –
Ussia et al42 181 No CoreValve 100% 32 / 53 / 15 34/ 48 / 18 – 43 / 47 / 10
Gilard et al3 3,195 No Edwards 67% 
CoreValve 33%
38 / 46 / 16 33 / 47 / 20 – –
AR: aortic regurgitation
Figure 4. Current 3-D transoesophageal probes permit simultaneous 
visualisation of the transcatheter aortic valve in orthogonal 
(long- and short-axis) views to exactly localise the paravalvular leak. 
The arrows indicate that the paravalvular leak is located at the 
posterior part of the aortic annulus, close to the anterior mitral valve 
leaflet. The paravalvular leak is mild in severity as it occupies <10% 
of the circumference of the prosthetic valve (A) and is moderate in 
severity as it occupies 10-20% of the circumference of the prosthetic 
valve (B).
tant fraction (ratio of forward to backflow volume across the valve). 
A recent study including 16 patients who underwent MRI following 
TAVI demonstrated a significant correlation between MRI-derived 
and angiography-estimated degree of AR (r=0.86, p<0.001) while 
only a limited correlation between MRI and 2-D TTE was observed 
(r=0.32, p=0.23)35. Moreover, TTE underestimated AR by at least 
one grade when compared to MRI in 44% of patients, indicating the 




Acute postprocedural evaluation of AR after TAVI is crucial since 
the presence of moderate and severe AR is associated with increased 
mortality at follow-up and several manoeuvres can be performed at 
the catheterisation laboratory/hybrid operating theatre to reduce the 
severity of AR. In addition, the presence of AR should be monitored 
during the days after TAVI since the regurgitation grade may change 
(Table 3). For example, the properties of the self-expandable pros-
thesis may lead to a reduction in the grade of PAR at follow-up. In 
126 patients undergoing TAVI with self-expandable prostheses, 
Buellesfeld et al reported a reduction in the prevalence of PAR of 
any grade from 41% at 30 days after TAVI to 37% at two-year fol-
low-up13. Experience with the balloon-expandable prostheses has 
also shown a progressive reduction in the prevalence of AR after 
TAVI. In the PARTNER cohort A trial, AR improved in 31.5% of 
patients at two-year follow-up14. Conversely, in the FRANCE 2 reg-
istry with 3,195 patients, the prevalence of AR remained unchanged 
at one-year follow-up3.
Anatomo-pathological analyses of explanted self-expandable pros-
theses have demonstrated neointimal coverage of the frame struts in 
contact with the aortic wall but not in areas of high velocity blood flow 
such as the coronary ostia36. This neointimal tissue may be beneficial in 
reducing the grade of PAR by closing the gaps between the prosthetic 
frame and the native annulus. However, it has been suggested that, in 
specific circumstances, this tissue proliferation may lead to more rapid 
structural valve deterioration. So far, structural valve deterioration is 
anecdotal37,38 and other complications such as stent fracture, deforma-
tion or valve migration have not been described.
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AR after TAVI has been associated with worse outcome and 
increased mortality at follow-up. Accurate assessment of AR dur-
ing the procedure is crucial to decide whether additional manoeu-
vres such as re-ballooning or valve-in-valve are needed to reduce 
the AR grade. Supra-aortic angiography or echocardiography 
(particularly 3-D TEE) are the preferred imaging techniques to 
assess AR immediately after valve deployment. In addition, con-
tinued evaluation of AR at follow-up is recommended since the 
grade of AR may change over time. For follow-up assessment, 
transthoracic echocardiography, particularly 3-D TTE, is the pre-
ferred imaging technique.
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Location and Severity of Aortic Valve Calcium and Implications
for Aortic Regurgitation After Transcatheter Aortic
Valve Implantation
See Hooi Ewe, MBBSa,b, Arnold C.T. Ng, MBBS, PhDa, Joanne D. Schuijf, PhDa,
Frank van der Kley, MDa, Andrea Colli, MDc, Meindert Palmen, MD, PhDa, Arend de Weger, MDa,
Nina Ajmone Marsan, MDa, Eduard R. Holman, MD, PhDa, Albert de Roos, MD, PhDd,
Martin J. Schalij, MD, PhDa, Jeroen J. Bax, MD, PhDa, and Victoria Delgado, MD, PhDa,*
Location of aortic valve calcium (AVC) can be better visualized on contrast-enhanced
multidetector row computed tomography. The present evaluation examined whether AVC
severity and its location could influence paravalvular aortic regurgitation (AR) after
transcatheter aortic valve implantation. A total of 79 patients (age 80  7 years, 49% men)
with preprocedural multidetector row computed tomography were included. Volumetric
AVC quantification and its location were assessed. Transesophageal echocardiography was
performed to assess the presence and site of AR after transcatheter aortic valve implan-
tation. Receiver operating characteristic curves were generated to evaluate the usefulness
of AVC in determining paravalvular AR at a specific site. Postprocedural AR of grade 1 or
more was observed in 63 patients. In most patients (n  56, 71%), AR was of paravalvular
origin. Calcium at the aortic wall of each valve cusp had the largest area under the curve
(0.93, p <0.001) in predicting paravalvular AR at the aortic wall site compared to calcium
at the valvular edge or body (area under the curve 0.58 and 0.67, respectively). Calcium at
the valvular commissure was better than calcium at the valvular edge (area under the curve
0.94 vs 0.71) in predicting paravavular AR originating from the corresponding commissure.
In conclusion, contrast-enhanced multidetector row computed tomography can be per-
formed to quantify AVC. Both AVC severity and its exact location are important in
determining paravalvular AR after transcatheter aortic valve implantation. © 2011
Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:1470–1477)
Multidetector row computed tomography (MDCT) al-
lows visualization of the precise location of aortic valve
calcium (AVC).1,2 The present evaluation aimed to deter-
mine whether the severity and location of AVC would
influence the occurrence and location of paravalvular aortic
regurgitation (AR) after transcatheter aortic valve implan-
tation (TAVI).
Methods
A total of 79 patients with symptomatic, severe aortic
stenosis (AS) who underwent MDCT before TAVI were
included. The patients with bicuspid aortic valves or failing
bioprosthetic valves (valve-in-valve) and those who did not
eventually receive TAVI were excluded. An Edwards-Sa-
pien device (Edwards Lifesciences, Irvine, California) was
implanted in all patients using either the transfemoral or
transapical approach.
According to the institutional protocol, all patients un-
derwent a detailed clinical evaluation and preoperative
transthoracic echocardiography to examine AS severity,
valve morphology, and left ventricular (LV) function. Pre-
operative multidetector row computed tomographic scans
were also performed to assess the aortic valve and aortic
root and the extent and distribution of AVC.3 Transesoph-
ageal echocardiography (TEE) was performed intraproce-
durally and to evaluate the function of the prosthesis imme-
diately after valve deployment, including the assessment of
the AR location, if present.3 The clinical, echocardio-
graphic, and multidetector row computed tomographic data
were prospectively collected in an electronic patient dossier
(EPD Vision, version 8.3.3.6, Leiden, The Netherlands) and
retrospectively analyzed.
The patients underwent imaging preoperatively using
a commercially available ultrasound system (Vingmed
Vivid-7, General Electric Vingmed, Horten, Norway). A
complete 2-dimensional, color, pulsed, and continuous-
wave Doppler echocardiographic examination was per-
formed.3–5 The LV end-diastolic volume and end-systolic
volume were measured (indexed to the body surface
area), and the LV ejection fraction was derived using
biplane Simpson’s method.3,4 Aortic valve morphology
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was evaluated using the parasternal short-axis view, and
the valve area was determined by the continuity equa-
tion.6 The peak and mean transaortic pressure gradients
were calculated.6 AR was assessed using color Doppler
after optimizing the gain and Nyquist limit, and its se-
verity was assessed.7
Figure 1. (A) Automatic segmentation of aortic root with center line by dedicated software (3mensio Valve, version 4.1.sp2, 3mensio Medical Imaging BV).
By moving the 2 orthogonal MPR planes and the third perpendicular transverse plane, manual adjustment of the center line is possible. Next, by moving the
transverse plane along the center line, the region of interest for quantification of calcium is defined manually using the help of the curved MPR view (from
the level of the LV outflow tract proximally to the level just below the coronary ostia distally). From the transverse MPR view (B), the aortic valve is
automatically divided into 3 cusps and manual adjustment of the divisions (arms) between the cusps is possible. The software will automatically detect areas
of calcium according to the predetermined threshold set by the user and provide their locations and corresponding volumetric measurements (C, D). (D)
Example shown. (C) Six locations of calcium can be identified on each cusp. a  along aortic wall; b  valvular body; c  valvular edge; d  commissure;
LC  left coronary cusp; NC  noncoronary cusp; RC  right coronary cusp.
Figure 2. Identification of sites of AR after TAVI using TEE. Short-axis view, at level of proximal (ventricular) end of prosthesis, permits visualization of
origin of paravalvular regurgitation. Interatrial septum helps to identify the noncoronary cusp (A). (B) Six possible sites of paravalvular regurgitation. c 
commissure site; IAS  interatrial septum; LA  left atrium; LC  left coronary cusp; NC  noncoronary cusp; RA  right atrium; RC  right coronary
cusp; w  aortic wall site.
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All patients underwent preoperative evaluation of the
aortic valve and aortic root with either a 64-detector or
320-detector row computed tomography scanner (Aquilion
64 and Aquilion ONE, respectively, Toshiba Medical Sys-
tems, Otawara, Japan). The acquisition protocols of the
multidetector row computed tomographic data for the Aq-
uilion 64 and Aquilion ONE have been previously de-
scribed.8 Before each scan, the patients with a heart rate
greater than the threshold of 65 beats/min received oral 
blockers (50 to 100 mg metoprolol), unless contraindicated.
All multidetector row computed tomographic scans were
acquired during midinspiratory breath-hold. To synchronize
the arrival of the contrast media, bolus arrival was detected
using a real-time bolus tracking technique with a threshold
of 180 Hounsfield units. All the multidetector row com-
puted tomographic data sets were recorded and stored for
postprocessing.
The assessment of AVC was performed using the dia-
stolic images, at 75% of the RR interval of the contrast-
enhanced multidetector row computed tomographic scans.8
The region of interest on the aortic valve, from which AVC
quantification was performed, included (from proximal to
distal) the LV outflow tract, aortic annulus, valvular cusps,
and the adjacent aortic walls (until the level before the
appearance of coronary ostium distally on the double
oblique transverse view). Mitral annular calcification and
atherosclerosis of the upper aortic root (distal to the coro-
nary ostia level) were excluded from AVC quantification.
AVC was measured quantitatively using a novel automated
data postprocessing software (3mensio Valve, version
4.1.sp2, 3mensio Medical Imaging BV, Bilthoven, The
Netherlands). An empiric threshold of 800 Hounsfield
units was used to detect areas of calcium in the region of
interest, because the luminal contrast enhancement ranged
from 250 to 760 Hounsfield units. As previously re-
ported,9,10 calcium quantification using the Agatston score
requires a nonlinear weighting factor in its derivation and
thus has been shown to exhibit greater variability than the
volumetric quantification of calcium. Accordingly, we
quantified AVC in cubic millimeters instead of using the
Agatston score.
First, from the 3 multiplanar reformation (MPR) planes
and the 3-dimensional reconstruction, the aortic root was
automatically segmented and a center line crossing the aor-
tic lumen displayed (Figure 1). The center line and the
perpendicular MPR plane were manually adjusted to im-
prove accuracy using the aortic cusps as a guide, whereby
the 2 orthogonal MPR planes would bisect the long axis of
the aortic cusps in parallel, and a third perpendicular trans-
verse plane would bisect the 3 aortic cusps. The true trans-
Table 1








Men 39 (49%) 30 (54%) 9 (39%) 0.32
Age (years) 80  7 80  7 81  6 0.54
Body mass index (kg/m2) 25.5  4.6 24.9  3.0 26.8  7.0 0.22
Body surface area (m2) 1.82  0.19 1.84  0.17 1.78  0.22 0.18
Logistic EuroSCORE (%) 23  13 23  12 21  14 0.44
Hypertension 46 (58%) 32 (57%) 14 (61%) 0.81
Hypercholesterolemia 33 (42%) 21 (38%) 12 (52%) 0.32
Diabetes mellitus 22 (28%) 18 (32%) 4 (17%) 0.27
Peripheral vascular disease 23 (29%) 16 (29%) 7 (30%) 1.00
Previous myocardial infarction 19 (24%) 13 (23%) 6 (26%) 0.78
Previous coronary artery bypass 31 (39%) 24 (43%) 7 (30%) 0.45
Continuous data are presented as mean  SD and categorical data as n (%).
EuroSCORE  European System for Cardiac Operative Risk Evaluation.
Table 2








Left ventricular end-diastolic volume (ml/m2) 67  26 70  27 58  21 0.06
Left ventricular end-systolic volume (ml/m2) 35  23 37  24 30  22 0.18
Left ventricular ejection fraction (%) 52  12 51  14 54  15 0.39
Mean transaortic gradient (mm Hg) 40  14 38  16 38  12 0.94
Peak transaortic gradient (mm Hg) 61  22 62  24 60  17 0.79
Aortic valve area (cm2) 0.74  0.18 0.76  0.18 0.69  0.18 0.15
Aortic regurgitation
None 18 (23%) 11 (20%) 7 (30%) 0.61
Mild 48 (61%) 35 (63%) 13 (57%)
Moderate 13 (16%) 10 (17%) 3 (13%)
Severe 0 0 0
Continuous data are presented as mean  SD and categorical data as n (%).
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verse plane should be seen to bisect the aortic cusps equally,
permitting visualization of the insertion points of all 3 aortic
cusps at the level of the aortic annulus. Subsequently, by
adjusting the level of the transverse plane, the center line
should sit in the center of the 3 aortic cusps at the level of
aortic sinus (Figure 1). Next, the software automatically
displayed the true short axis of the aortic valve in the
transverse MPR view (Figure 1). Then, the additional 2
orthogonal curved MPR views were used to define the
region of interest (from the LV outflow tract level to
the level before the appearance of the coronary ostium). The
software then automatically provided AVC quantification
and the exact location of calcium (Figure 1). Six locations of
calcium were identified on each cusp (Figure 1), and the
respective AVC could be quantified in cubic millimeters
(Figure 1).
Immediately after prosthesis deployment, the short-
and long-axis views of TEE were used to assess the
presence of AR and its severity and sites (origins of leak).
The severity of AR was assessed qualitatively using color
Doppler flow imaging and the maximal jet width at its
origin from the prosthesis.11 AR was graded as follows:
0, absent; 1, trace and mild; 2, mild-to-moderate; 3,
moderate-to-severe; and 4, severe.7,12 In addition, AR
was classified as paravalvular or intravalvular, or both.
To determine the exact site of origin of paravalvular AR,
a short-axis view (30° to 60°) at the level of the proximal
(ventricular) end of the implanted prosthesis was used.
Accordingly, 6 sites of paravalvular AR were identified
using the interatrial septum as a landmark, which helped
to identify the noncoronary cusp (Figure 2).
Continuous variables are presented as the mean  SD or
SEM and categorical variables as percentages. Comparisons
between patients with and without paravalvular AR after
TAVI were performed using unpaired Student’s t tests (for
continuous variables) and the chi-square or Fisher exact test
(for categorical variables). To relate the locations of AVC
with the sites of paravalvular AR after TAVI using TEE, the
locations of AVC with their respective sites of paravalvular
AR were matched. Receiver operating characteristic curves
were subsequently generated to evaluate the predictive
value of the AVC volume in determining paravalvular AR
at a specific site. All statistical analyses were performed
with the Statistical Package for Social Sciences, version
16.0 (SPSS, Chicago, Illinois). A p value 0.05 was con-
sidered statistically significant.
Results
The baseline clinical and echocardiographic characteris-
tics of the study population are presented in Tables 1 and 2.
The transfemoral approach was performed in 36 patients
Table 3
Baseline multidetector row computed tomographic measurements of total volume of aortic valve calcium (AVC) and its respective location at aortic






Total calcium volume (mm3) 367.1  35.9 222.3  43.3 0.023*
Calcium on left cusp (mm3) 105.4  14.3 40.6  10.5 0.007*
Calcium on right cusp (mm3) 102.2  13.1 61.9  77.3 0.082
Calcium on noncoronary cusp (mm3) 160.2  16.6 95.9  19.3 0.028*
Calcium on wall of left cusp (mm3) 28.6  3.5 10.8  5.4 0.008*
Calcium on wall of right cusp (mm3) 25.0  4.7 11.5  7.1 0.12
Calcium on wall of noncoronary cusp (mm3) 46.1  6.1 19.0  11.9 0.029*
Calcium on edge of left cusp (mm3) 33.3  5.9 15.6  5.6 0.076
Calcium on edge of right cusp (mm3) 37.7  5.7 25.6  5.8 0.21
Calcium on edge of noncoronary cusp (mm3) 42.7  7.0 33.0  7.5 0.42
Calcium on body of left cusp (mm3) 29.2  6.1 10.6  2.9 0.060
Calcium on body of right cusp (mm3) 23.8  5.0 13.2  4.5 0.20
Calcium on body of noncoronary cusp (mm3) 54.7  7.3 34.8  7.8 0.11
Calcium on left–right commissure (mm3) 13.4  2.2 2.8  1.1 0.003*
Calcium on left–noncoronary commissure (mm3) 9.8  2.7 1.2  0.6 0.050
Calcium on right–noncoronary commissure (mm3) 12.5  2.5 6.1  1.8 0.11
Calcium on left–right edge (mm3) 36.1  6.6 20.0  5.9 0.15
Calcium on left–noncoronary edge (mm3) 40.5  6.4 23.3  4.0 0.098
Calcium on right–noncoronary edge (mm3) 37.2  5.7 30.8  8.4 0.54
Continuous data are presented as mean  SEM.
Table 4
Prevalence of paravalvular regurgitation on transesophageal








Wall of left cusp 51 (10.8%) 25 (5.3%) 3 (0.6%)
Wall of right cusp 61 (12.9%) 16 (3.4%) 2 (0.4%)
Wall of noncoronary cusp 43 (9.1%) 33 (7.0%) 3 (0.6%)
Left–right commissure 70 (14.8%) 9 (1.9%) 0
Left–noncoronary commissure 74 (15.6%) 3 (0.6%) 2 (0.4%)
Right–noncoronary commissure 73 (15.4%) 6 (1.2%) 0
Data are presented as absolute number of transesophageal echocardio-
graphic sites with or without paravalvular AR (expressed as percentage of
474 potential sites in total); 6 sites in each patient for a total of 474 sites
in 79 patients.
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Figure 3. Total volume of baseline AVC on contrast-enhanced multidetector row computed tomographic scans for presence or absence of each type of AR:
(A) overall, (B) paravalvular, and (C) intravalvular. Data presented as mean and 95% confidence intervals.
Figure 4. Calcium load and its location as predictor of paravalvular AR at (A) aortic wall site or (B) commissure site.
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(46%), and the transapical approach in 43. In terms of
prosthesis size, 62 patients (78%) received a 26-mm valve
and 37 a 23-mm valve. The baseline measurements of the
total volume of AVC and volume of calcium on each loca-
tion of the aortic cusp are listed in Table 3. Because the
valvular commissures or valvular free edges were closely
related to each other on 2 apposing cusps (Figure 1), they
were considered as a unit when AVC was concerned.
Hence, the amount of calcium on the valvular commissures
or free edges was the summation of their respective volume
of calcium on the 2 associated cusps.
Grade 1 or greater AR immediately after initial pros-
thesis deployment was observed in 63 patients: grade 1
(mild) in 49 (62%), grade 2 (mild-to-moderate) in 11
(14%), and grade 3 (moderate-to-severe) in 1 (4%). The
remaining 16 patients (20%) did not have any detectable
AR. Severe AR (grade 4) was not observed. In terms of
the distribution of AR after TAVI (n  63), most patients
had paravalvular AR (n  56), and isolated intravalvular
AR was observed in a few patients (n  7). The propor-
tion of patients with and without postprocedural paraval-
vular AR was comparable among the patients who un-
derwent the transfemoral or transapical approach (45% vs
48% and 55% vs 52%, respectively; p  0.81) or those
who received a 23- or 26-mm prosthesis (21% vs 22%
and 79% vs 78%, respectively; p  1.00).
Among the patients with postprocedural paravalvular
AR, 6 potential sites of leakage using TEE in each patient
were identified (Figure 2). Hence, the total number of po-
tential sites for the entire population was 474. The preva-
lence of paravalvular AR at these 6 specified sites is listed
in Table 4. The total number of sites with paravalvular AR
was 102, and most occurred at the aortic wall sites (82 sites,
80%), with few originating from the valvular commissures
(20 sites, 20%).
Patients with a greater AVC volume at baseline had a
greater prevalence of AR after TAVI (Figure 3). In partic-
ular, the total AVC volume was related to the development
of paravalvular AR but not to intravalvular AR after TAVI
(Figure 3). Accordingly, the study population was dichoto-
mized into the presence and absence of paravalvular AR to
further assess the relation between AVC (and its locations)
and the occurrence of paravalvular AR.
To relate the locations of AVC with the presence of
paravalvular AR at the 6 specified sites after TAVI, we first
matched the locations of AVC with their respective sites of
paravalvular AR. For AR originating from the aortic walls
(1 from each cusp, 3 sites in total), each AR site was
matched with its AVC location on each cusp at the aortic
wall, valvular edge, and valvular body, respectively. Next,
receiver operating characteristic curves were generated to
determine the usefulness of the volume of calcium on its
respective AVC location in predicting the presence of para-
valvular AR (originating from the aortic wall site). As
demonstrated in Figure 4, calcium at the aortic wall had the
largest area under the curve (0.93, p 0.001) in predicting
the occurrence of paravalvular AR (at the aortic wall site)
Figure 5. (A) Example showing location and volume of AVC on contrast-enhanced multidetector row computed tomographic scan, as provided by automated
postprocessing software and subsequent development of paravalvular regurgitation after TAVI. (B) Example of patient without paravalvular regurgitation
after TAVI showing location and volume of AVC on contrast-enhanced multidetector row computed tomographic scan at baseline. Images of MDCT are
rotated for easy comparison with corresponding views on transesophageal echocardiogram. Abbreviations as in Figure 2.
1475Valvular Heart Disease/Calcium and Paravalvular Regurgitation After TAVI
94 Chapter 7
compared to calcium at the valvular edge or body (area
under the curve 0.58 and 0.67, respectively).
Similarly, for AR originating from the commissures (3
sites in total), each site was matched with its corresponding
AVC location on the valvular commissure and the respec-
tive valvular edge involved: the left–right, left–noncoro-
nary, and right–noncoronary, respectively. Figure 4 shows
that calcium at the valvular commissure had a greater area
under the curve than calcium at the valvular edge (0.94 vs
0.71) in predicting the occurrence of paravalvular AR orig-
inating from the commissures. Figure 5 shows examples of
a grade 1 paravalvular AR and no AR after TAVI and their
respective locations and severity of AVC.
Discussion
The present study highlighted that both the amount of
calcium and its exact location on the aortic valve are im-
portant in determining the development of paravalvular AR
after TAVI. The amount of calcium at the aortic wall was
the main determinant of subsequent paravalvular AR at the
corresponding aortic wall site, and the amount of calcium at
the valvular commissure could predict the occurrence of
subsequent paravalvular AR, originating from the corre-
sponding commissure.
Previous studies have shown that AVC can be objec-
tively quantified using electron beam computed tomography
and MDCT.13–16 In addition, differing amounts of calcium
on the surfaces of the cusps have been observed in excised
stenotic aortic valves.17 Recent studies that focused on the
role of AVC and its relation to post-TAVI AR1,8,13 have
been performed using the Agatston score. However, the
volumetric calcium scoring method has been shown to im-
prove interscan reproducibility compared with the Agatston
score.9,10,16 Using only unenhanced MDCT, visualization of
the valve leaflets can be challenging. Therefore, contrast-
enhanced MDCT is commonly performed for better visual-
ization of AVC and its precise location on the aortic
valve.1,2 The present study demonstrated the feasibility of
volumetric quantification of AVC, together with its detailed
location on the aortic valve, using the automated postpro-
cessing software using contrast-enhanced MDCT.
Although dramatic improvement has occurred in the
periprocedural complication rate in the recent TAVI se-
ries,18–20 there is still a significant proportion of patients
(72% to 84%) with at least some degree of paravalvular AR
after TAVI.18,21 This is consistent with the results of the
present study, which showed that 71% of patients had para-
valvular AR. The long-term effect of AR, however mild it
might be, is yet to be determined. A few recent studies have
alluded to the importance of AVC severity in the develop-
ment of AR after TAVI.1,2,8 In a recent study of 57 patients
who underwent TAVI (balloon-expandable valves in 33%
and self-expanding valves in 67%), Koos et al2 showed that
the severity of AR after deployment was positively related
to AVC severity. In addition, John et al1 demonstrated in
100 patients with self-expanding valve implantation that
although a significant relation exists between total calcium
at the device landing zone and the grade of paravalvular AR
after deployment, this relation was weak (r  0.33, p 
0.001). Therefore, the study by John et al1 suggested that the
location of AVC might be more important than the total
amount of AVC in determining AR after TAVI.
In the present study, we have confirmed the relation
between the location of AVC and the presence of paraval-
vular AR, the predominant type of AR observed after TAVI.
More importantly, we have shown that the main determi-
nant of any detectable paravalvular AR, originating from the
aortic wall site, was the amount of calcium at the corre-
sponding aortic wall. Calcium at other locations such as the
valvular edge or body was less important in determining the
presence of paravalvular AR arising from the aortic wall
site. When paravalvular AR originating from the commis-
sure was analyzed, the main determinant of any detectable
AR was the amount of calcium at the corresponding com-
missure of the native valve. Therefore, the results of the
present study have highlighted the important role of both the
AVC load and its location, in predicting the development of
paravalvular leakage after TAVI. Although the mechanism
is not entirely clear, the most likely explanation is that the
calcified, native aortic valve is pushed outward toward the
walls of the aorta initially during ballooning and later, by
the balloon expandable bioprosthesis (which has a height of
14 to 16 mm).22 Therefore, when a significant amount of
calcium is present at the circumference of the native valve,
it can potentially prevent perfect apposition between the
prosthesis and aortic walls and, thus, result in paravalvular
AR at these sites. These results suggest that extra caution
should be given to patients, particularly those with calcium
at the circumference of the native aortic annulus, and per-
haps, additional maneuvers such as prolonged ballooning or
reballooning might be necessary when paravalvular AR is
present after deployment.
We acknowledged that this was a relatively small study and
that it was insufficient to study the clinical end points of at
least moderate AR after TAVI. This will need to be ex-
plored in a larger population.
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Effect of Aortic Regurgitation Following Transcatheter
Aortic Valve Implantation on Outcomes
See Hooi Ewe, MBBSa,b,c, Manuela Muratori, MDd,e, Frank van der Kley, MDa,b, Mauro Pepi, MDd,e,
Victoria Delgado, MD, PhDa,b, Gloria Tamborini, MDd,e, Laura Fusini, MSd,e,
Arend de Weger, MD, PhDa,b, Paola Gripari, MDd,e, Antonio Bartorelli, MDd,e,
Jeroen J. Bax, MD, PhDa,b, and Nina Ajmone Marsan, MD, PhDa,b,*
The prognosis of aortic regurgitation (AR) after transcatheter aortic valve implantation
(TAVI) and the changes in AR grade over time remain unclear. This study evaluated the
midterm survival associated with AR after TAVI and examined the evolution of AR over
time and its effect on cardiac performance. Successful TAVI was performed in 314 patients
(age 81 – 7 years, 36% men). Serial transthoracic echocardiography and clinical assessment
were available in 175 patients who survived >12 months. AR was assessed in terms of
overall, paravalvular, and intravalvular severity. Significant post-TAVI AR (grade ‡2) was
observed in 82 patients (26%), and these patients showed a trend toward reduced survival at
1- (93% vs 91%) and 2-year (89% vs 74%, log-rank p [ 0.063) follow-up. Of the 175
patients who survived >12 months, grade ‡2 overall, paravalvular, and intravalvular AR
were noted in 47 (27%), 32 (18%), and 8 patients (5%), respectively. Significant overall and
paravalvular AR appeared to improve over time, particularly during the first 6 months
(p <0.05), whereas intravalvular AR remained unchanged. Although improvements in the
echocardiographic parameters were similar among patients with and without significant
AR, patients who remained with grade ‡2 AR at 6 months had significantly worse survival
than their counterparts at 2 years (80% vs 94%, log-rank p [ 0.032). In conclusion, sig-
nificant overall and paravalvular AR after TAVI appeared to improve over time. Although
improvements in the echocardiographic parameters were similar, patients with grade ‡2
AR, both immediately after TAVI and at 6 months, were associated with worse
survival.  2015 Elsevier Inc. All rights reserved. (Am J Cardiol 2015;115:664e669)
Transcatheter aortic valve implantation (TAVI) is an
established alternative therapy for patients with symptomatic
severe aortic stenosis (AS) who are deemed to have high risk
or contraindications for conventional surgery.1 Although
advances in technical devices and proper patient selection
have significantly improved TAVI results,2,3 aortic regurgi-
tation (AR) remains a common finding after TAVI. More-
over, significant AR after TAVI has been associated with an
increase in in-hospital mortality and less favorable clinical
outcomes.2,4e6 However, the changes in post-TAVI AR
during follow-up and its effect on long-term clinical out-
comes remain to be clarified. Therefore, the aim of the study
was twofold: first, to evaluate the midterm survival associ-
ated with AR after TAVI; and second, to examine the evo-
lution of AR over time and its effect on cardiac performance
and outcomes at mid- and long-term follow-up.
Methods
Patients with symptomatic severe AS who underwent
successful TAVI at Leiden University Medical Center,
Leiden, the Netherlands, and Centro Cardiologico Monzino,
IRCCS, Milan, Italy, were included. All patients had severe
AS, defined as an aortic valve area <1 cm2 or <0.6 cm2/m2,
and were considered at high risk or had contraindications
for conventional valve surgery. All consecutive patients
with successful TAVI procedures who survived the index
hospitalization, from November 2007 to March 2011, were
included. Patients with bicuspid aortic valves or previous
aortic or mitral prostheses were excluded. For the subsequent
analysis, which aimed at evaluating the changes over time of
AR after TAVI and its effect on cardiac hemodynamics and
clinical outcomes, patients with a follow-up duration of at least
12 months after implantation were included. According to the
institutional protocols, all patients underwent clinical and
echocardiographic evaluation at baseline, after the procedure
(before hospital discharge), at 6 months, and then annually.
Clinical and echocardiographic data were prospectively
recorded and subsequently analyzed. All patients received
either the 23- or 26-mm balloon-expandable Edwards-SA-
PIEN valves (Edwards Lifesciences, Inc., Irvine, California)
depending on the diameter of the aortic annulus.7 Only 2 pa-
tients received the 29-mm valve. The device was delivered
through either the transfemoral or transapical approach (in
patients with unsuitable aortoiliofemoral anatomy).8
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Standard 2-dimensional, color and Doppler transthoracic
echocardiography was performed in all patients at baseline,
after the procedure (before hospital discharge), at 6 months,
and annually, using a commercially available ultrasound
system (Vivid-7; General Electric, Horten, Norway). All
images were digitally stored for offline analysis (EchoPAC,
version 110.0.0; GE-Vingmed, Horten, Norway). The left
ventricular (LV) outflow tract, aortic annulus diameters, and
transaortic gradient were measured, as recommended, and
aortic valve area was calculated using the continuity equa-
tion.9,10 Standard LV dimensions were obtained, and LV
mass index was calculated according to Devereux et al and
corrected for body surface area.9,11 Using the biplane
Simpson’s method, LV end-diastolic and end-systolic vol-
umes and maximal left atrial (LA) volumes were measured,
and LV ejection fraction was derived.9
The presence of AR of the native aortic valve at baseline
was assessed using color Doppler recordings as recom-
mended.12 To evaluate the presence and severity of AR after
TAVI, a combination of the qualitative and semiquantitative
parameters was used according to the current guidelines, after
optimizing gain and Nyquist scale (50 to 60 cm/s).13,14 For
intravalvular AR, similar method for assessment of native
valvular regurgitation (in terms of ratio of the regurgitant jet
to the LV outflow tract width) was applied: <25% mild, 26%
to 64% moderate, and >65% severe.13,14 For paravalvular
AR, the proportion of the circumference of the prosthesis
occupied by the jet allowed semiquantitative assessment of
its severity as described: <10% mild, 10% to 20% moderate,
and >20% severe.13,15 Finally, the assessment of overall AR
severity involved integration of all these parameters and was
graded as follows: grade 0 (none), grade 1 (mild) when either
intravalvular or paravalvular AR was mild, grade 2 (mild to
moderate) when both mild intravalvular and mild para-
valvular AR were present or when either intravalvular or
paravalvular AR was moderate, grade 3 (moderate to severe)
when both moderate intravalvular and moderate paravalvular
AR were present, and grade 4 (severe) when either intra-
valvular or paravalvular AR was severe. Significant AR after
TAVI was defined as overall AR grade �2.
Before hospital discharge and at 6 months, and annually,
clinical evaluation was performed, including the classifica-
tion of heart failure symptoms according to the New York
Heart Association functional class. All adverse events15 and
mortality were recorded.
Continuous variables are presented as mean � SD.
Categorical variables are presented as percentages. Preproce-
dural and follow-up data were compared between patients with
(AR grade �2) and without significant AR (AR grade <2).
Unpaired Student t test, chi-square test, or Fisher’s exact test
was used to compare continuous or categorical variables, as
appropriate. In addition, the survival rates are presented as
Kaplan-Meier curves, and the log-rank test was used for
comparisons between patients with andwithout significant AR.
To examine the changes in AR severity over time, the
nonparametric Friedman test for repeated measures was used,
followed by post hoc analyses for significant results using a
paired Wilcoxon analysis. Finally, repeated-measures analysis
of variance was used to evaluate the repeated echocardio-
graphic variables (at different time points), followed by post
hoc analyses for significant results using Bonferroni correction.
A 2-tailed probability value of <0.05 was considered statisti-
cally significant. All statistical analyses were conducted using
SPSS for Windows, version 16 (SPSS Inc., Chicago, Illinois).
Results
Baseline clinical characteristics of the 314 patients (age
81 � 7 years, 36% men) are summarized (Table 1). Post-






Body surface area (m2) 1.72�0.20
Logistic EuroSCORE (%) 20.5�11.4
Systolic blood pressure (mmHg) 129�20
Diastolic blood pressure (mmHg) 71�10
NYHA functional class II 80 (26%)
III 172 (55%)
IV 62 (20%)
Previous myocardial infarction 62 (20%)
Previous coronary bypass surgery 63 (20%)
Previous percutaneous coronary intervention 80 (26%)
Peripheral vascular disease 126 (40%)
Hypertension* 255 (81%)
Hypercholesterolaemia* 165 (53%)
Diabetes mellitus 88 (28%)
Hemoglobin (g/dL) 12.0�1.6
Heart rhythm Sinus 238 (77%)
Atrial fibrillation 53 (17%)
Paced 23 (7%)
Frailty 75 (24%)
Aortic valve area (cm2) 0.68�0.17
Mean transaortic gradient (mmHg) 48�16
Left ventricular ejection fraction (%) 54.8�12.5
Approach Transfemoral 171 (55%)
Transapical 143 (46%)
Continuous data are presented as meanþSD and categorical data as n (%).
* Hypertension: history of high blood pressure and/or on antihyperten-
sive treatment. Hypercholesterolemia: history of hypercholesterolemia
and/or on statin therapy.
Figure 1. Survival Kaplan-Meier curves for patients with post-TAVI AR
grade �2 or <2 before hospital discharge.
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patients (76%). AR was classified as none in 77 (25%),
grade 1 in 155 (49%), and grade 2 in 81 patients (26%).
Only 1 patient (0.3%) had moderate-to-severe AR (grade 3)
at the end of the procedure despite reballooning. Significant
AR after TAVI, defined as AR grade �2, was observed in
82 patients (26%). Over a mean follow-up of 19 months
(median 18, 25th to 75th percentile 10 to 28), the overall
survival rates at 6 months, 1 year, and 2 years were 96%,
92%, and 84%, respectively. There were a total of 43 deaths:
18 (22%) in patients with post-TAVI AR grade �2 and 25
(11%) in patients with post-TAVI AR grade <2. Impor-
tantly, there was a trend toward a reduced survival in
patients with post-TAVI AR grade �2 compared with
patients without significant AR, at 1 year (93% vs 91%) and
at 2 years (89% vs 74%, log-rank p ¼ 0.06; Figure 1).
To evaluate the changes over time of AR after TAVI,
complete echocardiographic data were available in 175
patients who survived at least 12 months. Post-TAVI AR was
present in the majority (n ¼ 136, 78%). The overall AR was
considered grade 1 in 89 (51%) and grade 2 in 47 patients
(27%). In the presence of post-TAVI AR, paravalvular AR
was the most common (83%), whereas intravalvular AR was
less frequent (42%), with 25% of patients having both AR.
The evolution of overall, paravalvular, and intravalvular AR
severity was compared before discharge, at 6 months, and
�12 months after TAVI. No significant change in the overall
AR was observed over time (Friedman p ¼ 0.37; Figure 2).
Of note, paravalvular AR appeared to improve (Friedman
p ¼ 0.014; Figure 2), whereas intravalvular AR was un-
changed over time (Friedman p ¼ 0.95; Figure 2).
When the population was analyzed according to the
presence or absence of significant post-TAVI AR, marked
improvement in the overall AR was observed in patients
with overall AR grade�2 (n¼ 47, Friedman p <0.001) with
a significant change noted between after TAVI and at
6 months, which was stable over time (Figure 2). In contrast,
patients with overall AR grade <2 (n ¼ 128) did not show
any change over time (Figure 2). Concerning paravalvular
Figure 2. Comparison of changes in the overall (A), paravalvular (B), and intravalvular (C) AR severity after TAVI in the entire population, in patients with
(grade �2) and without (grade <2) significant post-TAVI AR. AR severity at the corresponding time point was given as mean � SD below each graph.
*p <0.05 by the Friedman test. Post hoc test: †p <0.05 between after TAVI and 6 months.
Table 2
Baseline clinical and echocardiographic characteristics in patients with and
without significant aortic regurgitation post-transcatheter aortic valve
implantation
Variable Aortic Regurgitation p-value*
�2 (n¼47) <2 (n¼128)
Age (years) 81.3�5.4 80.5�6.9 0.43
Men 21 (45%) 43 (34%) 0.22
Body surface area (m2) 1.75�0.22 1.73�0.19 0.62
Logistic EuroSCORE (%) 22.5�12.8 19.7�10.6 0.62
NYHA functional class II 8 (17%) 34 (27%) 0.24
III 25 (53%) 69 (54%)
IV 14 (30%) 25 (19%)
Previous myocardial infarction 11 (23%) 25 (20%) 0.64
Previous coronary bypass surgery 8 (17%) 29 (23%) 0.53
Previous percutaneous coronary
intervention
13 (28%) 34 (23%) 1.00
Peripheral vascular disease 16 (34%) 53 (41%) 0.49
Hypertension 38 (81%) 100 (78%) 0.84
Hypercholesterolaemia 22 (47%) 62 (48%) 0.87
Diabetes mellitus 14 (29%) 30 (23%) 0.43
Hemoglobin (g/dL) 12.0�1.3 12.1�1.7 0.60
Aortic valve area (cm2) 0.70�0.15 0.70�0.17 0.22
Mean transaortic gradient (mmHg) 48�17 48�16 0.91







Left ventricular ejection fraction (%) 53�12 56�13 0.25
Left ventricular mass index (g/m2) 163�55 144�37 0.03
Left atrial volume index (ml/m2) 57�17 51�19 0.11
Aortic regurgitation
pre-TAVI
Grade 0-1 33 (70%) 93 (73%) 0.85
Grade 2-3 14 (30%) 35 (27%)
Prosthesis size 23 mm 19 (40%) 51 (40%) 1.00
26 mm 28 (60%) 77 (60%)
Continuous data are presented as meanþSD and categorical data as n (%).
* p value for comparison between aortic regurgitation �2 and <2 using
unpaired t test or chi-square test.
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AR, no significant change in paravalvular AR was observed
over time in patients with post-TAVI paravalvular AR grade
<2 (n ¼ 143). Importantly, in patients with post-TAVI
paravalvular AR grade �2 (n ¼ 32), significant improve-
ment in paravalvular AR was observed (Friedman
p ¼ 0.002), particularly during the first 6 months (Figure 2).
Concerning intravalvular AR, most patients had no signifi-
cant intravalvular AR (n ¼ 167), whereas significant intra-
valvular AR was present in only 8 patients. Of note,
intravalvular AR remained stable, with no significant changes
observed over time, regardless of intravalvular AR grade �2
or <2 (Figure 2). In terms of absolute number of patients,
worsening in post-TAVI AR from AR grade <2 to �2 over
time was uncommon (n ¼ 7, 4%). Only 4 patients with mild
paravalvular AR developed moderate AR at 6 months, which
remained stable thereafter. Among the 3 patients with mild
intravalvular AR, 2 patients progressed to moderate AR,
while 1 patient developed severe intravalvular AR (from
endocarditis) by 6 months. In patients with post-TAVI par-
avalvular AR grade �2 (n ¼ 32), notably 9 patients (28%)
had reduction in AR to none or mild AR, while only 1 patient
(3%) developed severe AR because of endocarditis at
6 months. In contrast, among those with post-TAVI intra-
valvular AR grade �2 (n ¼ 8), AR remained unchanged in
the majority (n ¼ 7, 88%), and 1 patient (1%) developed
severe AR by 6 months, requiring surgery.
To evaluate the hemodynamic effect of significant post-
TAVI AR in the subgroup of 175 patients, the echocardio-
graphic variables at 6 and �12 months were compared.
Table 2 summarizes the baseline clinical and echocardio-
graphic characteristics of patients with post-TAVI AR grade
�2 (n ¼ 47) and AR grade <2 (n ¼ 128). During follow-up,
no significant changes in LV end-diastolic volumes were
observed in both groups (Figure 3). Importantly, patients
with post-TAVI AR grade �2 did not exhibit a significant
increase in LV end-diastolic volume over time. Of note, a
significant improvement in LV ejection fraction was
observed in both groups (Figure 3). Although patients with
post-TAVI AR grade �2 had a larger LV mass at baseline,
both groups showed significant LV mass regression over
time. In fact, LV mass regression was noted at 6 months and
continued to regress beyond 12 months (Figure 3). Similar
reduction in LA volume was also observed in both groups
over time (Figure 3). In terms of transvalvular hemody-
namics, significant improvement in mean gradient and aortic
valve area was noted at 6 months for patients with AR grade
�2 (48 � 17 vs 12 � 7 mm Hg and 0.70 � 0.15 vs 2.09 �
0.53 cm2) and with AR grade<2 (48� 16 vs 11� 4 mm Hg
and 0.70 � 0.17 vs 1.97 � 0.43 cm2), respectively. The
majority of patients (n¼ 166, 95%) reported an improvement
in New York Heart Association functional class by �I class,
compared with baseline. However, 6 patients (13%) with
post-TAVI AR grade �2 (n ¼ 47) compared with only 3
patients (2%) with post-TAVI AR grade <2 (n ¼ 128)
reported no improvement in functional class.
Given that significant changes in AR occurred within
6 months after TAVI, the effect of significant AR at 6 months
on survival was further examined in this group (n ¼ 175).
Figure 3. Comparison of changes in LV end-diastolic volume index (A), LV ejection fraction (B), LV mass index (C), and left atrial volume index (D) in
patients with (grade �2) and without (grade <2) significant post-TAVI AR. Measurement values (mean � SD) at the corresponding time point are given below
each graph. p Value by repeated measures of variance. Bonferroni post hoc test: *p <0.05 between baseline and 6 months. †p <0.05 between baseline and
�12 months. zp <0.05 between 6 and �12 months. xp <0.05 between AR grade <2 and �2.
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Forty-eight patients (27%) had significant 6-month AR grade
�2. Over a mean follow-up of 25 months (median 24, 25th to
75th percentile 18 to 30), more deaths were observed in pa-
tients with 6-month AR grade �2 (n ¼ 7, 15%) than in pa-
tients with 6-month AR grade <2 (n ¼ 5, 4%). A significant
reduction in survival was noted in patients with 6-month AR
grade �2 compared with those without significant 6-month
AR (n ¼ 127) at 1 year (97% vs 98%) and at 2 years (80%
vs 94%, log-rank p ¼ 0.032; Figure 4).
Discussion
The present study showed that significant AR is common
immediately after TAVI and that patients with AR grade �2
tended to have a less favorable clinical outcome. However,
significant AR after TAVI, and in particular paravalvular AR,
appeared to improve during the first 6 months after implan-
tation. Interestingly, improvement in LV ejection fraction,
together with LV mass regression and LA volume reduction,
was similar among patients with and without AR grade �2.
Nevertheless, patients who remained with AR grade�2 at 6-
month follow-up showed significantly worse survival than
patients with AR grade <2.
Trivial or mild AR, particularly paravalvular, is common
and often an acceptable finding after TAVI because of
incomplete annular sealing of the transcatheter valve within a
calcified aortic valve.3,4 Recently, there is a growing interest
in the effect of AR on outcomes after TAVI.2,5,6 In their
series, Abdel-Wahab et al5 showed that patients with AR
grade�2 had a significantly higher in-hospital mortality than
those with no or mild AR after TAVI. Because early in-
hospital mortality is mainly determined by procedural com-
plications,2 the present study, therefore, focused on patients
who survived the TAVI procedures and examined the
midterm all-cause mortality associated with AR. A strong
trend toward reduced survival among patients with post-
TAVI AR grade �2 was observed. This is consistent with
recent studies that identified presence of moderate or severe
post-TAVI AR as an independent predictor of survival at
1 year2,6 The Placement of Aortic Transcatheter Valves A
trial further confirmed that the effect on mortality at 2 years
was proportional to post-TAVI AR severity, even when AR
was only mild.4 These observations underscore the impor-
tance of reducing AR to a minimum after TAVI.
Currently, it is still unclear how post-TAVIAR evolves over
time. This study observed that paravalvular AR appeared to
diminish in severity over time. Importantly, significant para-
valvular AR (grade �2) after TAVI appeared to improve,
particularly within the first 6 months. In a 3-year follow-up
study with balloon-expandable valves, patients with moderate
AR after TAVI reported improvement to mild AR or remained
unchanged by 6 months, although the components of AR were
not described.16 A possible explanation for the progressive
reduction in paravalvular AR after balloon-expandable valve
implantation is the presence of positive remodeling of the aortic
annulus.17 Over time, the stented prosthesis may adapt to better
accommodate and seal the calcified native commissures and
thus, minimizing the paravalvular leak.
There are limited data regarding the effect of AR on
cardiac performance after TAVI. Although significant AR
after TAVI is associated with worse clinical outcomes,2,5,6
the direct causal relation between AR and mortality
remains to be determined, and it is unclear if this is mediated
by its hemodynamic consequences on the LV or by other
mechanisms associated with noncardiovascular events.18 In
patients with severe AS, the stiff and hypertrophied LV has
adapted to the long-standing pressure overload state and is
associated with impaired relaxation and elevated LV end-
diastolic pressure.19 Accordingly, when AR develops after
TAVI, there is a concern that the AR volume may precipitate
a further increase in the already elevated LV end-diastolic
pressure, resulting in acute pulmonary edema or inducing
LV dilatation in the midterm. This study confirmed that LV
ejection fraction improved, accompanied by LV mass
regression in both groups of patients (AR grade �2 and <2)
after TAVI. Interestingly, LV volumes did not increase over
time in patients with significant AR, suggesting that the
derived hemodynamic benefit of TAVI after the relief of AS
still outweighed the perceived negative effect of AR after
TAVI, at least at midterm follow-up. In a 5-year follow-up of
84 patients with surgical aortic valve, Rallidis et al20 also
reported that LV dimensions did not differ in patients with or
without paravalvular leak, whereas the wall thickness
decreased and fractional shortening increased in both groups.
Although significant AR was not associated with overt
harmful effect on LV structure and function on echocardi-
ography, its undesirable effects on clinical outcomes should
not be overlooked. More patients with significant post-TAVI
AR reported no improvement in functional class, compared
with patients with AR grade <2 in this study, which is
consistent with the study by Gotzmann et al,21 that identified
moderate and severe AR as an independent predictor of no
improvement of functional class at 6 months. Moreover, the
present study highlighted that patients with significant AR
that persisted at 6 months were also associated with worse
survival (Figure 4). In comparison with previous studies that
focused on post-procedural AR and its negative effect on
early survival,2,4e6 this study observed the negative associ-
ation between significant AR at 6 months after TAVI and late
survival. Other mechanisms that are beyond the scope of this
study may be responsible for the poor outcomes, such as
undesirable neurohumoral changes, impaired coronary flow,
and possible higher risk of hemolysis.
We acknowledge that inclusion of only patients who
survived at least 12 months may have limited the ability to
Figure 4. Survival Kaplan-Meier curves for patients with 6-month AR �2
or AR <2 after TAVI.
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draw definite conclusion. However, the aim of the study was
to examine how AR after TAVI changes over time, and this
could only be studied in patients who survived a period of
time after the procedure and underwent systematic echocar-
diographic examination. Moreover, transthoracic Doppler
echocardiography only provides a semiquantitative hemo-
dynamic assessment of AR severity and is subjected to
variability and requires further validation.
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Hemodynamic and Clinical Impact
of Prosthesis–Patient Mismatch
After Transcatheter Aortic Valve Implantation
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Objectives This study examined the mid-term hemodynamic and clinical impact of prosthesis–patient mismatch (PPM) in
patients undergoing transcatheter aortic valve implantation (TAVI) with balloon-expandable valves.
Background PPM can be observed after aortic valve surgery. However, little is known about the incidence of PPM in patients
undergoing TAVI.
Methods Echocardiography and clinical assessment were performed in 165 patients at baseline, before hospital dis-
charge, and at 6 months after TAVI. PPM was defined as an indexed effective orifice area 0.85 cm2/m2.
Results Thirty patients (18.2%) showed PPM before hospital discharge. At baseline, patients with PPM had a larger body
surface area (1.84  0.18 m2 vs. 1.73  0.18 m2, p  0.003) and a greater severity of aortic stenosis (indexed
valve area 0.35  0.09 cm2/m2 vs. 0.40  0.10 cm2/m2, p  0.005) than patients without PPM. Patients with
PPM demonstrated a slower and smaller reduction in mean transaortic gradient, limited left ventricular (LV)
mass regression, and left atrial volume reduction over 6 months compared with patients without PPM. LV filling
pressure, measured by E/e=, tended to remain elevated in patients with PPM. Importantly, a higher proportion of
patients with PPM did not improve in New York Heart Association functional class compared with patients with-
out PPM (36.7% vs. 1.5%, p  0.001), although major adverse valve-related and cardiovascular events did not
differ between the 2 groups.
Conclusions PPM may be observed after TAVI and when present may be accompanied by less favorable changes in trans-
valvular hemodynamics, limited LV mass regression, persistent elevated LV filling pressure, and less improve-
ment in clinical functional status. (J Am Coll Cardiol 2011;58:1910–8) © 2011 by the American College of
Cardiology Foundation
Prosthesis–patient mismatch (PPM) can be observed after
surgical aortic valve replacement for severe aortic stenosis
(AS) (1–4) when the effective orifice area (EOA) of a
normally functioning prosthesis is too small in relation to
the patient’s body size (5). The presence of significant PPM
after aortic valve surgery has been associated with worse
transvalvular hemodynamics and limited regression of left
ventricular (LV) hypertrophy as a result of increased LV
afterload (6). In addition, reduced indexed EOA has been
reported to negatively affect clinical outcomes (1–4).
See page 1919
So far, only a few small series (7–9) have described the
incidence of PPM after transcatheter aortic valve implan-
tation (TAVI), and little is known about its impact on
LV performance and clinical outcomes in these patients.
Therefore, we aimed to evaluate the mid-term hemody-
namic and clinical impact of PPM in patients with severe
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AS undergoing TAVI with the balloon-expandable Ed-
wards SAPIEN bioprosthesis (Edwards Lifesciences, Inc.,
Irvine, California).
Methods
Patient population. A total of 190 consecutive patients
with symptomatic severe AS who underwent TAVI at
Leiden University Medical Center, Leiden, the Nether-
lands, and Centro Cardiologico Monzino, IRCCS, Milan,
Italy, were included. Based on a multidisciplinary team
assessment, all patients had severe AS, defined as an aortic
valve area 1 cm2 or 0.6 cm2/m2, and were considered at
high operative risk or had contraindications to conventional
aortic valve surgery. Patients with previous aortic or mitral
prostheses, unsuccessful TAVI, or an echocardiographic
follow-up 6 months were excluded from the present
analysis.
According to the institutional protocols, all patients
underwent clinical and echocardiographic evaluation at
baseline, post-procedure (before hospital discharge), and at
6 months follow-up. The incidence of PPM and the
hemodynamic and clinical impact of the presence of PPM
during follow-up were assessed. Clinical and echocardio-
graphic data were prospectively recorded and retrospectively
analyzed.
TAVI procedure. The balloon-expandable Edwards-
SAPIEN prostheses (Edwards Lifesciences, Inc.) of either
23 or 26 mm was used in all patients when the aortic
annulus was 18 to 22 mm and 21 to 25 mm (as confirmed
by transesophageal echocardiography), respectively (10).
This valve consists of a trileaflet bovine pericardial tissue
valve, mounted within a stainless steel balloon-expandable
stent. As previously described (11), the device was delivered
via either a transfemoral (retrograde) or transapical (ante-
grade) approach. The transapical approach was performed
in patients with unsuitable aortoiliofemoral anatomy such as
iliofemoral arteries 7 to 8 mm, marked tortuosity, abdom-
inal aortic aneurysm, porcelain aorta, and/or previous aor-
toiliac surgery or intervention (12). All procedures were
performed under transesophageal echocardiographic and
fluoroscopic guidance.
Transthoracic echocardiography. Transthoracic echocar-
diography was performed in all patients at baseline, before
hospital discharge, and at 6-month follow-up, using a
commercially available ultrasound system (Vivid-7, General
Electric, Horten, Norway). All images were digitally stored for
offline analysis (EchoPAC version 108.1.5, GE-Vingmed,
Horten, Norway) and included standard 2-dimensional, color,
pulsed, and continuous-wave Doppler acquisitions (13–15).
Standard linear LV dimensions were obtained (14), and LV
mass was calculated as recommended (14). LV end-diastolic
and -systolic volumes were measured from the standard apical
views according to the biplane Simpson method (14) and
indexed to body surface area (BSA). Next, LV ejection fraction
was derived. Similarly, maximal left atrial (LA) volumes were
measured using the biplane Simp-
son method and indexed to BSA
(14). Pulmonary artery systolic
pressure was estimated from the
Doppler spectral signal of tricuspid
regurgitation jet (16). The pres-
ence of aortic or mitral regurgita-
tion was evaluated using color
Doppler, and the severity was as-
sessed according to current guide-
lines (15).
To assess LV diastolic func-
tion, transmitral early (E-wave)
and late (A-wave) velocities and
E-wave deceleration time were
measured using pulsed-wave
Doppler at the mitral leaflet tips
(16). Pulmonary venous flow ve-
locities during systole and dias-
tole were also recorded (16). By
integrating transmitral and pul-
monary venous flow analysis, diastolic dysfunction was
classified as follows: 1) impaired relaxation if mitral E/A
0.8 and pulmonary venous systolic velocity  diastolic
velocity; 2) pseudonormal filling if mitral E/A  0.8 to 1.5,
E-wave deceleration time  160 to 200 ms and pulmonary
venous systolic velocity  diastolic velocity; and 3) restric-
tive filling if E/A 2, E-wave deceleration time 160 ms,
and pulmonary venous systolic velocity  diastolic velocity
(16). In addition, peak early diastolic velocities of the septal
mitral annulus (e=) were measured by pulsed wave tissue
Doppler imaging from the apical 4-chamber view (16).
Then, the ratio of E/e= was calculated. In patients who were
not in sinus rhythm, e= was used as an additional parameter
to help determine the degree of LV diastolic dysfunction:
impaired relaxation if e= 10, pseudonormal filling if e= 8,
and restrictive filling if e= 5 (17).
The aortic annulus was measured in a zoomed-up para-
sternal long-axis view as recommended (14). Similarly, the
left ventricular outflow tract (LVOT) diameter was mea-
sured within 5 to 10 mm into the LVOT from the level of
the aortic annulus in mid-systole (13). Pulsed-wave Doppler
was used for LVOT measurements and continuous-wave
Doppler was used for transaortic measurements. Using the
continuity equation (13), the aortic valve area was obtained
and indexed to BSA. In patients with sinus rhythm, the 3
best available signals were recorded and averaged. In pa-
tients who were not in sinus rhythm, a minimum of 5
measurements was averaged (13).
Definition of PPM after TAVI. After TAVI, the EOA of
the prosthesis was similarly calculated using the continuity
equation approach. From the parasternal long-axis view in a
zoomed mid-systolic frame, the LVOT was measured just
below the ventricular end of the prosthesis (but not inside it)
to avoid the area of subvalvular flow acceleration. The EOA
was subsequently calculated, assuming a circular geometry
Abbreviations
and Acronyms
AS  aortic stenosis
BSA  body surface area
EOA  effective orifice
area
LA  left atrium
LV  left ventricular
LVOT  left ventricular
outflow tract
MAVCE  major adverse
valve-related and
cardiovascular event(s)




TAVI  transcatheter aortic
valve implantation
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of the LVOT, and indexed to BSA. PPM was defined as an
indexed EOA 0.85 cm2/m2 (3,6).
Follow-up data collection. Before hospital discharge and
at 6-month follow-up, clinical evaluation included the
classification of heart failure symptoms according to the
New York Heart Association (NYHA) functional class.
In addition, all adverse procedural and in-hospital events
and mortality were recorded. In particular, major adverse
valve-related events, defined as any structural deteriora-
tion or nonstructural prosthesis dysfunction, valve throm-
bosis, embolism, bleeding event, or valve endocarditis,
were recorded (18).
During follow-up, major cardiovascular events, such as
death, myocardial infarction, stroke, and heart failure, were
recorded. A combined endpoint of major adverse valve-
related and cardiovascular events (MAVCE) was used for
Kaplan-Meier survival analysis.
Statistical analysis. Continuous variables are presented as
mean and SD unless otherwise specified. Categorical vari-
ables are presented as frequencies and percentages. Pre-
procedural and follow-up data were compared between
patients with PPM (indexed EOA 0.85 cm2/m2) and
without PPM (indexed EOA 0.85 cm2/m2). An unpaired
Student t test or chi-square test or the Fisher exact test was
used to compare continuous or categorical variables, as
appropriate. A chi-square test was used to compare cate-
gorical variables when no cells had an expected count 5,
whereas the Fisher exact test was performed when 1 cell
had an expected count 5. A 2-way repeated-measures
analysis of variance was used to evaluate the effects of time
(baseline vs. hospital discharge vs. 6-months follow-up) and
the presence or absence of PPM on each echocardiographic
variable (EOA, transaortic gradient, LV ejection fraction
and mass, LA volume, and E/e=), followed by post hoc
analyses for significant results performed using Bonferroni
correction with 3 pairwise comparisons. In addition, the
interaction between group (presence or absence of PPM)
and time was also analyzed for each echocardiographic
variable and expressed as group-by-time analysis of variance.
Finally, the MAVCE-free survival rates were presented as
Kaplan-Meier curves, and the log-rank test was used for
comparison between groups. A 2-tailed probability value of
0.05 was considered statistically significant. All statistical
analyses were conducted using SPSS for Windows version
16 (SPSS Inc., Chicago, Illinois).
Results
Patient population. A total of 190 patients were initially
included. Of these patients, 25 patients were excluded for
different reasons. Eight patients were excluded due to previous
aortic or mitral prostheses, and 4 patients did not have a
successful implantation procedure. Nine patients died before 6
months and were subsequently excluded from further analysis.
These events were due to in-hospital deaths from massive
stroke (n  1), pulmonary disease (n  2), heart failure (n 
3), and deaths within 6 months from end-stage lung disease
(n  1), chronic renal disease (n  1), and myocardial
infarction (n  1). They were unrelated to PPM as none of
these patients demonstrated PPM post-TAVI. In addition, a
further 4 patients were excluded due to extremely poor acoustic
windows and echocardiographic images unsuitable for accurate
interpretation. Therefore, a total of 165 patients composed the
final study population.
The incidence of PPM (indexed EOA 0.85 cm2/m2)
post-TAVI was 18.2% (n  30), as assessed by transthoracic
echocardiography before hospital discharge. Baseline clinical
and echocardiographic characteristics of patients with and
without PPM are summarized in Tables 1 and 2. Patients with
PPM had a significantly larger BSA (Table 1) (19). In
addition, patients with PPM had a greater severity of AS at
baseline (indexed aortic valve area 0.35  0.09 cm2/m2 vs. 0.40
 0.10 cm2/m2, p  0.005) compared with patients without
PPM, although the calculated valve areas were not significantly
different. There was also a trend toward a smaller LVOT,
sinotubular junction, and ascending aorta in patients with
PPM. However, the aortic annulus diameter, on which the
prosthesis sizing was based, did not differ between the 2 groups
(Table 2).
Hemodynamic impact of PPM assessed by echocardiography.
Echocardiographic Doppler data at baseline, hospital dis-
charge, and 6-month follow-up are summarized in Figure 1.
Per the definition, patients with PPM were characterized by
a smaller EOA at discharge and 6-month follow-up com-
pared with those without PPM (Fig. 1A). Accordingly,
patients with PPM demonstrated a slower and smaller
reduction in mean transaortic gradient post-TAVI, result-
ing in a higher transvalvular gradient at 6-month follow-up
(16  8 mm Hg vs. 10  4 mm Hg, p  0.001) compared
with patients without PPM (Fig. 1B).
Small improvements in LV ejection fraction were noted in
both groups of patients with and without PPM post-TAVI,
and no significant difference in LV ejection fraction was
observed between the 2 groups (Fig. 2A). However, in terms of
LV mass regression, patients with PPM had a smaller LV mass
regression 6 months post-procedure (with a reduction in LV
mass index of 7.2  4.6% vs. 21.1  10.6%, p  0.001)
compared with patients without PPM (Fig. 2B). Similarly,
patients with PPM had a smaller reduction in LA volume 6
months post-TAVI (with a reduction in LA volume index of
8.0  9.7% vs. 26.0  10.5%, p  0.001) compared with
patients without PPM (Fig. 2C).
With regard to LV filling pressure, E/e= remained elevated
in patients with PPM at 6 months despite TAVI (Fig. 2D). In
contrast, TAVI resulted in the significant reduction of LV
filling pressure in patients without PPM (with a reduction
in E/e= of 29.7  7.0% vs. 4.6  21.4%, p  0.001)
(Fig. 2D). When LV diastolic function was analyzed ac-
cording to diastolic dysfunction grade, a higher proportion
of patients without PPM showed improvement in LV
diastolic function than those with PPM (47.4% vs. 10%,
p  0.001) (Fig. 3A).
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In terms of aortic regurgitation, there was no difference in
the proportion of patients with aortic regurgitation grade
2 before hospital discharge (13.3% vs. 23.0%, p  0.33)
and at 6-month follow-up (13.3% vs. 28.1%, p  0.11) in
the group with and without PPM. During 6-month follow-
up, the presence of PPM did not have a significant effect on
aortic regurgitation post-TAVI. The proportion of patients
who did (33.3% vs. 29.6%) or did not improve (66.7% vs.
70.4%, p  0.83) in terms of aortic regurgitation grade
was similar in patients with and without PPM. Similarly,
mitral regurgitation was not affected by the presence of
PPM. Patients with PPM who did (26.7% vs. 25.2%) or
did not improve (73.3% vs. 74.8%, p  0.82) in terms of
mitral regurgitation grade was similar to the group
without PPM.
Clinical impact of PPM. The majority of patients (n 
152, 92.1%) reported a significant improvement in
NYHA functional class at 6 months after TAVI. How-
ever, there was a significant proportion of patients with
PPM (n  11, 36.7%) who did not demonstrate an
improvement in functional class status. In contrast,
among patients without PPM post-TAVI, only a small
minority of patients (n  2, 1.5%) did not show an
improvement in functional status (Fig. 3B).
No patients were lost during the follow-up period (mean
17.6  7.0 months) and a total of 18 MAVCE were
observed. Three events (10%) occurred in the group with
PPM: end-stage lung disease, bleeding event, and infective
endocarditis. The remaining 15 events (11.1%) occurred in
patients without PPM: 2 deaths (liver cirrhosis, intestinal
ischemia), myocardial infarction (n  3), stroke (n  2),
heart failure (n  5), and bleeding events (n  3).
Importantly, there was no significant difference between
patients with and without PPM in terms of MAVCE
(log-rank p  0.82) (Fig. 4).
Discussion
The present evaluation demonstrated that PPM is rather
common and occurred in 18.2% of patients undergoing
TAVI with balloon-expandable valves. In particular, pa-




(n  135) p Value*
Age, yrs 77.8  9.8 81.1  6.2 0.084
Male 36.7 39.3 0.84
Body surface area, m2 1.84  0.18 1.73  0.18 0.003
Body mass index, kg/m2 26.6  4.0 25.5  5.1 0.25
Logistic EuroSCORE 22.2  9.9 21.9  12.3 0.91
NYHA functional class
II 23.3 17.0 0.46†
III 56.7 68.2
IV 20.0 14.8
Previous myocardial infarction 16.7 16.3 1.00
Previous coronary bypass surgery 23.3 18.5 0.80
Previous percutaneous coronary intervention 10.0 22.2 0.13
Peripheral vascular disease 26.7 28.9 0.82
Hypertension 70.0 75.5 0.62
Hypercholesterolemia 43.3 36.3 0.67
Diabetes 33.3 17.0 0.080
Smoking 20.0 31.1 0.18
Frailty‡ 26.7 21.5 0.81
Heart rhythm
Sinus 80.0 81.5 0.80
Atrial fibrillation 10.0 14.8 0.77†
Pacemaker 10.0 3.7 0.16†
Creatinine clearance, ml/min 46.8  6.0 49.3  21.3 0.57
Hemoglobin, g/dl 11.3  2.5 11.6  2.1 0.53
Approach
Transfemoral 63.3 46.7 0.11
Transapical 36.7 53.3
Prosthesis size, mm
23 50.0 35.6 0.15
26 50.0 64.4
Values are mean  SD or %. *p value for comparison between PPM and no PPM using an unpaired t test or chi-square test. †p value by Fisher exact
test. ‡Frailty assessed according to Fried et al. (19).
NYHA  New York Heart Association; PPM  prosthesis–patient mismatch.
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tients with PPM were accompanied by less favorable
changes post-TAVI compared with patients without PPM,
with higher transvalvular gradient, limited LV mass regres-
sion, and LA volume reduction, and with persistent elevated
LV filling pressures. Finally, more patients reported a lack
of clinical improvement in the group with PPM, although
the MAVCE-free survival did not differ between the 2
groups.
Incidence of PPM in patients undergoing TAVI. To
minimize paravalvular regurgitation and to ensure adequate
annular sealing, it is generally recommended that the
implanted prosthesis be slightly larger than the native aortic
annulus for the currently applied percutaneous systems (20).
For example, in the balloon-expandable delivery system of
the Edwards SAPIEN valves, the 23-mm valve is used for
aortic annulus between 18 and 22 mm, whereas the 26-mm
valve is used for aortic annulus between 21 and 25 mm
(10,21). Despite these indications, the current study
showed that PPM developed before hospital discharge in
18.2% of patients who underwent Edwards SAPIEN
valve implantation.
Using the definition of an indexed EOA 0.85 cm2/m2,
the incidence of PPM post-TAVI has been reported to be
higher (32% to 39%) in patients who underwent CoreValve
implantation (8,9). This difference can be partially explained
by the fact that only 1 size of the device (26 mm, the
smallest) was available at the time of TAVI in one-fourth of
the patients (27%) in the reported series (9). In addition, the
differences in prosthesis design may play a role. The Edwards
SAPIEN valve is a trileaflet valve mounted on a balloon-
expandable stainless stent frame that is 14.5 mm or 16 mm
in height (for the 23- or 26-mm valve, respectively) and is
implanted intra-annularly (21). Conversely, the CoreValve
(designed for supra-annular implantation) has a longer
frame of 53 or 55 mm (for the 26- or 29-mm device,
respectively), with the lower third sitting within the LVOT




(n  135) p Value*
Aortic valve area, cm2 0.64  0.16 0.69  0.17 0.096
Aortic valve area index, cm2/m2 0.35  0.09 0.40  0.10 0.005
Left ventricular outflow tract, cm 19.8  2.1 20.4  1.9 0.065
Aortic annulus, cm 21.2  2.1 21.9  2.2 0.15
Aortic sinus, cm 32.7  4.7 32.7  4.1 0.99
Sinotubular junction, cm 26.0  4.0 27.5  4.2 0.067
Ascending aorta, cm 32.0  4.8 33.0  4.2 0.062
Mean transaortic gradient, mm Hg 44  18 49  17 0.081
Left ventricular end-diastolic volume index, ml/m2 68  31 61  20 0.23
Left ventricular end-systolic volume index, ml/m2 32  28 27  16 0.13
Left ventricular ejection fraction, % 52  16 55  11 0.30
Left ventricular mass index, g/m2 149  50 151  38 0.84
Left atrial volume index, ml/m2 48  11 52  15 0.095
E-wave, cm/s 92  24 92  29 0.96
A-wave, cm/s 96  44 100  33 0.64
Mitral E/A ratio 1.20  0.78 1.02  0.61 0.20
Mitral deceleration time, ms 219  82 222  77 0.86
E=, cm/s 4.4  0.9 4.7  1.1 0.19
E/e= 22.2  8.3 20.6  7.1 0.28
Diastolic function
Impaired relaxation 30.0 43.0 0.38†
Pseudonormal filling 53.3 45.9
Restrictive filling 16.7 11.1
Pulmonary artery systolic pressure, mm Hg 45  7 42  9 0.100
Aortic regurgitation grade









Values are mean  SD or %. *p value for comparison between PPM and no PPM using unpaired t test or chi-square test. †p value by Fisher exact test.
PPM  prosthesis–patient mismatch.
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(21). These differences may account for a potentially higher
incidence of PPM with the CoreValve prosthesis. Finally,
optimal prosthesis positioning may be important for good
expansion and functioning of the transcatheter aortic bio-
prosthesis. Recently, Jilaihawi et al. (8) reported that a lower
incidence of PPM could be achieved with optimal position-
ing of the prosthesis compared with suboptimal positioning
(16% vs. 48%, p  0.015) in 50 patients who underwent
CoreValve implantation.
Of interest, the incidence of PPM has been reported to be
lower with the balloon-expandable transcatheter valve com-
pared with surgical bioprosthesis. In a recent matched study
of 50 patients who underwent TAVI with an Edwards
SAPIEN valve and 2 other groups of 50 patients who
underwent surgery with a stented or a stentless bioprosthesis
valve (7), the incidence of severe PPM (defined as an
indexed EOA 0.65 cm2/m2) was significantly higher in
patients with either a stented (26%) or a stentless (28%)
bioprosthetic valve than in patients who underwent TAVI
(11%). Our findings extended this to a larger population
of patients who underwent Edwards SAPIEN valve
implantation. The lower incidence of PPM in the TAVI
series compared with the surgical series may be partly
explained by the absence of a sewing ring and a thinner
transcatheter stent frame. Furthermore, sizes of surgical
prostheses are generally smaller than transcatheter pros-
theses, although this might be offset by a routine annular
debridement and removal of the native valve before
implantation during surgery, which cannot be performed
during TAVI (7).
The current study showed that patients with a larger BSA
were more prone to the development of PPM post-TAVI.
This is probably due to a higher transvalvular flow along
with a higher cardiac output required in patients with a
larger BSA. Similar findings were observed in the cited
study of Jilaihawi et al. (8), including 50 patients who
underwent TAVI with a CoreValve prosthesis, in which a
larger BSA was observed in patients with PPM compared
with patients without PPM (1.8  0.3 vs. 1.7  0.2). It is
important to highlight that currently the choice of trans-
catheter bioprosthesis size depends exclusively on the aortic
valve annulus, which was not different between the 2 groups
of patients in the present study. These observations suggest
that the limited transcatheter prosthesis sizes currently
available (for either system) are probably inadequate to avoid
PPM, especially in a subset of patients with a larger BSA
and taking into account that additional maneuvers, such as
removal of the calcified native valve before implantation and
root enlargement, cannot be performed. To avoid PPM, a
larger selection of transcatheter valve sizes (taking BSA into
consideration) and continued improvement of valve design
with a better hemodynamic profile (to provide a larger
cross-sectional area for blood flow) may be necessary.
However, excessive oversizing of the currently used trans-
catheter prosthesis has to be weighed against the risk of
aortic rupture during balloon expansion, especially in pa-
tients with a calcified aortic root.
Hemodynamic impact of PPM. In the present study, a
marked reduction in the mean transvalvular gradient was
observed in all patients post-TAVI, in line with previously
reported TAVI series (11). However, this study highlighted
that patients with PPM showed less benefit in terms of
mean transvalvular gradient reduction compared with pa-
tients without PPM. Similar findings have been described
Figure 1 Impact of PPM on Transvalvular Hemodynamics
Comparison of changes in aortic effective orifice area index (A) and mean transaortic gradient (B) in patients with and without prosthesis–patient mismatch (PPM).
The p value is for the group-by-time analysis of variance. Error bars denote the SEM. Measurement values (mean  SD) at the corresponding time point are given
below each graph. *p  0.05 between PPM and no PPM. Bonferroni post-hoc test: †p  0.05 versus baseline. ‡p  0.05 versus baseline.
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for patients with PPM with a surgical prosthesis who
showed high transvalvular gradient even in the presence of
a normally functioning prosthesis (6).
The impact of small indexed EOA and its residual
high post-operative gradient on the delay of LV mass
regression has been well documented in patients who
underwent aortic valve replacement (22,23). Tasca et al.
(23) showed that the extent of LV mass regression was
related to the extent of the increase in indexed EOA after
aortic valve surgery. Similarly, the current study showed
that LV mass regression post-TAVI was more pro-
nounced in patients without PPM, whereas in patients
with PPM, the regression of LV hypertrophy was less
marked (Fig. 2B). This observation might have important
clinical implications because regression in LV hypertro-
phy has been reported to be an important predictor of
survival after aortic valve replacement (24). Whether this
finding extends to the TAVI population needs to be
determined in future studies. In the current study, pa-
tients with PPM were observed also to exhibit a more
delayed reduction in LA volume and persistently elevated
LV filling pressures at 6 months post-TAVI (Fig. 2)
compared with patients without PPM. These observa-
tions are presumably the result of a combination of
incomplete relief of outflow tract obstruction and of a
residual significant LV hypertrophy. Ikonomidis et al.
(25) previously showed that abnormal LV relaxation was
associated with residual LV hypertrophy in patients with
isolated AS who had undergone aortic valve replacement.
Accordingly, in the present study, only a small proportion
(10%) of patients with PPM had improvement in their
LV diastolic grades despite the relief of severe AS,
whereas more patients without PPM (47%) exhibited a
significant improvement in LV diastolic function.
Figure 2 Hemodynamic Impact of PPM
Comparison of changes in left ventricular ejection fraction (A), left ventricular mass index (B), left atrial volume index (C), and E/e= (D) in patients with and without
prosthesis–patient mismatch (PPM). Error bars denote the SEM. Measurement values (mean  SD) at the corresponding time point are given below each graph.
*p  0.05 between PPM and no PPM. Bonferroni post-hoc test: †p  0.05 versus baseline. ‡p  0.05 versus baseline. §p  0.05 versus discharge.
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Clinical impact of PPM. Another major finding of the
present study is that the presence of PPM negatively
affected the improvement in NYHA functional class at 6
months post-TAVI. This is in line with previous studies
that showed that PPM (defined as an indexed EOA 0.85
cm2/m2) was independently associated with limited im-
provement NYHA functional class after aortic valve re-
placement with a stented bioprosthesis (26). In 312 patients
who underwent bioprosthetic aortic valve replacement, Ble-
iziffer et al. (27) also observed that patients without PPM
could achieve a better physical exercise capacity compared
with patients with PPM. The suboptimal improvements in
valvular hemodynamics and the higher residual afterload
post-TAVI in patients with PPM could have contributed to
the lack of clinical improvement. However, a recent study by
Tzikas et al. (9), which included 74 patients who underwent
TAVI with the CoreValve, reported that the functional
status in terms of NYHA functional class did not differ
between patients with (n  12) and without (n  62) severe
PPM. One of the plausible explanations is that this obser-
vation was made by comparing the proportion of patients
with NYHA functional class I to II versus III to IV 6
months post-TAVI in the 2 groups (9). Examining the
paired changes in NYHA functional class from baseline to
6 months post-TAVI (Fig. 3B) may provide more reliable
information on the impact of PPM on an individual patient
basis.
So far, there are conflicting reports on the impact of PPM
on clinical outcome after aortic valve replacement
(1,2,4,28,29). Part of the controversy stems from the use of
either the in vitro or the in vivo EOA measurement used to
define PPM (5). Nonetheless, using the indexed EOA as a
parameter to define PPM, recent series (1–4) demonstrated
that patients without significant PPM had better early and
late mortality benefits. In addition, patients without PPM
exhibit more freedom from congestive heart failure after
aortic valve replacement (30). However, the present study
showed that there was no significant difference in terms of
freedom from MAVCE between patients with or without
PPM post-TAVI, which is similar to the finding of a recent
series of TAVI using the CoreValve system (9).
Study limitations. Due to a relatively short follow-up
period and few major adverse events observed in the present
study, the effect of PPM on clinical outcomes will need to be
verified in a larger population with a longer follow-up
period post-TAVI.
Conclusions
In patients with AS who underwent TAVI with balloon-
expandable valves, PPM may be observed. When present,
Figure 4 Kaplan-Meier Curves for Major Adverse Events
After Transcatheter Aortic Valve Implantation
Kaplan-Meier probability of freedom from combined major adverse valve-related
and cardiovascular events (MAVCE) in patients with and without prosthesis–
patient mismatch (PPM).
Figure 3 Impact of PPM on Left Ventricular
Diastolic Function and Symptoms
Comparison of the proportion of patients with changes in left ventricular dia-
stolic dysfunction grade (A) and New York Heart Association (NYHA) functional
class (B) at 6 months after transcatheter aortic valve implantation in patients
with and without prosthesis–patient mismatch (PPM). p value denotes the com-
parison between patients with and without PPM.
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PPM may be accompanied by less favorable changes in
transvalvular hemodynamics post-TAVI, together with lim-
ited LV mass regression and LA volume reduction and with
persistent elevated LV filling pressure. More importantly,
PPM may be also associated with less functional improve-
ment after TAVI.
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Impact of left ventricular systolic function on clinical and
echocardiographic outcomes following transcatheter
aortic valve implantation for severe aortic stenosis
See Hooi Ewe, MBBS,a,b,d Nina Ajmone Marsan, MD,a,d Mauro Pepi, MD,c Victoria Delgado, MD,a
Gloria Tamborini, MD,c Manuela Muratori, MD,c Arnold C. T. Ng, MBBS,a Frank van der Kley, MD,a
Arend de Weger, MD,a Martin J. Schalij, MD, PhD,a Melissa Fusari, MD,c Paolo Biglioli, MD,c and
Jeroen J. Bax, MD, PhDa Leiden, The Netherlands; Singapore, Singapore; and Milan, Italy
Background This study aimed to evaluate the impact of baseline left ventricular (LV) systolic function on clinical and
echocardiographic outcomes following transcatheter aortic valve implantation (TAVI). Survival of patients undergoing TAVI
was also compared with that of a population undergoing surgical aortic valve replacement.
Methods One hundred forty-seven consecutive patients (mean age = 80 ± 7 years) undergoing TAVI in 2 centers were
included. Mean follow-up period was 9.1 ± 5.1 months.
Results At baseline, 34% of patients had impaired LV ejection fraction (LVEF) (<50%) and 66% had normal LVEF (≥50%).
Procedural success was similar in these 2 groups (94% vs 97%, P = .41). All patients achieved improvement in transvalvular
hemodynamics. At follow-up, patients with a baseline LVEF <50% showed marked LV reverse remodeling, with improvement of
LVEF (from 37% ± 8% to 51% ± 11%). Early and late mortality rates were not different between the 2 groups, despite a higher
rate of combined major adverse cardiovascular events (MACEs) in patients with a baseline LVEF <50%. The predictors of
cumulative MACEs were baseline LVEF (HR = 0.97, 95% CI = 0.94-0.99) and preoperative frailty (HR = 4.20, 95% CI = 2.00-
8.84). In addition, long-term survival of patients with impaired or normal LVEF was comparable with that of a matched
population who underwent surgical aortic valve replacement.
Conclusions TAVI resulted in significant improvement in LV function and survival benefit in high-risk patients with severe
aortic stenosis, regardless of baseline LVEF. Patients with a baseline LVEF <50% were at higher risk of combined MACEs.
(Am Heart J 2010;160:1113-20.)
Symptomatic severe aortic stenosis (AS) is associated
with high mortality if left untreated,1 and surgical aortic
valve replacement (SAVR) is currently the recommended
therapeutic approach.2 When severe AS is associated
with left ventricular (LV) dysfunction, due to either
afterload mismatch3 or primary myocardial dysfunction,
SAVR still results in significant improvement of LV
function and survival.4-6 However, patients with de-
pressed LV ejection fraction (EF) undergoing SAVR are
associated with higher perioperative and mid-term
mortality4-8 as compared with those with normal LV
systolic function. Furthermore, the combination of LV
dysfunction with advanced age and significant comorbid-
ities could result in high predicted operative risk9 that
may outweigh the benefits of SAVR and preclude the
surgical intervention.10
Over the last few years, transcatheter aortic valve
implantation (TAVI) has been proposed as a feasible and
effective therapeutic alternative in patients with symp-
tomatic severe AS and high operative risk.11 In fact,
studies have shown excellent and sustained transvalvular
hemodynamics post-TAVI,12 together with a significant
improvement in symptoms and quality of life.12,13 In
addition, good survival rates have been reported post-
TAVI, ranging from 74% to 78% at the 1-year follow-
up.12,14 However, no studies have examined the impact
of baseline LV systolic function on the outcomes of
patients undergoing TAVI. Therefore, the aims of this
study were:
1. to compare early and long-term clinical outcomes
post-TAVI in patients with normal versus impaired
LV systolic function;
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2. to evaluate early and long-term changes in LV
volumes and function post-TAVI in these 2 groups
of patients; and
3. to compare the survival of patients undergoing TAVI
with that of a group undergoing SAVR matched for
age, gender, aortic valve area, and LVEF.
Methods
Patient population
In total, 147 consecutive patients with symptomatic severe AS
who underwent TAVI in 2 centers (Leiden University Medical
Center, Leiden, The Netherlands, and Centro Cardiologico
Monzino, IRCCS, Milan, Italy) were included. Detailed clinical
evaluation, transthoracic echocardiography, and invasive angiog-
raphy of the coronary/aortoiliofemoral arterial systems were
performed in all patients before the procedure.11 In particular,
clinical evaluation included the assessment of operative risk based
on the logistic EuroSCORE9 and identification of associated
comorbidities and physical frailty according to the criteria of
Fried et al.15 The decision to offer TAVI to patients was evaluated
by a multidisciplinary team approach. All patients underwent
clinical and echocardiographic evaluation immediately post-TAVI
(within 48 hours) and at the 3-, 6-, and 12-month follow-up points.
The current study received no extramural funding. We, the
authors, are solely responsible for the design and conduct of this
study, all study analyses, the drafting and editing of this article,
and its final contents.
Transthoracic echocardiography
Patientswere imagedusing a commercially available ultrasound
system (Vivid-7, General Electric, Horten, Norway). Transaortic
pressure gradients and AVA were calculated for all patients.16
Severe AS was defined as a mean transaortic pressure gradient of
at least 40-50 mm Hg or an AVA <1 cm2.2 Presence of aortic
regurgitation and its severity were evaluated as recommended.17
LV end-diastolic volume (LVEDV) and LV end-systolic volume
(LVESV) were measured and indexed to body surface area.18
LVEF was derived according to the biplane Simpson method.18
LV systolic function was defined as normal when LVEF was
≥50% and as impaired when LVEF was <50%.19 Standard LV
ventricular dimensions18 were also obtained, and LV mass was
calculated according to Devereux et al.18,20
In addition, LV diastolic function was assessed by the ratio of
the transmitral early filling velocity (E wave) to the late diastolic
filling velocity (A wave) and the deceleration time of the E
wave.21 Maximal left atrial (LA) area was measured from the
standard apical 4-chamber view.18 Pulmonary artery systolic
pressure was calculated as recommended.21
TAVI
All patients underwent TAVI with a balloon-expandable
Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA). The
procedures were performed at the catheterization laboratory
under general anesthesia with transesophageal echocardiogra-
phy and fluoroscopy guidance. The prosthesis was implanted via
the transfemoral or transapical approach, as previously
described.22 The transapical approach was performed in
patients with unfavorable iliofemoral anatomy.22 Procedural
success was defined as implantation of a functioning aortic
prosthetic valve without intraprocedural mortality.12 Duration
of fluoroscopy, length of the procedure, and the total contrast
volume used during the procedure were also recorded.
Follow-up and data collection
Intraprocedural mortality was defined as any death that
occurred before extubation in the catheterization laboratory.
Intraprocedural adverse events, such as vascular complication,
cardiac tamponade, myocardial infarction, and severe aortic
regurgitation, were recorded. The diagnosis of acute myocardial
infarction was made on the basis of typical electrocardiographic
changes and/or ischemic chest pain associated with elevation of
cardiac biomarkers.23
In-hospital adverse events, defined as those occurring during
the index hospital stay, included all cardiovascular events (such
as cardiovascular death, heart failure, stroke, and heart
conduction block requiring pacemaker) and noncardiovascular
events. Combined major adverse cardiovascular events
(MACEs), defined as a composite of death, nonfatal stroke,
heart failure, or nonfatal myocardial infarction, were recorded.
Total early mortality included both intraprocedural, in-hospital
deaths and deaths occurring ≤30 days of the procedure.
No patient was lost to follow-up, and the mean follow-up
period was 9.1 ± 5.1 months. Long-term follow-up outcomes
included all-cause mortality and major cardiovascular and
noncardiovascular-related adverse events.
Statistical analysis
Continuous variables are presented as mean ± SD or as median
(interquartile range). Categorical variables are presented as
frequencies (percentages). Clinical and echocardiographic
characteristics of patients were compared based on LV systolic
function (LVEF ≥50% vs LVEF <50%) at baseline.19 Unpaired
Student's t test or the Mann-Whitney U-test was used to compare
the continuous variables, as appropriate. To compare categor-
ical variables, we used χ2 test or Fisher's exact test, as
appropriate. Repeated-measures analysis of variance (ANOVA)
was used to analyze the repeated paired continuous variables,
and post hoc analysis for significant results was performed using
Bonferroni's correction. In addition, survival rates were
presented as Kaplan-Meier curves, and the log-rank test was
used for comparisons between groups. To identify predictors of
cumulative major adverse events after TAVI, we used a Cox
proportional hazards model. Variables with P < .2 in the Cox
univariate analysis were used in the multivariate model. Finally,
the survival rate of patients who received TAVI was compared
with that of a reference cohort who underwent SAVR in the last
10 years at the Leiden University Medical Center matched for
age, gender, AVA, and LVEF. A 2-tailed probability value <.05
was considered statistically significant. All statistical analyses
were conducted using SPSS version 16 (SPSS, Chicago, IL).
Results
Baseline characteristics
All patients underwent TAVI due to high operative risk
(mean logistic EuroSCORE = 21.8% ± 11.0%) and multiple
comorbidities (Table I).




Of the total population, 50 patients (34%) had an LVEF
<50% and the remaining patients (n = 97, 66%) had an
LVEF ≥50% before TAVI. Patients with an LVEF <50%
tended to be in a New York Heart Association functional
class of III or higher and to have a higher cardiovascular
risk profile (with higher prevalence of diabetes and
smoking) as compared with patients with an LVEF ≥50%
(Table I).
The AVA was similar in patients with an LVEF <50% and
those with that of ≥50%, however, the mean transaortic
gradient was lower in patients with impaired LV function
(40 ± 15 vs 52 ± 17 mm Hg, P < .001). In addition,
patients with an LVEF <50% exhibited larger LV volumes,
higher LV mass, and larger LA area (Table I).
Intraprocedural outcomes
The procedural success rate was 96% (n = 141) in the
population. There were 6 cases of unsuccessful proce-
dure: 4 cases of intraprocedural mortality (3 died from
vascular complications, and the fourth patient developed
massive aortic regurgitation after prosthesis deployment)
and 2 procedures were abandoned (due to risk of
ventricular rupture via transapical approach in 1 patient,
and because the other patient required emergency
surgery after iliac artery perforation).
Finally, there were no significant differences in
procedural success, intraprocedural mortality, or MACEs
between patients with an LVEF≥50% and those with that
of <50% (Table II). The duration of procedure and
amount of contrast used were similar (Table II).
Early clinical outcomes
Total early mortality (≤30 days) was 7% (n = 10) in the
entire population, which included 4 (3%) intraprocedural
deaths (Table II). The remaining deaths were due to heart
failure (n = 3), stroke (n = 1), and noncardiac-related
respiratory cause (n = 2).
The difference between patients with an LVEF ≥50%
and those with that of <50% in terms of early mortality or
each individual adverse event (≤30 days) did not reach
statistical significance (Table II). However, the MACE rate
was significantly higher in the group with an LVEF <50%
when compared with the group with an LVEF≥50% (20%
vs 7%, P = .029).
Echocardiographic outcomes
Immediately post-TAVI, significant reduction in the
mean transaortic gradient (from 48 ± 17 to 11 ± 5 mm Hg,
P < .05) and a corresponding increase in the effective
AVA were observed in all patients (Table III). These
desirable transaortic hemodynamics were maintained at
long-term follow-up.
All echocardiographic variables obtained at baseline,
immediately post-TAVI, and the latest follow-up in
patients with a baseline LVEF ≥50% and those with that
of <50% are summarized in Table III. The mean
echocardiographic follow-up was 7.2 ± 4.2 months
(median = 6.3 months). In both groups, LVEDV index
did not change significantly post-TAVI. In contrast, LVESV
index decreased significantly from 47 ± 23 mL/m2 at
baseline to 45 ± 20 mL/m2 and then to 40 ± 20 mL/m2
(ANOVA P = .004) in patients with a baseline LVEF <50%,
whereas no significant changes in LVESV index were
observed in patients with a baseline LVEF ≥50%.
Accordingly, LVEF increased significantly from 37% ±
8% to 46% ± 11% post-TAVI and to 51% ± 11% (ANOVA
P < .001) at follow-up in patients with a baseline LVEF
<50%. In the group with a baseline LVEF≥50%, however,
LVEF remained within normal limits over time. Impor-
Table I. Baseline clinical and echocardiographic characteristics







Age (y) 80.5 ± 6.3 79.8 ± 7.5 .57
Male [n (%)] 35 (36) 28 (56) .023
Logistic EuroSCORE (%) 20.7 ± 10.6 24.0 ± 11.6 .09
New York Heart Association
functional class of III or higher
[n (%)]
65 (67) 45 (90) .002
Previous myocardial infarction
[n (%)]
15 (16) 12 (24) .26
Previous coronary bypass surgery
[n (%)]
14 (25) 14 (28) .69
Previous percutaneous coronary
intervention [n (%)]
20 (21) 13 (26) .53
Peripheral vascular disease [n (%)] 35 (36) 17 (34) .86
Hypertension [n (%)] 78 (80) 35 (70) .22
Hypercholesterolemia [n (%)] 45 (46) 27 (54) .39
Diabetes [n (%)] 17 (18) 20 (40) .005
Smoking [n (%)] 26 (27) 25 (50) .006
Frailty [n (%)]† 33 (34) 15 (30) .71
Heart rhythm
Sinus rhythm [n (%)] 81 (84) 31 (62) .007
Atrial fibrillation [n (%)] 16 (17) 14 (28) .13
Pacemaker [n (%)] 3 (3) 9 (18) .003
Renal dysfunction [n (%)]‡ 18 (19) 12 (24) .39
Hemoglobin (g/dL) 12.2 ± 1.5 13.7 ± 2.6 .22
Echocardiography
AVA (cm2) 0.66 ± 0.16 0.68 ± 0.17 .49
Mean aortic gradient (mm Hg) 52 ± 17 40 ± 15 <.001
LVEDV index (mL/m2) 56 ± 23 79 ± 27 <.001
LVESV index (mL/m2) 25 ± 18 47 ± 23 <.001
LVEF (%) 61 ± 7 37 ± 8 <.001
LV mass index (g/m2) 149 ± 40 174 ± 59 .010
Mitral E/A ratio 0.96 ± 0.73 1.27 ± 0.95 .037
Mitral deceleration time (ms) 244 ± 80 223 ± 93 .017
LA area (cm2) 23.7 ± 5.7 27.2 ± 6.6 .002
Pulmonary artery systolic
pressure (mm Hg)
41 ± 10 46 ± 10 .25
Aortic regurgitation grades
I and II [n (%)]
75 (77) 38 (76) .86
Transfemoral approach [n (%)] 48 (50) 27 (54) .73
⁎ P for comparison between baseline LVEF ≥50% and that of <50%.
† Frailty was assessed according to the criteria of Fried et al.15
‡Renal dysfunction is defined as serum creatinine level N130 μmol/L.
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tantly, all patients showed a significant reduction in LV
mass index, regardless of the baseline LVEF (Table III).
In addition, patients with a baseline LVEF <50% showed
significant improvement in LV diastolic function, with a
reduction in both LA area and pulmonary artery systolic
pressure (Table III). Similarly, patients with a normal
baseline LVEF showed a trend toward a decrease in LA
area (23.7 ± 5.7 vs 23.0 ± 6.2 cm2, P = .068).
Long-term clinical outcomes
During the follow-up period, there were 12 more cases
of death in the total population: 4 cases of cardiovascular
death (myocardial infarction, stroke, and infective
endocarditis) and 8 cases of noncardiovascular death
(gastrointestinal, renal, pulmonary, and orthopedic
causes). In addition, further MACEs occurred in 9
patients. Noncardiovascular events (pulmonary diseases)
were observed in 2 other patients.
In the Kaplan-Meier analyses of clinical outcomes, the
percentage of patients free of MACEs at 6 months and that
at 1 year were lower in patients with a baseline LVEF
<50% (76% and 65%, respectively) as compared with
patients with a baseline LVEF ≥50% (87% and 81%,
respectively; log-rank P = .025; Figure 1, A). In addition,
the univariate Cox proportional hazards analysis identi-
fied 5 potential baseline predictors of cumulative MACEs:
logistic EuroSCORE (hazard ratio [HR] = 1.02, 95%
confidence interval [CI] = 1.00-1.05, P = .10), presence
of frailty (HR = 3.14, 95% CI = 1.59-6.20, P = .001),
peripheral vascular disease (HR = 1.73, 95% CI = 0.88-
3.38, P = .11), history of previous coronary artery bypass
(HR = 1.75, 95% CI = 0.88-3.47, P = .11), and baseline
LVEF (HR = 0.98, 95% CI = 0.96-1.00, P = .063). In the
Table II. Comparison of intraprocedural and early clinical















141 (96) 94 (97) 47 (94) .41
Mortality [n (%)] 4 (3) 2 (2) 2 (4) .61
Vascular complication
[n (%)]
10 (7) 5 (5) 5 (10) .31
Fatal [n (%)] 3 (2) 1 (1) 2 (4) .27
Nonfatal [n (%)] 7 (5) 4 (4) 3 (6) .69
Cardiac tamponade
[n (%)]
4 (3) 4 (4) 0 .30
Acute myocardial
infarction [n (%)]
2 (1) 1 (1) 1 (2) .57
Severe aortic
regurgitation [n (%)]
2 (1) 2 (2) 0 .43
Fluoroscopy time
(min)†




















16 (11) 10 (10) 6 (12) .78
Heart failure [n (%)] 5 (3) 2 (2) 3 (6) .34
Fatal [n (%)] 3 (2) 2 (2) 1 (2) 1.00
Nonfatal [n (%)] 2 (1) 0 2 (4) .11
Stroke [n (%)] 4 (3) 1 (1) 3 (6) .11
Fatal [n (%)] 1 (1) 0 1 (2) .79




7 (5) 6 (6) 1 (2) .42
Infection [n (%)] 2 (1) 0 2 (4) .11
Early (≤30 days)





17 (12) 7 (7) 10 (20) .029
⁎ P for comparison between baseline LVEF ≥50% and that of <50%.
†Data are presented as median (interquartile range).
Table III. Comparison of echocardiographic parameters at










LVEF ≥50% 0.66 ± 0.16 2.09 ± 0.42⁎ 2.12 ± 0.58† <.001
LVEF <50% 0.68 ± 0.17 2.08 ± 0.49⁎ 2.00 ± 0.53† <.001
Mean gradient (mm Hg)
LVEF ≥50% 52 ± 17 11 ± 5⁎ 11 ± 9† <.001
LVEF <50% 40 ± 15 10 ± 4⁎ 10 ± 4† <.001
LVEDV index (mL/m2)
LVEF ≥50% 56 ± 23 55 ± 20 55 ± 21 N.99
LVEF <50% 79 ± 27 79 ± 24 78 ± 23 N.99
LVESV index (mL/m2)
LVEF ≥50% 25 ± 18 24 ± 17 23 ± 16 .89
LVEF <50% 47 ± 23 45 ± 20 40 ± 20† .004
LVEF (%)
LVEF ≥50% 61 ± 7 59 ± 11 60 ± 11 N.99
LVEF <50% 37 ± 8 46 ± 11⁎ 51 ± 11†‡ <.001
LV mass index (g/m2)
LVEF ≥50% 149 ± 40 144 ± 36 130 ± 38†‡ .004
LVEF <50% 174 ± 59 172 ± 52 143 ± 37†‡ <.001
Mitral E/A ratio
LVEF ≥50% 0.96 ± 0.73 1.10 ± 0.89 0.87 ± 0.50‡ .032
LVEF <50% 1.27 ± 0.95 1.30 ± 0.87 0.93 ± 0.61 .24
Mitral deceleration time (ms)
LVEF ≥50% 243 ± 80 232 ± 83 251 ± 90 .56
LVEF <50% 223 ± 93 204 ± 68 205 ± 115 .61
LA area (cm2)
LVEF ≥50% 23.7 ± 5.7 24.3 ± 6.4 23.0 ± 6.2 .068
LVEF <50% 27.2 ± 6.6 27.4 ± 5.7 25.5 ± 6.2† .028
Pulmonary artery systolic pressure (mm Hg)
LVEF ≥50% 41 ± 10 39 ± 11 38 ± 12 .11
LVEF <50% 46 ± 10 43 ± 9 39 ± 11† .012
⁎ P < .05 between baseline and immediately post-TAVI.
† P < .05 between baseline and latest follow-up.
‡ P < .05 between immediately post-TAVI and latest follow-up.




final multivariate model, presence of frailty (HR = 4.20,
95% CI = 2.00-8.84, P < .001) and baseline LVEF (HR =
0.97, 95% CI = 0.94-0.99, P = .017) emerged as the only
independent predictors of cumulative MACEs.
Nonetheless, the general survival rates at 1, 6, and 12
months in patients with a baseline LVEF ≥50% and those
with that of <50% were not significantly different, as
illustrated in Figure 1, B (95%, 90%, and 86% vs 90%, 86%,
and 82%, respectively; log-rank P = .49).
TAVI versus surgery
Ninety-nine patients who underwent SAVR at the
Leiden University Medical Center were retrospectively
recruited from the surgical database and divided into 2
subgroups based on an LVEF <50% (n = 30) or that of
≥50% (n = 69) before surgery to evaluate whether the
clinical outcome of TAVI is similar to that of the surgical
approach. Table IV summarizes the baseline character-
istics of patients who underwent SAVR. These control
patients were frequency matched to the studied popula-
tion in terms of age (79.3 ± 5.6 vs 80.5 ± 6.3 years, P =
.23), male gender (34.8% vs 36.1%, P = .86), and AVA
(0.71 ± 0.14 vs 0.66 ± 0.16 cm2, P = .06) for the group
with a baseline LVEF ≥50%. In patients with a baseline
LVEF <50%, similar matching was performed with regard
to their age (77.3 ± 5.0 vs 79.8 ± 7.5 years, P = .08), male
gender (73.3% vs 56.0%, P = .12), and AVA (0.73 ± 0.24 vs
0.68 ± 0.17 cm2, P = .37). Figure 2 demonstrates that
survival of patients who underwent TAVI compared
favorably with that of patients who underwent SAVR (log-
rank P = .40), regardless of LV function at baseline.
Discussion
The Euro Heart Survey indicated that apart from
advanced age, LV systolic dysfunction is the other major
reason to deny surgery in patients with severe AS.10 In
fact, the outcome of SAVR is highly dependent on
preoperative LV function.4,7,24 Recently, TAVI has been
introduced as a therapeutic alternative in patients with
excessive operative risk. However, little is known on the
impact of preoperative LV function on clinical and
echocardiographic outcomes post-TAVI.
The present study demonstrates that TAVI is a feasible
and effective therapeutic option for high-risk patients
with severe AS, irrespective of baseline LVEF. Significant
improvements in transvalvular hemodynamics and in LV
performance were observed post-TAVI. In particular,
patients with an LVEF <50% showed LV reverse
remodeling, with marked improvements of LV systolic
function and diastolic function.
In addition, early and late all-cause mortality rates were
not significantly different between patients with normal
and those with impaired LV function, despite a higher
rate of combined MACEs in patients with a baseline LVEF
<50%. Predictors of cumulative MACEs were the pres-
ence of frailty and baseline LVEF. Importantly, the long-
term survival curves of patients with normal and those
with impaired LV function who underwent TAVI were
comparable with those of patients who underwent SAVR
(the standard therapy for severe symptomatic AS2).
Early clinical outcomes
In the current study, the procedural success rate for
TAVI was 96%, in line with results of a recent series that
reported improved procedural success rates of 91%-
Figure 1
A, Kaplan-Meier curves of freedom from death, nonfatal stroke, heart
failure, or nonfatal myocardial infarction for patients who underwent
TAVI with a baseline LVEF ≥50% and those with that of <50%. B,
Kaplan-Meier curves of survival for patients who underwent TAVI with
a baseline LVEF ≥50% and those with that of <50%.
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94%.12,14 Despite their higher risk profile, patients with a
baseline LVEF <50% showed similar success rate (97% vs
94%) and perioperative adverse events relative to patients
with a baseline LVEF≥50% (Table II). Of note, procedure-
specific variables, such as procedure duration and total
contrast volume, were also similar. Therefore, the present
study highlights the feasibility of TAVI in a multicenter
setting and regardless of baseline LV function.
The overall early 30-day mortality was 7%, which
compares favorably with the recently published multi-
center Canadian experience of 10%.14 Although no
significant differences in terms of 30-day mortality were
observed between patients with preserved and thosewith
impaired LV function (10% vs 5%, P = .31), patients with
an LVEF <50%had amore than 2-fold increase in the risk of
combined MACEs (20% vs 7%, P = .03) as compared with
patients with an LVEF ≥50%. Therefore, in patients
undergoing TAVI, the presence of LV dysfunction has an
additional negative impact on early morbidity with an
increased incidence of combined MACEs without affect-
ing the early all-cause mortality significantly.
Echocardiographic outcomes
As a result of chronic LV pressure overload associated
with severe AS, the LV wall thickens initially in an
attempt to limit wall stress and to maintain adequate
systolic function.16 However, when the wall stress
exceeds LV compensatory capacity, LV systolic dysfunc-
tion ensues from the effect of afterload mismatch.3
Consequently, in the absence of significant primary
myocardial dysfunction, valve replacement (TAVI or
SAVR) results in improvement of LV function.16 Accord-
ingly, marked LV reverse remodeling and improvement
in LV systolic function were observed especially in
patients with a baseline LVEF <50%, in whom the mean
LVEF increased over time. Thus, the present study
confirms that LV dysfunction, when it is due to afterload
mismatch associated with severe AS, may be reversible
following TAVI.
Significant improvement in other echocardiographic
parameters was also observed. LV mass regression
occurred in all patients due to the marked improvement
in LV hemodynamics post-TAVI. Similarly, as a result of
the reduction in LV filling pressure, significant improve-
ment in LV diastolic function was observed (a reduction
in LA area and pulmonary artery systolic pressure)
(Table III). Of note, this improvement was more marked
in patients with a baseline LVEF <50%, who also showed a
larger LA area at baseline. LA dilatation has been
recognized as a marker of disease progression in patients
with AS, reflecting the increase in LV filling pressures
associated with severe AS.25 This study highlights that LA
enlargement could also be attenuated post-TAVI.
Long-term clinical outcomes
This study shows that during long-term follow-up post-
TAVI, patients with a baseline LVEF <50%were associated
with higher incidence of combined MACEs as compared
with those with a normal LVEF (Figure 1, A). Moreover,
other than baseline LVEF, the physical performance status
of patients (expressed by frailty in the present study) was
an independent predictor of MACE-free survival. Similarly,
preprocedural functional status, as expressed using a
different scoring index (Karnofsky index),26 has been
shown to be able to predict outcome post-TAVI in a recent
study of 168 patients who underwent self-expanding
prosthesis implantation.27 These findings suggest that
incorporating the functional assessment of high-risk
patients with AS in the selection criteria for TAVI may
be more appropriate than the currently used scoring
systems to identify those patients who will derive
maximum benefit from this new intervention.
In terms of all-cause mortality, the cumulative survival
rates were similar in both groups (Figure 1, B). A possible
explanation for this finding is that most deaths occurring
after 30 days were not from cardiovascular causes but
were related to advanced age and the presence of
comorbidities. In the series of Webb et al,12 who followed
up on 168 patients post-TAVI, late mortality was also
primarily determined by underlying comorbidities.
Furthermore, in the present study, patients who
underwent TAVI had survival curves similar to those of
patients who underwent SAVR (Figure 2). In particular,
no significant differences were observed in survival rates
at 6 months (92% vs 90%) and 1 year (84% vs 86%, log-rank
Table IV. Baseline clinical and echocardiographic
characteristics of patients who underwent SAVR with a baseline





Age (y) 79.3 ± 5.6 77.3 ± 5.0
Male [n (%)] 24 (35) 22 (73)
Logistic EuroSCORE (%) 9.6 ± 5.1 17.8 ± 13.0
New York Heart Association functional
class of III or higher [n (%)]
30 (44) 14 (47)
Previous myocardial infarction [n (%)] 10 (15) 11 (37)
Previous coronary bypass surgery [n (%)] 8 (11) 7 (23)
Hypertension [n (%)] 35 (51) 11 (37)
Hypercholesterolemia [n (%)] 17 (25) 9 (30)
Diabetes [n (%)] 15 (22) 8 (27)
Smoking [n (%)] 14 (20) 6 (20)
Renal dysfunction [n (%)]⁎ 4 (6) 6 (20)
Hemoglobin (g/dL) 12.6 ± 1.9 13.3 ± 2.0
Echocardiography
AVA (cm2) 0.71 ± 0.14 0.73 ± 0.24
Mean aortic gradient (mm Hg) 49 ± 18 33 ± 16
LVEF (%) 60 ± 6 35 ± 8
Concomitant coronary bypass
surgery [n (%)]
29 (42) 15 (50)
⁎Renal dysfunction is defined as serum creatinine level N130 μmol/L.




P = .82) between patients with a baseline LVEF ≥50%
who underwent SAVR and those who underwent TAVI.
Similarly, the type of procedure (SAVR or TAVI) did not
have an impact on the survival rates at 6 months (80% vs
86%) or 1 year (75% vs 82%, log-rank P = .99) in patients
with a baseline LVEF <50%. Therefore, the present study
suggests that in patients at high operative risk, in whom
SAVR would be excluded due to advanced age or
depressed LVEF or a combination of factors, TAVI should
be strongly considered. In fact, these patients, if left on
medical therapy, would have high morbidity and
mortality rates. Varadarajan et al6 studied a cohort of
277 elderly patients (mean LVEF = 52% ± 20%) and
showed that patients with symptomatic severe AS and left
unoperated have significantly worse prognosis than those
undergoing SAVR (52% vs 87% survival rate at 1 year).
Moreover, previous studies5,6,8 have indicated that the
presence of LV dysfunction has further negative impact
on the survival of patients with severe AS. Tarantini et al8
reported that in patients with severe AS and depressed
LVEF, the mortality rate was very high, with only 16%
of patients alive at 2 years. Therefore, the current
study suggests that TAVI may improve the survival of
high-risk patients with severe AS to a level that is
possibly comparable with that of SAVR (the standard
therapy for symptomatic severe AS2), regardless of
baseline LV function.
Limitations
Although the data were prospectively collected, all
adverse events were collected from the electronic
database of each center. Nonetheless, the investigators
endeavored to ensure accuracy of the information
provided. In addition, we acknowledge the limitations
in comparing TAVI versus SAVR (using a control cohort)
and in particular the presence of potential confounding
factors despite the matching criteria. For example, due to
a selection bias associated with TAVI (after SAVR was
denied), patients who underwent TAVI carry significantly
higher operative risk compared with those who under-
went SAVR. Nonetheless, this inherent difference would
have biased the results toward a larger difference in
outcomes, favoring those of surgery. On the contrary, the
present study shows that patients who underwent TAVI
had comparable long-term survival outcome as those who
underwent SAVR. The present study may shed some light
on the difference in outcomes between these 2
approaches before the results of a randomized controlled
trial become available.
Conclusions
The present study shows that the patients with severe
AS at high operative risk benefited from TAVI in terms of
improvement in LV function and survival, regardless of
Figure 2
Kaplan-Meier curves of survival for patients with a baseline LVEF ≥50% and those with that of <50% who underwent SAVR or TAVI. The asterisk
indicates comparison between SAVR and TAVI.
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baseline LVEF. Although patients with an LVEF <50%
were at higher risk of combined MACEs when compared
with patients with an LVEF≥50%, the early and long-term
all-cause mortality rates were similar. Importantly, TAVI
resulted in a long-term survival that was comparable with
that of a matched group of patients who underwent SAVR
(the current standard of care for severe AS2).
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Outcomes After Transcatheter Aortic Valve
Implantation: Transfemoral Versus
Transapical Approach
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Arend de Weger, MD, Giuseppe Tavilla, MD, PhD, Eduard R. Holman, MD, PhD,
Martin J. Schalij, MD, PhD, and Jeroen J. Bax, MD, PhD
Department of Cardiology and Cardiothoracic Surgery, Leiden University Medical Center, Leiden, The Netherlands; and
Department of Cardiology, National Heart Centre, Singapore
Background. Transcatheter aortic valve implantation is
commonly implanted through a transfemoral (TFA) or
transapical approach (TAA) for patients with severe
aortic stenosis. This study aimed to describe the clinical
and echocardiographic outcomes of TFA versus TAA.
Methods. Clinical and echocardiographic evaluations
were performed at baseline, post-TAVI (transcatheter
aortic valve implantation), at 6 and 12 months follow-up
in 107 consecutive patients who underwent TAVI with
balloon-expandable valves.
Results. The TFA was performed in 44% and the
remaining patients underwent TAA. Although proce-
dural complications were not significantly different in
both approaches, more vascular complications were ob-
served in the TFA group (18% vs 5%, p  0.053). Patients
with TAA required shorter fluoroscopy time (median 5 vs
12 min, p < 0.001), less contrast volume (median 80 vs 173
mL, p < 0.001), and similar length of hospitalization, as
compared with TFA. Importantly, the early 30-day mor-
tality (TFA: 11.1% vs TAA: 8.5%, p  0.74) were not
significantly different between the 2 approaches. Mid-
term survival at 6 months and 1 year was comparable
between TFA and TAA (6 months: 88.9% vs 85.7% and 1
year: 80.2% vs 85.7%). All patients achieved immediate
and sustained improvements in transvalvular hemody-
namics, together with significant left ventricular mass
regression (137  39 vs 113  30 g/m2, p < 001) and left
atrial volume reduction (48  17 vs 34  14 mL/m2, p <
0.001) at 6 months or less.
Conclusions. Early, midterm, clinical, and echocardio-
graphic outcomes were comparable in both approaches.
However, TAA has the additional benefit of reducing
radiation exposure and contrast use intraoperatively
without prolonging the length of hospital stay.
(Ann Thorac Surg 2011;92:1244–51)
© 2011 by The Society of Thoracic Surgeons
Transcatheter aortic valve implantation (TAVI) is afeasible therapeutic alternative for patients with
symptomatic severe aortic stenosis (AS) and high opera-
tive risk [1–3]. In addition, TAVI has been shown to
improve both the symptoms and clinical outcomes of
these patients [3, 4]. Currently, the balloon-expandable
Edwards SAPIEN bioprosthetic valve (Edwards Life-
sciences Inc, Irvine, CA) can be implanted through a
transfemoral (TFA) or a transapical approach (TAA).
Although the TFA is the preferred approach for its less
invasive nature, this option is not feasible in patients with
unfavorable anatomy of the peripheral arteries and aorta,
and with subsequent risk of major vascular complications
[5]. Accordingly, the TAA, which involves a minithora-
cotomy, has been explored with promising results [1–3,
6]. However, there are limited studies comparing the
immediate, short-term, and midterm clinical results of
both approaches, TFA versus TAA.
Furthermore, favorable left ventricular (LV) remodel-
ing and function postsurgical aortic valve replacement
for AS have been documented [7] but little is known
about the changes in valvular hemodynamics and its
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129Transfemoral versus transapical TAVI
consequence on LV function after TAVI. The present
study describes the early and midterm clinical outcomes
of the 2 approaches (TFA vs TAA) and evaluates the
changes in LV performance immediately postprocedure
and at midterm ( 6 months) follow-up.
Patients and Methods
Over a period of 2.5 years, a total of 107 consecutive
patients with severe symptomatic AS and high surgical
risk or contraindications for surgical aortic valve replace-
ment were referred for TAVI at the Leiden University
Medical Center. The patients were evaluated by a mul-
tidisciplinary team including cardiothoracic surgeons
and interventional cardiologists. The preprocedural eval-
uation consisted of clinical evaluation, transthoracic
echocardiography, coronary angiography, and angiogra-
phy of the aorto-ilio-femoral system. Clinical evaluation
included the assessment of operative risk according to
the logistic European system for cardiac operative risk
evaluation [8] and the Society of Thoracic Surgeons score,
evaluation of comorbidities, previous thoracic surgery, or
radiation and physical frailty [9]. This evaluation was
conducted according to the clinical protocol of the insti-
tution. All patients provided informed consent for the
procedures. Clinical and echocardiographic data were
prospectively collected in electronic patient dossier (EPD
vision version 8.3.3.6; Leiden, The Netherlands) and
retrospectively analyzed with approval of the Institu-
tional Review Board.
All patients underwent transthoracic echocardiography
at baseline, postprocedure, and at 6 and 12 months follow-
up. The LV end-diastolic and end-systolic volumes were
measured, indexed to body surface area, and the LV ejec-
tion fraction was derived from the biplane Simpson method
[10]. Standard LV dimensions and mass were measured
[10, 11]. Peak and mean transaortic pressure gradients were
calculated and aortic valve area was determined by the
continuity equation [12]. Severe AS was defined as a mean
pressure gradient of 40 to 50 mm Hg or greater, or a valve
area less than 1 cm2 [13, 14]. Aortic regurgitation (AR) was
assessed using color Doppler and its severity was assessed
according to current guidelines [13–15]. In addition, dia-
stolic function was assessed by the ratio of the transmitral
early filling velocity (E-wave) to the late diastolic filling
velocity (A-wave) and deceleration time of the E-wave.
Pulmonary artery systolic pressure was also calculated from
the peak velocity of the tricuspid regurgitation jet [16].
Finally, maximal left atrial volumes were measured using
the biplane Simpson method and indexed to body surface
area [10].
All procedures were performed at the catheterization
laboratory under general anesthesia with transesophageal
echocardiography and fluoroscopy guidance. The Edwards
SAPIEN valves (Edwards Lifesciences Inc) of either 23 mm
or 26 mm were used. The retrograde TFA was considered
first option whereas the TAA was recommended if any of
the following criteria were present: previous peripheral
vascular surgery or aortoiliac intervention; significant pe-
ripheral artery disease; iliofemoral arteries less than 7 to 8
mm (for 23 or 26 mm valve, respectively); marked tortuosity
of the aorto-ilio-femoral system; or abdominal aortic aneu-
rysm and porcelain aorta [2, 5].
As previously described, the implantation of the valve
was preceded by balloon dilatation of the native aortic
valve and rapid pacing was required during valve de-
ployment [3]. For the TFA, transarterial access was
gained after surgical cut-down, whereas an anterior
minithoracotomy followed by direct needle puncture of
the LV apex was performed for the TAA [3]. At the end of
procedure, all the access sites were closed surgically.
Procedural success was defined as successful implanta-
tion of a functioning aortic prosthesis without intrapro-
cedural mortality [2, 3]. Total iodinated contrast volume
consumed, duration of fluoroscopy, and the procedure
were recorded. Procedural duration was measured from
the time of skin incision or arterial puncture to the
closure of the access site.
Systematic clinical evaluations were obtained post-TAVI,
before hospital discharge, and at 6 and 12 months. Intrap-
rocedural mortality included any death that occurred be-
fore extubation in the catheterization laboratory. In-hospital
events included all-cause mortality, stroke, atrioventricular
conduction block requiring pacemaker, bleeding, infection,
and heart failure decompensation. Bleeding was defined as
any significant blood loss requiring surgical intervention,
blood transfusion, or both. Infection was defined as any
utilization of intravenous antibiotics for clinically identifi-
able source or elevated inflammatory markers. In addition,
septicemia, valvular endocarditis, and wound infection
were recorded as major infection events. Total early mortal-
ity included both intraprocedural, in-hospital deaths, and all
deaths within the first 30 days. Midterm outcome measures
included all major adverse cardiac, cerebrovascular, valve
related, or noncardiac events requiring hospitalization.
Statistical Analysis
Continuous variables were presented as mean (SD) or
median (interquartile ranges) and categoric variables as
frequencies (percentages), as appropriate. Clinical and
echocardiographic characteristics of the patients were
compared based on the approach of TAVI (TFA vs TAA).
Continuous variables were compared using the unpaired
Student t test or Mann-Whitney U test, and for categoric
variables the 2 test or Fisher exact test, as appropriate.
Repeated measures analysis of variance (ANOVA) was
used to analyze the repeated continuous data and post
hoc analysis for significant results were performed using
the Bonferroni correction. Survival was evaluated using
the Kaplan-Meier analysis and the log-rank test was used
to measure the differences between groups. A p value
less than 0.05 was considered statistically significant. All
statistical analyses were conducted using SPSS for Win-
dows, version 16 (SPSS Inc, Chicago, IL).
Results
A total of 107 patients underwent TAVI after multidisci-
plinary screening. Three cases (2.8%) were abandoned
during the procedure due to the risk of coronary occlu-
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sion from heavily calcified valve leaflets or ventricular
rupture from friable myocardium by the TAA. Two
patients subsequently received balloon valvuloplasty
and were alive at last follow-up. The third patient, who
did not receive balloon valvuloplasty due to the risk of
worsening of baseline AR, died from heart failure 8
months later. The final analysis included only patients
who received TAVI (n  104). Table 1 shows the baseline
clinical characteristics. Fifty-nine patients (56.7%) under-
went TAA due to unsuitable arterial anatomy for TFA.
Accordingly, there were more patients with significant
peripheral vascular disease in the TAA group (67.8% vs
11.1%, p  0.001). Patients with peripheral arterial dis-
ease, but had adequate ilio-femoral anatomy, proceeded
with the TFA [2, 5].
Procedural success rate was 92.5% and the intraproce-
dural mortality rate was 4.8%. The duration of fluoros-
copy (median 12 vs 5 minutes, p  0.001), total contrast
volume use (median 173 vs 80 mL, p  0.001), and
procedural duration (median 71 vs 64 minutes, p  0.008)
were significantly more in the TFA than the TAA group.
Five (4.8%) intraprocedural deaths were the following: 3
fatal vascular complications through the TFA with perfo-
ration of iliac arteries (n  2) and rupture of the descend-
ing aorta (n  1), and 2 deaths during TAA (severe AR
after prosthesis deployment and cardiogenic shock). At-
tempts to seal off the iliac artery perforation with covered
stents were unsuccessful in the first 2 cases, leading to
death despite emergency laparotomy. The remaining
patients died before bailout procedures such as emer-
gency valve-in-valve or endovascular aortic repair could
be attempted. There was a strong trend toward more
vascular complications in the TFA group (17.8% vs 5.1%,
p  0.053). All 3 cases of cardiac tamponade were suc-
cessfully drained.
A comparison of in-hospital outcomes between the 2
approaches is summarized in Table 2. The total 30-day
mortality was 9.6%. There were 4 cases of in-hospital
mortality: heart failure (n  3) and stroke (n  1). One
additional death occurred on day 22 (massive bleeding
peptic ulcer) after the first hospitalization. Length of
hospitalization was similar in both approaches (median 6
days for both, p  0.21).
Median follow-up duration was 12.2 (interquartile range 5.6
to 22.1) months. Late complications were uncommon after 30
days. Six deaths occurred between 30 days and 1 year: 3
cardiovascular deaths (endocarditis, myocardial infarction and
stroke) and the remaining cases were noncardiac related








(n  59) p Value
Age (years) 80.6  7.9 82.2  7.1 79.4  8.3 0.072
Male 50.0% 46.7% 52.5% 0.69
Body surface area (m2) 1.8  0.2 1.8  0.2 1.8  0.2 0.82
Logistic EuroSCORE (%) 21.3  11.8 20.1  11.7 22.6  11.9 0.20
STS score (%) 8.7  3.6 8.5  3.8 8.9  3.5 0.61
New York Heart Association functional class  III 68.3% 64.4% 71.2% 0.53
Heart rhythm
Sinus rhythm 72.1% 77.8% 67.8% 0.28
Atrial fibrillation 21.2% 17.8% 23.7% 0.63
Pacemaker 6.7% 4.4% 8.5% 0.70
Renal dysfunctiona 22.1% 22.2% 22.0% 1.00
Hemoglobin (g/dL) 12.2  1.6 12.0  1.6 12.3  1.5 0.36
Previous myocardial infarction 23.1% 22.2% 23.7% 1.00
Previous coronary bypass surgery 40.0% 33.3% 42.4% 0.42
Peripheral vascular disease 43.3% 11.1% 67.8% 0.001
Previous aortofemoral bypass or stenting 3.8% 0% 6.8% 0.13
Abdominal aortic aneurysm 2.9% 0% 5.1% 0.26
Porcelain aorta 3.8% 0% 6.8% 0.13
Hypertension 59.6% 51.1% 66.1% 0.16
Hypercholesterolemia 44.2% 33.3% 52.5% 0.073
Diabetes 27.9% 28.9% 27.1% 1.00
Chronic obstructive pulmonary disease 26.9% 24.4% 28.8% 0.16
Previous stroke 11.5% 4.4% 17.0% 0.064
Frailty 36.5% 28.9% 42.4% 0.12
Smoking 35.6% 26.7% 42.4% 0.11
a Renal dysfunction was defined as serum creatinine exceeding 130 mol/L.
EuroSCORE  European system for cardiac operative risk evaluation; STS  The Society of Thoracic Surgeons.
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131Transfemoral versus transapical TAVI
(bleeding peptic ulcer and end-stage lung disease). Overall
survival at 1, 6, and 12 months was 90.4%, 87.2%, and 83.0%,
respectively. Figure 1 shows no significant difference between
the 2 approaches in terms of survival (log-rank, p  0.63).
Significant improvement in New York Heart Association func-
tional class was noted post-TAVI (from 2.8  0.8 to 1.5  0.6 at
6 months, p  0.001), which was maintained at 1 year. No
difference in functional class was observed between the 2
approaches (Fig 2).
All echocardiographic data obtained at baseline, post-
procedure, and at 6 months or greater were compared
(Table 3). Significant increase in aortic valve area was







(n  59) p Value
Intraprocedural:
Mortality 4.8% 6.7% 3.4% 0.65
Vascular complication 10.6% 17.8% 5.1% 0.053
Fatal 2.9% 6.7% 0% 0.078
Non-fatal 7.7% 11.1% 5.1% 0.29
Cardiac tamponade 3.8% 2.2% 5.1% 0.63
Fluoroscopy time (minutes)a 8 (5–12) 12 (10–15) 5 (4–8) 0.001
Procedure duration (minutes)a 68 (53–85) 71 (58–98) 64 (49–80) 0.008
Contrast load (mL)a 100 (75–170) 173 (118–200) 80 (70–109) 0.001
In-hospital:
Mortality 3.8% 4.4% 3.4% 1.00
Heart failure 2.9% 4.4% 1.7% 0.58
Fatal stroke 1.0% 0% 1.7% 1.00
Stroke 3.8% 4.4% 3.4% 1.00
Non-fatal 2.9% 4.4% 1.7% 0.58
AV conduction block requiring pacemaker 3.8% 4.4% 3.4% 1.00
Bleeding 11.5% 6.7% 15.3% 0.22
Major infection 0% 0% 0% 1.00
Minor infection 8.7% 4.4% 11.9% 0.29
Hospital stay, daysa 6 (5–8) 6 (5–7) 6 (5–8) 0.21
Early (30 days)
Total mortality 9.6% 11.1% 8.5% 0.74
a Data are presented as median (interquartile range).
AV atrioventricular.
Fig 1. Kaplan-Meier curves of survival after transcathether aortic
valve implantation by the two approaches, transapical (TAA) versus
transfemoral (TFA).
Fig 2. Follow-up of New York Heart Association (NYHA) functional
class at 6 and 12 months in the 2 approaches (transapical versus
transfemoral). (*Comparison between 2 approaches. Absolute num-
bers are shown inside the bars; NS  not significant.)
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Aortic valve area (cm2)
All patients 0.7  0.2 2.0  0.4a 1.9  0.4b 0.001
Transfemoral 0.7  0.2 2.0  0.5a 1.8  0.4b 0.001
Transapical 0.8  0.2 2.0  0.3a 1.9  0.3b 0.001
Mean transaortic gradient (mm Hg)
All patients 41  16 8  3a 9  6b 0.001
Transfemoral 43  19 8  3a 10  7b 0.001
Transapical 39  12 8  3a 8  4b 0.001
Left ventricular end-diastolic volume index (mL/m2)
All patients 69  28 68  25 71  27 0.31
Transfemoral 63  26 64  25 65  24 0.70
Transapical 76  29 73  25 78  30 0.30
Left ventricular end-systolic volume index (mL/m2)
All patients 36  25 33  22 36  23 0.18
Transfemoral 32  24 29  21 31  21 0.25
Transapical 40  25 38  22 41  24 0.43
Left ventricular ejection fraction (%)
All patients 53  14 55  13 52  13 0.16
Transfemoral 55  14 59  13 55  15 0.07
Transapical 52  14 50  13 50  12 0.48
Left ventricular septal wall thickness (mm)
All patients 13  3 13  3 11  2b,c 0.001
Transfemoral 12  3 12  2 10  1b,c 0.001
Trans-apical 12  2 12  2 11  2b,c 0.001
LV posterior wall thickness (mm)
All patients 12  2 12  2 11  2b,c 0.001
Transfemoral 13  3 12  2 11  2b,c 0.001
Transapical 12  2 12  2 11  2b,c 0.003
Left ventricular mass index (g/m2)
All patients 137  39 132  37 113  30b,c 0.001
Transfemoral 130  40 123  31 104  30b,c 0.001
Transapical 143  37 140  40 122  29b,c 0.001
Mitral E/A ratio
All patients 1.0  0.8 1.4  1.1a 0.9  0.7c 0.003
Transfemoral 0.9  0.6 1.5  1.4a 0.8  0.5c 0.010
Transapical 1.1  0.9 1.3  0.8 1.0  0.9 0.15
Mitral E wave deceleration time (ms)
All patients 233  80 217  81 235  78 0.25
Transfemoral 230  81 214  93 240  69 0.36
Transapical 235  81 219  70 230  86 0.48
Pulmonary artery systolic pressure (mmHg)
All patients 42  13 41  14 36  14b,c 0.005
Transfemoral 41  14 42  16 37  16 0.10
Transapical 43  11 39  11 32  8b 0.036
Left atrial volume index (mL/m2)
All patients 48  17 45  20 34  14b,c 0.001
Transfemoral 50  20 49  25 32  17b,c 0.001
Transapical 47  14 42  15a 36  12b,c 0.001
a p  0.05 between baseline and postprocedure. b p  0.05 between baseline and latest follow-up echocardiography. c p  0.05 between
postprocedure and latest follow-up echocardiography.
ANOVA  analysis of variance; E/A ratio  early transmitral flow velocity to atrial flow velocity.
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133Transfemoral versus transapical TAVI
observed in all patients postprocedure and maintained at
6 months or greater (from 0.7  0.2 cm2 to 2.0  0.4 cm2,
and then to 1.9  0.4 cm2), regardless of the approach.
This was paralleled with similar reduction in mean
gradient.
Although there was no significant change in LV vol-
umes and ejection fraction, LV mass index decreased
significantly from 137  39 g/m2 to 132  37 g/m2, and
then to 113  30 g/m2 in the whole group (ANOVA p 
0.001). This LV mass regression remained significant
when analyzed according to procedural approach (Table
3). Regarding the analysis of diastolic function, left atrial
volume decreased from 48  17 mL/m2 to 34  14 mL/m2
at 6 months or greater for the whole population (ANOVA
p  0.001), which remained significant in both ap-
proaches (Table 3). Mild AR was noted in 57.7% and
50.7% of patients postprocedure and at 6 months or
greater, respectively. Conversely, significant AR post-
TAVI (of grade  II) was infrequent and was only
observed in 5 patients postprocedure (Fig 3). Importantly,
no severe AR was observed over time. The TFA or TAA
did not affect the outcome of AR post-TAVI.
Comment
The present study demonstrated that TAVI by the TAA
or TFA had comparable clinical outcomes and midterm
survival in high-risk patients with severe AS. Impor-
tantly, the TAA did not prolong hospital stay but reduced
fluoroscopy time, amount of contrast used intraprocedur-
ally, and procedural duration. Furthermore, TAVI re-
sulted in favorable and sustained improvements in trans-
valvular hemodynamics, with regression in LV mass and
left atrial volume on midterm follow-up.
The procedural success rate of 92.5% in our initial
single-center experience is encouraging and is in line
with the 91% to 94% reported in other series [2, 3].
Although the overall early 30-day mortality for this
high-risk group is not low (9.6%) in this study, this
compares well to the reported 30-day mortality rate of
7.5% to 10.5% for this group of octogenarians (n  282)
undergoing isolated aortic valve surgery [17]. More im-
portantly, the survival rate after TAVI is superior to that
observed in patients who did not undergo aortic valve
surgery for severe AS. In a recent randomized trial of 358
patients who were not candidates for surgery and as-
signed to TFA-TAVI or standard therapy including bal-
loon valvuloplasty [18], the survival 1 year was 69.3%
with TAVI, compared with only 49.3% with current
standard therapy for severe AS.
Currently, the TFA is the initial preferred approach for
TAVI in most centers. In this study, 56.7% of patients
were not candidates for the TFA due to unsuitable
peripheral arterial or aortic anatomy. As such, these
patients would be denied a potentially life-saving and
symptom-relief procedure if an alternative access such as
TAA was not available. This is consistent with the study
of Rodes-Cabau and colleagues [19], in which at least
51% of their patients underwent TAA due to unfavorable
peripheral anatomy. Accordingly, expertise in both ap-
proaches and a multidisciplinary care are vital in provid-
ing optimal treatment to this group of high-risk patients
with symptomatic AS.
The present study highlighted several important tech-
nical differences between the 2 approaches. First, the
TAA group was associated with significantly less contrast
use. This observation may be clinically important as most
of these elderly patients are susceptible to contrast-
induced nephropathy by virtue of advanced age and
multiple comorbidities. Bagur and colleagues [20] have
highlighted that acute kidney injury occurred in 12% of
the patients’ post-TAVI and its occurrence was associ-
ated with at least a fourfold increase in postoperative
mortality. Thus, TAA may be a preferred approach in
patients with concomitant renal dysfunction and unfa-
vorable vascular access. Second, consistent with the
study of Bleiziffer and colleagues [21], we found shorter
total fluoroscopy time in patients with TAA than with
TFA. A plausible explanation for this is that less time is
required for valve implantation by the TAA due to easier
manipulation and control of the device with a shorter
distance between the aortic valve and the access site. This
was reflected in shorter total fluoroscopy time associated
with TAA. Finally, we observed similar length of hospital
stay in both approaches. Currently, there is limited data
comparing the procedural time and hospital stay.
In terms of intraprocedural complications, there was a
trend toward a higher prevalence of vascular complica-
tions in patients who underwent TFA (Table 2). Similar
nonstatistical significant observation was reported by
Webb and colleagues [3] in 168 patients, where more
vascular injury occurred in patients with TFA than TAA
(8% vs 3.6%). The development of smaller-sized delivery
system, better patient preprocedural screening and the
experience of the operators are vital in improving the
immediate outcomes of TAVI, particularly with the TFA
Fig 3. Comparison of aortic regurgitation severity assessed at base-
line, postprocedure, and at latest follow-up echocardiography ( 6
months) for transfemoral and transapical approaches. (*Comparison
between 2 approaches. Absolute numbers are shown inside the bars;
AR  aortic regurgitation; NS  not significant; post-TAVI  post-
transcatheter aortic valve implantation.)
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[3, 5, 22]. The present study showed comparable stroke
occurrence in the 2 approaches. In contrast, Himbert and
colleagues [22] observed 3 stroke events after TFA but
none occurred by TAA (p  0.23). Finally, the incidence of
permanent pacing after TAVI in our population was low
(3.8%), which is consistent with the observation of Webb
and colleagues who reported only 5.4% of patients re-
quired permanent pacemaker after balloon-expandable
valves implantation. Importantly, the present study dem-
onstrated that implantation approach did not affect both
the early survival at 30 days and midterm survival at 6
months (TFA: 88.9% vs TAA: 85.7%) and at 12 months
(TFA: 80.2% vs TAA: 85.7%, Fig 1).
Both approaches achieved similar improvement in the
transaortic hemodynamics post-TAVI (Table 3) and are
consistent with the findings of other series [3, 23]. In
addition, TAVI has been shown to provide superior
hemodynamics comparable with that of stentless surgical
bioprosthesis and yet with a lower risk of prosthesis-
patient mismatch, as reported by Clavel and colleagues
[23]. The transprosthetic gradients were similar in patients
with TAVI and stentless surgical bioprothesis (10 mm Hg vs
9 mm Hg) but lower when compared with patients with
stented surgical prostheses (13 mm Hg) [23].
The changes in LV dimensions and function observed
in this study also reflect the improvements in transaortic
hemodynamics post-TAVI. The LV mass reduced signif-
icantly and returned to within normal limits (113  30
g/m2) at 6 months or greater. In this respect, reduction in
LV mass can occur as early as 5 days post-aortic valve
surgery [24] and will continue even years postsurgery [7].
Although no significant changes in LV volumes or sys-
tolic function post-TAVI were noted in this study,
changes in LV diastolic function were observed. The
reduction in LV filling pressure and subsequent im-
provement of diastolic dysfunction post-TAVI were ac-
companied by a significant reduction in left atrial volume
in our patients. Finally, consistent with previous studies
[3, 25], paravalvular AR post-TAVI was not uncommon,
with the majority of patients having mild AR postproce-
dure and remained stable over time in this study (Fig 3).
In summary, the present study shows that high-risk
patients with severe AS can benefit from TAVI, in terms
of favorable clinical outcomes and improved LV perfor-
mance on echocardiography. These desirable changes
can be observed early and at midterm follow-up. Com-
paring the approaches, the outcomes of TAA are compa-
rable with that of TFA, but the TAA group has additional
benefit of reduced radiation exposure and contrast use
intraoperatively, without prolonging hospital stay. We
acknowledge that this study was based on a relatively
small patient cohort and reflects a single-center experi-
ence. In addition, selection bias associated with TAA
(after TFA was denied) may form a limitation and pa-
tients who underwent TAA might potentially carry a
higher perioperative risk, as compared with patients who
underwent TFA. Nonetheless, this inherent difference
would have biased the results toward a larger difference
in outcomes, favoring that of TFA. On the contrary, this
study showed that patients who underwent TAA had
comparable early and midterm survival to those who
underwent TFA.
See Hooi Ewe is financially supported by the Ministry of Health
Training Scholarship, Singapore.
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The general introduction of this thesis (Chapter 
1) outlines the epidemiology and the impact of 
aortic valve (AV) disease in the western world. 
The thesis further discuss the current and future 
role of advanced cardiac imaging modalities, using 
3-dimensional (3D) echocardiography and speckle 
tracking echocardiography (STE) strain imaging in 
the diagnostic and clinical management of patients 
with aortic regurgitation (AR). In addition, the clini-
cal applications of multimodality cardiac imaging in 
transcatheter aortic valve implantation (TAVI) for 
the treatment of severe aortic stenosis (AS) will be 
discussed: from pre-procedural patient evaluation, 
to the understanding of complications post-TAVI 
such as paravalvular regurgitation (PVR), and the 
assessment and monitoring of patients after TAVI.
part I: Novel imaging to assess aortic valve 
regurgitation – incremental role in diagnosis
The first part of the thesis evaluates the incremental 
value of 3D echocardiograhy over the conventional 
2-dimensional (2D) echocardiographic method to 
quantify AR, using 3D 3-directional velocity encoded 
magnetic resonance imaging (MRI) as the reference 
method (which has been proposed as an accurate 
method to assess transvalvular flow, after correct-
ing for throughplane motion). Regurgitant volume 
obtained by 3D echocardiography showed excellent 
agreement with MRI, better than when comparing 
2D echocardiography and MRI. When these two 
echocardiographic modalities are applied in the 
assessment of eccentric jets, 3D echocardiography 
showed a far better correlation with MRI (r=0.95), 
whereas the correlation with 2D echocardiography 
and MRI was weak (r=0.66). Therefore, quantifica-
tion of AR using 3D echocardiography has shown 
to be superior to 2D echocardiography, particularly 
in patients with eccentric jets (Chapter 2). These 
observations are related to the fact that 3D echo-
cardiography has the advantage of unlimited plane 
orientation, allowing the exact shape and size of the 
true cross-sectional view of the regurgitant orifice 
area to be planimetered, without any geometric or 
flow assumptions or multiple computation steps.
Chapter 3 evaluated the usefulness of myocar-
dial strain imaging using 2D STE, in patients with 
chronic AR and baseline preserved left ventricular 
(LV) systolic function, and its predictive value of 
myocardial strain for future need of AV surgery was 
also assessed. In this evaluation, the extent of global 
longitudinal strain (GLS), circumferential strain and 
radial strain was calculated in each patient. Despite 
preserved LV ejection fraction (EF), multidirectional 
LV strain was more impaired in patients with chronic 
AR with symptoms than those without symptoms. 
In chronic AR, the LV adapts in the early course 
of the disease, normalizing wall stress and permit-
ting normal filling pressures despite a substantial 
increase in LV volume overload. Hence, LVEF is 
normally preserved during the compensated phase, 
and many patients may remain asymptomatic for 
years. With time, the progressive LV enlargement 
and the increase in LV pressure will result in an 
increase in LV wall stress, and marks the onset of 
impairment in LV performance. New parameters 
such as myocardial strain, is more sensitive tech-
nique than LVEF to detect the subtle change in LV 
performance.
 In the same chapter, in asymptomatic patients 
who were followed-up conservatively, GLS pro-
vided a significant incremental value over clinical 
and established echocardiographic predictors of 
poor outcome (including LV volume, parameters 
of AR severity) to predict those who are at risk 
of requiring AV surgery. Accordingly, GLS may 
serve as a potential screening tool in clinical risk 
stratification of asymptomatic patients with chronic 
AR and preserved LV ejection, in whom more ag-
gressive follow-up and early intervention should 
be considered in patients with more impaired GLS.
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pArT II: roLe of muLTImoDALITy ImAgINg 
IN TrANscATheTer AorTIc VALVe 
ImpLANTATIoN – from screeNINg To 
ouTcomes
The second part of the thesis focuses on the 
clinical applications of multimodality cardiac 
imaging in TAVI for the treatment of severe AS. 
First and foremost, as opposed to conventional 
surgical aortic valve replacement (SAVR), direct 
visualization of the AV is lacking during the TAVI 
procedure. As a result, imaging becomes manda-
tory before the procedure, to ensure appropriate 
sizing of the valve prosthesis. Moreover, the best 
possible access to reach the valve, either via the 
transfemoral (TF), transapical (TA), transaortic or 
transsubclavian approach, needs to be evaluated 
carefully. Multidetector row computed tomography 
(MDCT), which has superior spatial resolution and 
3D volumetric data sets, is capable of allowing 
unlimited plane reconstructions and thus, is a highly 
valuable screening modality in the pre-procedural 
work up of patients who are being considered for 
TAVI. Chapter 4 summarizes the evolving role of 
MDCT in the patient selection and strategy plan-
ning of transcatheter valve intervention. Although 
transcatheter technology and its delivery and valve 
systems have improved over the years, and recent 
randomized studies have shown encouraging results 
with TAVI, there is still a high early risk of death 
and complications such as vascular complications, 
stroke, conduction block, coronary injury and PVR 
following the intervention. Some of these areas of 
concern can be minimized by careful patient selec-
tion, valve sizing and planning of the procedure. 
Therefore, the clinical application of multimodality 
imaging is proposed in the pre-TAVI evaluation 
algorithm (in Chapter 5), highlighting the impor-
tant factors that need to be considered before the 
intervention.
Despite the combined effort of learning curve, 
advances in device technology and the better 
understanding of aortic root anatomy, AR remains 
frequent after TAVI. Accurate assessment of AR 
post-TAVI is clinically relevant since moderate to 
severe AR have been associated with poor clinical 
outcomes. In this respect, supra-aortic angiography 
and transesophageal echocardiography (particularly 
3D echocardiography), is the preferred cardiac 
imaging technique to assess and to provide an evalu-
ation of the mechanisms underlying AR immediately 
after valve deployment during the TAVI procedure 
(Chapter 6). This assessment step is crucial to 
decide whether additional maneuvers such as re-
ballooning or valve-in-valve are needed to reduce 
the AR grade.
Severe AV calcification has been associated with 
PVR after TAVI due to bulky calcification that may 
prevent complete annular sealing by the deployed 
prosthesis, leaving gaps where the regurgitations 
jets may arise. Chapter 7 highlighted that both the 
amount of AV calcification and its location (which 
can be visualized and quantified on pre-procedural 
MDCT) are important in determining PVR after 
TAVI. In particular, the amount of calcium at the 
valvular commissure and at the aortic wall could 
predict the occurrence of PVR, whereas the calcium 
at the valvular body or edge could not. The likely 
mechanism for this is that when there is significant 
amount of calcium present at the circumference of 
the native valve, it may prevent perfect apposition 
between the new transcatheter valve and the aortic 
wall, resulting in PVR at these sites.
Although many studies have reported worse clini-
cal outcomes with significant AR immediately post-
TAVI, there is limited data on how post-TAVI AR 
evolve over time. Chapter 8 reported that significant 
AR (grade >2) appeared to improve over time, 
particularly within the first 6 months. Interestingly, 
significant PVR (grade >2) followed similar course 
with improvement over time, whereas intravalvular 
AR (AR within the prosthesis) remained unchanged 
over time. Importantly, patients who remained with 
significant AR (grade >2) at 6 months, continued to 
have negative impact on survival, when compared 
to those with AR grade <2.
Prosthesis-patient mismatch (PPM) occurs when 
the effective orifice area of a normally function-
ing prosthetic valve is too small in relation to the 
patient’s body size. This phenomenon is not uncom-
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mon in SAVR, particularly in patients with large 
body size and small aortic annulus. The incidence of 
at least moderate PPM (indexed effective orifice area 
<0.85cm2/m2) is 18% in our TAVI experience, and 
larger body size is a risk factor (Chapter 9). Similar 
to the experience of SAVR, PPM is also associated 
with less improvement in clinical functional status 
and less LV mass regression, together with persistent 
elevated LV filling pressure (as measured on se-
rial echocardiography), when compared to patients 
without PPM after TAVI.
Finally, whether patients with depressed or 
preserved LVEF derive similar benefits from TAVI 
are explored in Chapter 10. Although higher periop-
erative and midterm mortality have been associated 
with patients with depressed LVEF undergoing 
SAVR, our experience showed that TAVI could be 
safely performed with similar procedural success in 
patients with LVEF <50% or >50% after careful pre-
procedural patient selection and screening. In fact, 
patients with baseline LVEF <50% showed marked 
LV reverse remodeling, with marked improvement 
in LVEF after TAVI. In the last Chapter 11 of the 
thesis, the clinical outcomes and changes in cardiac 
performance on echocardiographic evaluations 
were compared between patients undergoing TAVI 
through a TF or TA approach. Not surprisingly, 
patients who underwent TF approach had more 
vascular complications, although the early, and mid-
term survival rates were comparable. Both groups 
achieved similar improvements in transvalvular he-
modynamics and LV mass regression. Interestingly, 
patients with TA approach had significantly shorter 
fluoroscopy time and less use of contrast volume, 
when compared to patient with TF approach. A 
likely explanation for this observation is that less 
time is required for valve implantation via the TA 
approach due to better control of the device with 
a shorter distance between the AV and the apical 
access site.
coNcLusIoNs
Advanced cardiac imaging modalities play a 
central role in the diagnostic process and clinical 
management of patients with AV disease and in 
patients undergoing transcatheter AV therapy. In 
particular, 3D echocardiography is a very useful 
addition to cardiac imaging modality, which has 
demonstrated several advantages over the conven-
tional 2D echocardiography, such as a more accurate 
assessment of valvular regurgitation, and the pos-
sibility of presenting real-time visualization of 3D 
cardiac structures with unlimited imaging plane, 
which is integral for guiding transcatheter valve 
intervention. Therefore, 3D echocardiography will 
be part of routine echocardiographic assessment of 
valvular heart disease. Myocardial strain imaging 
has also undergone tremendous development. With 
STE, it has become relatively easy to perform and 
is reproducible. In fact, GLS is now considered an 
established marker of global LV systolic function, 
which is far more sensitive and superior as compared 
to LVEF, and has prognostic value in patients val-
vular heart disease.
Finally, advanced multimodality imaging 
(combining echocardiography, MDCT and MRI) 
has provided superior anatomic and physiologic 
information that is crucial in the evaluation of 
patients with severe AS referred for transcatheter 
valve therapy. Post-procedural results and its impact 
on outcomes can also be accurately evaluated and 
monitored using advanced cardiac imaging over 
time, providing insights into the understanding of 
this relatively new therapy, which is regarded as an 






De algemene inleiding tot dit proefschrift (Hoofd-
stuk 1) beschrijft de epidemiologie en impact van 
aortaklep lijden in de Westerse wereld. Verder in 
deze thesis geven we de actuele en toekomstige 
rol van geavanceerde cardiale beeldvorming weer, 
waaronder de rol van 3D-echocardiografie en 
speckle tracking strain beeldvorming bij de diagnose 
en het management van patiënten met aortaklep 
lekkage. Bovendien worden klinische toepassingen 
van multimodaliteit beeldvorming bij transcatheter 
aortaklep implantatie (TAVI) ter behandeling van 
ernstige aortaklep stenose toegelicht: van pre-
procedurele patiënt evaluatie tot het begrijpen van 
complicaties na TAVI zoals para-valvulaire lekkage, 
alsook de evaluatie en monitoring van patiënten na 
TAVI interventie.
DeeL I: NIeuwe 
beeldvormingstechnieken bij bepaling 
VAN AorTAkLep LekkAge – INcremeNTeLe 
rol bij diagnose
Het eerste deel van dit proefschrift evalueert de 
rol van 3D-echocardiografie versus conventionele 
2D-echocardiografische technieken ter kwantificatie 
van aortaklep lekkage, gebruik makend van 3D 
3-directional velocity encoded magnetische reso-
nantie imaging (MRI) als referentie methode. Deze 
techniek werd voorgesteld als een accurate methode 
om transvalvulaire flow te bepalen, na correctie 
van beweging doorheen het scanvlak. Excellente 
overeenkomst tussen het regurgiterend volume be-
komen op basis van 3D-echocardiografie en MRI 
werd aangetoond, beter dan 2D-echocardiografie 
versus MRI. Wanneer deze twee echocardiografische 
modaliteiten worden toegepast bij de evaluatie van 
excentrisch verlopende jets, werd een significant 
betere correlatie tussen 3D-echocardiografie en MRI 
aangetoond (r=0.95), terwijl de correlatie tussen 
2D-echocardiografie en MRI zwak bleek (r=0.66). 
Daarom besloten we dat kwantificatie van aortaklep 
lekkage op basis van 3D-echocardiografie superieur 
is versus 2D-echocardiografie, meer bijzonder bij 
patiënten met excentrische jets (Hoofdstuk 2). 
Deze observaties zijn gerelateerd aan het feit dat 
3D-echocardiografie het voordeel biedt van een 
ongelimiteerde vlak oriëntatie, wat toelaat om 
planimetrie te doen van de exacte vorm en grootte 
van het ware cros-sectionele vlak van de lekkage op-
pervlakte, zonder geometrische of flow gebaseerde 
assumpties, noch multipele berekeningsstappen.
Hoofstuk 3 beschrijft het nut van myocardiale 
strain beeldvorming op basis van 2D speckle trac-
king echocardiografie bij patiënten met chronische 
aortaklep lekkage en initieel bewaarde kamerfunctie. 
Bovendien werd de predictieve waarde van myocar-
diale strain voor toekomstige noodzaak aan aor-
taklep heelkunde geëvalueerd. In deze studie werd 
de waarde van globale longitudinale strain (GLS), 
circumferentiële strain en radiale strain berekend 
bij elke patiënt. Ondanks bewaarde linker kamer 
ejectie fractie (LVEF), bleek multi-directionele 
strain gedaald in patiënten met chronische aortaklep 
lekkage. De linker kamer past zich vroeg in het 
ziekteverloop aan door normalisatie van de wand 
stress en het toelaten van normale vullingsdrukken 
ondanks een substantiële toename in linker kamer 
volume overbelasting. Daarom is de LVEF normaal 
behouden tijdens de gecompenseerde fase en blijven 
vele patiënten asymptomatisch gedurende multipele 
jaren. Na verloop van tijd zullen de progressieve 
linker kamer dilatatie en de verhoging van de linker 
kamer drukken uitmonden in een toename van de 
wand stress, wat het keerpunt vormt in het ontstaan 
van linker kamer performantie. Nieuwe parameters 
zoals myocardiale strain zijn veel gevoeliger dan 
LVEF om subtiele wijzigingen in linker kamer per-
fomantie te detecteren. In hetzelfde hoofdstuk, bij 
asymptomatische patiënten die conservatief werden 
opgevolgd, bood GLS een significante meerwaarde 
bovenop klinische en gevestigde echocardiografi-
sche predictoren van slechte uitkomst (waaronder 
linker kamer volume en parameters omtrent ernst 
van de aortaklep lekkage) om te voorspellen wie 
een risico heeft tot nood aan aortaklep heelkunde. 
Daarom zou GLS kunnen fungeren als een potentieel 
screening middel bij klinische risico stratificatie 
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van asymptomatische patiënten met chronische 
aortaklep lekkage en bewaarde linker kamer functie. 
In geval van meer gedaalde GLS, zou een meer 
agressieve opvolging en vroegtijdige interventie 
kunnen worden overwogen.
DeeL II: roL VAN muLTI-moDALITeIT 
beeLDVormINg IN TrANscATheTer 
AorTAkLep ImpLANTATIe – VAN screeNINg 
ToT uITkomsT
Bij het tweede deel van dit proefschrift ligt de 
focus op klinische toepassingen van multimodaliteit 
beeldvorming bij TAVI bij behandeling van ernstige 
aortaklep stenose. Ten eerste en meest belangrijk, 
is directe visualisatie tijdens de TAVI interventie 
onmogelijk in tegenstelling tot conventionele 
heelkundige aortaklep vervanging. Hierdoor wordt 
beeldvorming voor een procedure dwingend, om 
adequate maatkeuze van de aortaklep prothese 
te faciliteren. Bovendien moet de best mogelijke 
route om de klep te bereiken zorgvuldig worden in 
kaart gebracht; trans-femoraal, trans-apicaal, trans-
aortisch of via de arteria subclavia. Multi-detector 
computerized tomografie (MDCT) biedt superieure 
spatiale resolutie en de mogelijkheid tot 3D da-
tasets en laat ongelimiteerde vlak reconstructies 
toe. Daarom is deze modaliteit uiterst geschikt bij 
de pre-procedurele uitwerking van patiënten die 
overwogen worden voor een TAVI ingreep.
Hoofdstuk 4 vat de evoluerende rol samen van 
MDCT voor patiënten selectie en strategie plan-
ning bij transcatheter klep interventie. Hoewel 
transcatheter technologie en diens delivery en klep 
systemen verbeterd zij over de jaren en recente 
gerandomiseerde studies bemoedigende resultaten 
voorgelegd hebben bij TAVI, blijft er nog steeds 
een hoog vroegtijdig risico op overlijden en 
complicaties zoals beroerte, geleidingsblok, coro-
naire beschadiging en para-valvulaire lekkage na 
interventie. Sommige van deze aandachtsgebieden 
kunnen geminimaliseerd worden door zorgvuldige 
patiënten selectie, klepmaat keuze en planning van 
de interventie. Daarom wordt de klinische toepas-
sing van multimodaliteit beeldvorming naar voor 
geschoven in het pre-TAVI evaluatie algoritme (in 
Hoofdstuk 5), waarbij de belangrijkste factoren die 
dienen te worden overwogen voor een interventie 
worden aangestipt.
Ondanks de gecombineerde inspanning van 
leercurve, evoluties in device technologie en beter 
begrip van aortawortel anatomie, blijft aortaklep 
regurgitatie na TAVI een frequent probleem. Ac-
curate bepaling van aortaklep lekkage na TAVI 
is klinisch uiterst relevant aangezien matige tot 
ernstige aortaklep lekkage geassocieerd is aan een 
slechte klinische uitkomst. In deze optiek zijn supra-
aortische angiografie en slokdarm echocardiografie 
(voornamelijk 3D-echocardiografie) de technieken 
die preferentieel aangewend worden bij het vaststel-
len en de evaluatie van het mechanisme van aoart-
klep lekkage, onmiddellijk na de ontplooiing van de 
aortaklep prothese bij TAVI (Hoofdstuk 6). Deze 
bepaling is cruciaal om te beslissen of additionele 
manoevers zoals re-ballooning of klep-in-klep nodig 
zijn om de graad van aortaklep lekkage te reduceren.
Ernstige aortaklep calcificatie is geassocieerd aan 
para-valvulaire aortaklep lekkage na TAVI omdat 
omvangrijke calcificaties complete annulaire sealing 
door de ontplooide prothese kunnen tegenwerken, 
waarbij openingen ontstaan die aanleiding kunnen 
geven tot lekkage jets. Hoofdstuk 7 onderstreepte 
dat zowel de hoeveelheid als de locatie van aor-
taklep calcificaties (die kunnen in het licht worden 
gesteld door pre-procedurele MDCT) belangrijke 
determinanten zijn van para-valvulaire lekkage na 
TAVI. Meer in het bijzonder konden de hoeveelheid 
calcium ter hoogte van de klep commissuren alsook 
de aortawand het ontstaan van para-valvulaire klep 
lekkage voorspellen, terwijl de calcium hoeveel-
heid ter hoogte van het klepblad lichaam of tip niet 
voorspellend bleek. De meest plausibele verklaring 
voor dit fenomeen is dat wanneer er een significante 
hoeveelheid calcium aanwezig is ter hoogte van de 
omtrek van de natieve klep, dit een barrière kan 
vormen om perfecte appositie tussen de nieuwe klep 
prothese en de aortawand te verzekeren, uitmondend 
in para-valvulaire lekkage op deze locaties.
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Hoewel vele studies slechte klinische uitkomst 
gedocumenteerd hebben in geval van significante 
aortaklep lekkage onmiddellijk na TAVI, zijn data 
omtrent de evolutie van aortaklep lekkage na TAVI 
schaars. In Hoofdstuk 8 documenteerden we dat 
significante aortaklep lekkage (≥ graad 2) bleek 
te verbeteren over verloop van tijd, voornamelijk 
gedurende de eerste 6 maanden. Een interessante be-
vinding was dat significante para-valvulaire lekkage 
(≥ graad 2) eenzelfde verloop kende met verbetering 
over tijd, terwijl intra-valvulaire lekkage (aortaklep 
lekkage binnenin de klepprothese) onveranderd 
bleef. Belangrijk is dat patiënten dewelke een sig-
nificante aortaklep lekkage (≥ graad 2) behielden na 
6 maanden, een minder gunstige overleving kenden 
in vergelijking met lekkage < graad 2.
Patiënt-prothese mismatch (PPM) ontstaat wan-
neer de effectieve klep openingsoppervlakte van 
een normaal functionerende prothese te klein is in 
relatie tot de lichaamsoppervlakte van de receptor. 
Dit fenomeen is zeker niet weinig frequent na 
chirurgische aortaklep vervanging, voornamelijk 
bij patiënten met een grote lichaamsbouw en 
een kleine aorta annulus. In onze TAVI ervaring 
bedraagt de incidentie van ten minste matige PPM 
(effectieve aortaklep openingsoppervlakte ≤ 0.85 
cm²/m²) 18%, en grotere lichaamsbouw is hiertoe 
een risico factor (Hoofdstuk 9). Tevens is, net zoals 
bij de ervaring na heelkundige aortaklep vervanging, 
PPM geassocieerd aan minder verbetering van de 
klinische functionele status en minder linker kamer 
massa regressie, tezamen met persistente verhoogde 
vullingsdrukken in de linker kamer (gemeten door 
seriële echocardiografie), vergeleken met patiënten 
zonder PPM na TAVI.
Tot slot exploreerden we in Hoofdstuk 10 
of patiënten met een gedaalde versus bewaarde 
LVEF dezelfde voordelen ondervinden van TAVI 
interventie. Alhoewel hogere perioperatieve en 
mid-term mortaliteit geassocieerd is aan patiënten 
met gedaalde LVEF die chirurgische aortaklep 
vervanging ondergaan, toonde ons onderzoek 
aan dat TAVI veilig kon worden uitgevoerd met 
gelijkaardig procedureel succes bij patiënten met 
LVEF < 50% versus ≥ 50%, zorgvuldige patiënten 
selectie en screening in acht nemend. Patiënten met 
initieel LVEF < 50% toonden zelfs markante linker 
kamer reverse remodeling en verbetering van LVEF 
na TAVI.
In het laatste Hoofdstuk 11 van dit proefschrift, 
vergeleken we de klinische uitkomst en veran-
deringen in cardiale performantie op basis van 
echocardiografische evaluaties bij TAVI patiënten 
die een trans-femorale dan wel een trans-apicale 
interventie ondergingen. Niet geheel onverwacht 
werden meer vasculaire complicaties vastgesteld 
bij trans-femoraal behandelde patiënten, hoewel de 
vroegtijdige en mid-term overleving vergelijkbaar 
bleken. Beide groepen bereikten vergelijkbare ver-
beteringen van de trans-valvulaire hemodynamica 
en linker kamer massa regressie. Een interessante 
vaststelling was dat we bij trans-apicaal behandelde 
patiënten een significant kortere fluoroscopie tijd 
noteerden en een lager contrast volume verbruik, in 
vergelijking met de trans-femoraal behandelde pati-
entengroep. Een voor de hand liggende verklaring 
is dat minder tijd nodig is voor klep implantatie via 
een trans-apicale route omwille van betere device 
controle met tevens een kortere afstand tussen de 
aortaklep en de apicale toegangsplaats.
coNcLusIes
Geavanceerde cardiale beeldvorming modaliteiten 
spelen een centrale rol bij het diagnostisch proces 
en het klinische management van patiënten met 
aortaklep aandoeningen, naast patiënten die een 
transcatheter aortaklep ingreep ondergaan. In het 
bijzonder is 3D-echocardiografie een zeer nuttige 
additionele beeldvormingstechniek dewelke multi-
pele voordelen heeft aangetoond ten opzichte van 
2D-echocardiografie. Enkele van deze voordelen 
omvatten meer accurate bepaling van klep lekkage 
en de mogelijkheid om real-time 3-dimensionele 
cardiale structuren te visualiseren met ongelimi-
teerde beeldvorming vlakken, wat cruciaal kan zijn 
bij begeleiding van transcatheter klep interventies. 
Daarom zal 3D-echocardiografie deel worden van 
routine evaluatie bij beoordeling van hartklep 
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aandoeningen. Myocardiale strain beeldvorming 
onderging tevens ook ingrijpende ontwikkelingen. 
Gebruik makend van speckle tracking technologie, is 
myocardiale strain beeldvorming relatief makkelijk 
geworden om uit te voeren en meer reproduceerbaar. 
GLS is thans een gevestigde merker van globale 
systolische linker kamer functie geworden, dewelke 
significant gevoeliger en superieur is vergeleken 
met LVEF en daarenboven duidelijk prognostische 
waarde heeft in patiënten met kleplijden.
Tot slot biedt geavanceerde multimodaliteit 
beeldvorming (waaronder een combinatie van 
echocardiografie, MDCT en MRI) de mogelijk-
heid tot vergaren van superieure anatomische en 
fysiologische informatie, dewelke een sleutelrol 
hebben bij de evaluatie van patiënten met ernstige 
aortaklep stenose die verwezen worden voor een 
transcatheter klep interventie. Bovendien kunnen 
post-procedurele resultaten en de impact op kli-
nische uitkomsten eveneens accuraat beoordeeld 
en gemonitord worden door gebruik te maken van 
geavanceerde cardiale beeldvorming over verloop 
van tijd. Hierbij worden inzichten verworven ter 
begrip van deze relatief nieuwe therapie die als een 
alternatief kan worden beschouwd voor heelkundige 
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